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Abstract 
Glucagon-like peptide 1 is a hormone involved in the regulation of glucose.  
Glucose-dependent activation of brain GLP-1R stimulates GLP-1 secretion 
from the L-cells of the intestine in response to ingested nutrients and it enters 
the blood stream to direct insulin secretion and to regulate growth and 
apoptosis of pancreatic cells, regulate the uptake of glucagon secretion as 
well as other metabolic processes. GLP-1 agonists are a new class of anti-
diabetes agent and current research suggests a role in weight and blood 
pressure reduction. A primary function of GLP-1 is postulated to act as a 
neuropeptide in the regulation of metabolic and cardiovascular function 
through gut-brain regulatory feedback.  As a secondary effect, GLP-1 may 
also increase natriuresis by direct action on sodium transport molecules in 
the kidney and hence play a role in long-term blood pressure homeostasis.  
The aims of this thesis is to 1) ascertain the effects of GLP-1 agonists on 
blood pressure, heart rate and body weight in T2DM patients through a 
systematic review and meta-analysis and 2) to explore the expression of 
renal GLP-1R during metabolic syndrome (obesity) and diabetes in animals 
and also hyperglycaemia-like conditions in isolated cells of the human renal 
proximal tubule and collecting duct.  I also investigate for the first time GLP-
1R mediated expression of sodium transport molecules in cells of the human 
collecting duct.  I confirm that GLP-1 agonists produce significant weight 
reducing effects and also a beneficial reduction in blood pressure in T2DM 
patients.  However, there is a tendency for these agents to increase heart 
rate which may be related to their effects on the autonomic nervous system 
and direct activation of sino-atrial node GLP-1R.  I show evidence that renal 
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GLP-1R expression is inhibited during obesity and diabetes which might be a 
consequence of peripheral insulin signalling or regulatory feedback from 
pancreatic β-cells to the CNS but which needs to be further clarified.  GLP-1 
was also shown to modestly up-regulate α- ENaC mRNA and protein 
expression, possibly as a consequence of activation by SGK-1 and PKC- 
dependent ERK activation in HCD cells. The significance of this paradoxical 
finding in a clinical scenario is unknown because 1) GLP-1(7-36) should 
theoretically undergo enzymatic degradation in peripheral tissues and further 
degradation and elimination in the proximal tubule.   However, potential for 
long-acting GLP-1 agonists to remain in the kidney for longer might mean 
that these agents reach the collecting duct whereby paradoxical sodium 
reabsorption may occur.  This might also be reflected in the meta-analysis 
findings that exenatideLAR preparations reduce blood pressure less than 
shorter acting formulations. 
 I conclude that GLP-1 signalling is dysregulated in obesity and diabetes and 
that treatment with GLP-1 agonists confer favourable effects on body weight 
and blood pressure.  However, due to effects on heart rate further safety 
studies are required to reassure long term cardiovascular safety and 
autonomic mechanisms behind the cardiovascular and metabolic effects of 
GLP-1 needs to be explored further.   
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1.0 General introduction  
1.1 Type 2 diabetes 
Recent advances in molecular biology have increased our understanding of 
type 2 diabetes which is currently considered to be “a complex metabolic 
disorder with multiple causes” (Leroith, 1999).  Impaired insulin action give 
rise to abnormalities in non-oxidative glucose disposal, as well as defects in 
glucose uptake by skeletal muscle and phosphorylation (Leroith, 1999; Khan 
et al, 1996).  Consequently, release of free fatty acids by adipocytes and 
enhanced glucose production in liver leads to hyperglycaemia.  It is 
understood that defects in an early post-receptor step in insulin action result 
in insulin resistance (Abate & Chanalia, 2001; Leroith, 1999).  Over a period 
of years, the ensuing hyperglycaemia results in damage to the heart, blood 
vessels, kidneys and nerves (WHO, 2008).  Global mortality is estimated at 
2.9 million deaths attributable to diabetes of which large proportions were the 
result of concomitant heart disease and stroke. In 2004, 68% and 16% of 
deaths were attributed to these two disorders, respectively (CDCP, 2011).  In 
2010, the estimated world-wide prevalence of diabetes was 285 million 
(6.4%) which is predicted to rise to 439 million (7.7%) by 2030 (Shaw et al, 
2010). Type 2 diabetes is understood to account for more than 90% of all 
diabetes cases (Gonzalez et al, 2009).  The burden to healthcare systems 
and through loss of earnings is a global concern, especially in low income 
countries where the disease is most prevalent due to transition to a 
westernised diet and lifestyle (otherwise coined “nutrition transition”).  For 
example, in 2005 the estimated loss of national income due to heart disease, 
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stroke and diabetes was $1.6 billion for United Kingdom with China being the 
country with the highest loss of $18 billion (WHO, 2006). 
 
1.2  Aetiology and pathogenesis of T2DM:  
1.2.1  Relationship of diabetes to nutrition and the development of 
obesity.  
Type 2 diabetes mellitus (T2DM) is a progressive disease signified by 
marked β-cell dysfunction and insulin resistance. Over 90% of those who 
suffer from T2DM are or have been obese (Nolan et al, 2011). Transition 
from traditional rural environments to urbanisation particularly raises the risk 
of developing obesity and T2DM.  It has been well documented that the 
important preventative factor seen in the diets of certain ethnic groups is the 
presence of allelochemicals and complex polysaccharides in unrefined foods 
that are largely removed from the Western diet to increase palatability and 
hasten preparation times.  These allelochemicals have been shown to 
regulate the absorption of sugar through the small intestine, for example 
through inhibition of α-glucosidase and thereby inhibit post-prandial glucose 
excursions and fasting glucose concentrations (Day & Bailey, 1988; Jenkins 
et al, 1976; Ali et al, 1996).  Some polysaccharides have been found to slow 
gastric emptying and act on the endocrine system to increase secretion of 
gastro-intestinal hormones, as well as the action of short chain fatty acids, 
coming from fermentation (Dall’ Agnoll & Lino von Poser, 2000). The 
composition of foods is well documented to modulate the release of gastro-
intestinal hormones involved in glucose metabolism, hunger and satiety as 
has been reviewed previously (Karhunan et al, 2008). Deregulation of gastro-
intestinal hormones such as Glucagon-like peptide-1, leptin and ghrelin 
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possibly as a consequence of over-nutrition has been implicated in the 
pathogenesis of T2DM. 
1.2.2 Maternal and child health 
Until 1990, type 2 diabetes was considered to be a disease only affecting 
people later in life as has been reviewed by Nolan (2009).  Nolan points out, 
that with more and more younger people becoming obese, pregnant women 
the disorder is now affecting pregnant women (Reinehr et al, 2010; McIntyre 
et al, 2009), the majority of whom are from migrant ethnic groups (Mayer-
Davis et al, 2009). Many young women are not diagnosed as suffering from 
T2DM until they become pregnant and unfortunately the prognosis is often 
poor with high rates of congenital malformations and perinatal death (Cundy 
et al, 2000; Clausen et al, 2005). Intrauterine growth restriction has been 
implicated as a causal link for adult diseases such as obesity, hypertension, 
T2DM and CVD (Chen et al, 2009; Plagemann et al, 2009).  Furthermore 
there are suggestions that gestational or T2DM in pregnancy can affect 
diabetes risk in offspring.  Interestingly, in his review, Nolan highlights results 
from a Danish study comparing the offspring of mothers with and without 
diabetes, the probability for pre-diabetes or T2DM was higher in the offspring 
of women who had gestational diabetes or type 1 diabetes at age 22 years 
(Clausen et al, 2008, reviewed in Nolan, 2009). The concomitant risk of 
T2DM in offspring of Type 1 diabetes mothers was found to be greater if 
maternal hyperglycaemia was present in the third trimester (Clausen et al, 
2008).  Evidence from animal studies indicates that neonatal programming 
can affect neurohormonal weight control signalling and development of 
pancreatic islets (Chen et al, 2009). 
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1.2.3 Adiposity and anthropometric determinants 
Studies of obesity are highly relevant to the aetiology of T2DM. Genetic 
factors contribute to the occurrence of T2DM and obesity, respectively.  It 
has been known for many years that obesity is a causative factor of type 2 
diabetes and cross-sectional and longitudinal studies have shown that high 
body mass index (BMI) seems to be associated with increased risk of 
diabetes in both genders and between all ethnic groups (Nakagami et al, 
2003). More recently it has been documented that certain ethnic groups 
convey a greater susceptibility to diabetes than do Caucasians at lower BMI 
(Misra et al, 2005; Nakagami et al, 2003). 
Another major pathogenic factor seems to be the actual distribution of 
adipose, namely android (intra-abdominal) distribution. Central abdominal 
obesity acts as an independent diabetogenic factor due to the fact that it is 
more closely related to insulin resistance.  This has been attributed to its high 
lipolytic rate that as a consequence elevates portal and peripheral levels of 
free fatty acids leading to hepatic and muscle resistance, respectively (Abate 
& Chandalia, 2001). 
1.3 Animal models for the study of diabetes and obesity 
Many researchers have attempted to construct mouse models of Type 2 
diabetes mellitus. Murine models such as ob/ob (C57BL/6, BL/6) and db/db 
(C57BL/Ks, BL/Ks) mice and the Zucker fatty rat are primarily models of 
obesity which has been comprehensively reviewed by Leroith (Leroith, 
1999).  Obesity is sequelae to diabetes in these animals where massive 
weight gain is caused by mutations in leptin or its receptor (Zhang et al, 
1994; Chen et al, 1996).  Roughly 75-80% of patients with type 2 diabetes is 
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or has previously been obese. A characteristic of the BL/6 mouse model is 
that they are massively overweight due to being homozygous for the obese 
(ob) gene.  It has also been suggested that obesity in humans involves 
defects in the brain receptor for the ob protein and not a failure to synthesise 
the protein itself (Blackburn & Kanders, 1994). The finding that the ob genes 
protein product, leptin, is a regulatory protein that, if administered to the 
obese mice can control the accumulation of adipose, thus aiding weight loss 
was considered to be a breakthrough in this research area as leptin might 
alleviate obesity and aid to prevent development of type 2 diabetes. 
McKeigue and colleagues believe this finding to be especially important in 
the prevention or maintenance of diabetes due to the fact that it controls 
maturity- onset obesity (McKeigue et al, 1991), and diabetes is largely 
associated with increasing age.  However, suggestions that leptin is 
important in glucose homeostasis in humans has since been disproved by 
Froguel (2001) and his team who found evidence to suggest that 
melanocortin 4 (MC4), which is initiated by leptin, has a more important role 
in glucoregulation (Froguel & Boutin, 2001).  Froguel and Boutin (2001) also 
state that “although leptin is a prime candidate gene for monogenic obesity, it 
still may not reside at the core of this metabolic disorder but may instead 
highlight our ignorance to the intricate biological processes involved” 
(Froguel & Boutin, 2001).  More recently it has been noted that there is 
considerable inter- individual variability in the relationship of leptin to total 
adiposity.  Therefore, many people who are obese have normal levels of 
leptin.  This finding may suggest that other genes may play a significant role 
in this disease.  Franks and co-workers suggest that disparities between 
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studies of the role of leptin may be due to differences in experimental design 
(Franks et al, 2003).  These researchers carried out a large population based 
cohort study (The Ely Study).  It was demonstrated that a significant inverse 
association exists between physical activity energy expenditure and plasma 
leptin concentrations after adjustments for percent body fat or body mass 
index (Franks et al, 2003). 
A detailed description of the genetics of the BL/6 and BL/Ks mice is detailed 
in a review by Clee & Attie (Clee & Attie, 2007) The BL/6 strain shares some 
Mus musculus molossinus genomic regions and is evolutionarily diverged 
from other transgenic strains except for other C57 and C58 strains (Williams 
et al, 2001). The BL/Ks strain background is composed of BL/6 with 
contributions from at least 3 mouse strains including C57BL/10, 129 and 
another unidentified strain that composes approximately 10% of the genome 
(Clee & Attie, 2007). The severity of diabetes differs in both BL/6 and BL/Ks 
strains and is dependent on homozygosity for defective genes, Lepob 
(encoding the protein product, leptin) or Lepdb (encoding for the leptin 
receptor), respectively.  BL/6 mice display decreased insulin secretion and 
glucose intolerance, although in comparison to BL/Ks these mice are 
relatively resistant to obesity-induced diabetes (Harris et al, 2001).  Original 
experiments by Douglas Coleman over 30 years ago exemplified the 
differences in strain background to obesity-induced diabetes (Hummel et al, 
1972; Coleman et al, 1973). Coleman showed the obese mice in the BL/Ks 
strain background to display a high severity of diabetes whereas the obese 
BL/6 mouse, although displaying severe insulin resistance did not develop 
overt diabetes (Coleman et al, 1992). The BL/6 strain background displays 
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approximately 220 mg/dl fasting blood glucose, equating to moderate 
hyperglycaemia but this returns to near normal levels as a result of β-cell 
expansion and corresponding insulin secretion (Hummel et al, 1972).  This 
characteristic is not seen in BL/Ks background and hence these were named 
db/db mice due to ensuing islet atrophy which results in sustained 
hyperglycaemia (282.9 ± 77.48 mg/dL plasma glucose by 10 weeks of age) 
and overt diabetes (Sharma et al, 2003; Hummel et al, 1972).  The generally 
accepted threshold for diagnosis of diabetes in mice is 250 mg/ dL (Clee et 
al, 2007).  BL/6 strains are also relatively resistant to diabetic nephropathy.  
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a) 
 
b) 
 
 
Figure 1.3.0.1 - Typical glycaemic profiles of a) ob/ob (C57BL/6, BL/6) 
and b) db/db (C57BL/Ks, BL/Ks) strains. Figures obtained from Jackson 
laboratory website, 2011: BL/Ks mice show marked hyperglycaemia by 8 
weeks of age as compared to BL/6 mice which display moderate 
hyperglycaemia.  Compensation of high circulating glucose by increased β-
cell proliferation and hyperplasia protects BL/6 strains from the development 
of overt diabetes.  
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The tamoxifen-induced hyperglycaemic mouse model is a model of diabetes 
cleverly designed to allow a direct comparison to be made between the 
effects of high circulating glucose levels and normoglycaemia in the same 
animal. During chronic hyperglycaemia there are alterations in β-cell gene 
expression, survival and function.  Therefore in models of hyperglycaemia, β-
cells display decreased expression of genes important for glucose 
stimulation of insulin secretion such as glucose transporter 2 (GLUT2), 
glucokinase and pre-proinsulin (Ppi) and some transcription factors that 
control their expression (Pascal et al, 2008). The c-MYC proto-oncogene is 
understood to be a transcription factor involved in modulating a large number 
of genes involved in cell proliferation, differentiation and apoptosis (Evan & 
Littlewood, 1993; Harrington et al, 1994).  Up-regulation of c-MYC during 
chronic hyperglycaemia has been shown to trigger apoptosis in β-cells and 
reduce the expression of Ppi and other genes important for β-cell function, 
leading to diabetes. Furthermore, forced activation of c-MYC has also been 
shown to reduce expression of Ppi, induce β-cell apoptosis and thus result in 
the induction of hyperglycaemia (Pascal et al, 2008).  
In the tamoxifen model, fusion of the hormone binding domain of the 
oestrogen receptor to the Ppi promoter initiates c-MYC activation upon 
administration of oestrogen, and thus makes c-MYC dependent on exposure 
to oestrogen. The major drawback to this method is the potential for 
endogenous oestrogens to bind to the hormone binding domain in vivo which 
therefore hinders the interpretation of consequent transcriptional activation of 
β-cell regulatory genes (Littlewood et al, 1995).  Therefore, Littlewood and 
co-workers modified this method to use a transcriptionally inactive mutant of 
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the murine oestrogen receptor which binds to the synthetic ligand, 4-
hydroxytamoxifen.  This method was further developed to specifically alter c-
MYC in the β-cell by Professor Khan and co-workers to enable researchers 
to directly study the effects of hyperglycaemia in vivo.  Fusion of the mutant 
oestrogen receptor to the C-terminus of the c-MYC protein results in β-cell 
apoptosis (more so than proliferation) which is dependent on 4-
hydroxytamoxifen, but is not influenced by 17- β-oestradiol (Littlewood et al, 
1995). 
1.3.1 Hypertension in obesity and diabetes: Focus on sodium 
transport by epithelial sodium channel (ENaC) 
The kidneys play a pivotal role in regulation of blood volume (BV), and hence 
blood pressure by adjusting sodium and water loss into urine. Renal control 
of BV is achieved in various ways. An increase in BV raises arterial pressure, 
renal perfusion and glomerular filtration rate (GFR) through an increase in 
renal water and sodium concentration and is termed “pressure natriuresis”. 
Key hormones, angiotensin and aldosterone stimulate distal tubular sodium 
reabsorption by activating intracellular sodium transporters and thus 
decrease sodium and water loss by the kidney.  Activation of the renin 
angiotensin aldosterone system (RAAS) is complimented by another 
important hormone, vasopressin (antidiuretic hormone, ADH) which is 
secreted from the posterior pituitary gland.  One of the actions of vasopressin 
is to stimulate water reabsorption by the collecting duct thereby decreasing 
water loss and increasing BV.  The principle role of counter-regulatory 
hormones such as atrial natriuretic peptide is to increase water and sodium 
loss by the kidney and thus a concert of mechanisms ultimately maintains 
blood volume (and blood pressure) within set limits. 
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An increase in BV results in a corresponding increase in arterial pressure by 
raising central venous pressure, right atrial pressure and right ventricular end 
diastolic pressure and volume.  An increase in left ventricular preload and 
stroke volume results from the augmented right ventricular stroke volume 
and hence pulmonary venous blood flow to the left ventricle.  The resultant 
increase in stroke volume raises cardiac output and arterial blood pressure, a 
phenomenon coined, the Frank Starling mechanism.  
Obesity alone and as sequelae to T2DM results in abnormal renal function 
and treatment resistant hypertension.  In human obesity, excess renal 
sodium reabsorption in the Loop of Henle results in a shift of pressure 
natriuresis which initiates raised blood pressure as a result of weight gain.  
Mechanisms behind the increased sodium reabsorption and altered pressure 
natriuresis in obesity include activation of renin, aldosterone-angiotensin 
system (RAAS) and sympathetic nervous systems, physical compression  of 
the kidneys due to excess intra-renal adipose tissue and increased extra-
cellular matrix (Hall, 1999).  In human obesity, sympathetic activation is 
mediated in part by elevated leptin and interactions with neuropeptides in the 
hypothalamus.  In the early phases of obesity, glomerular hyperfiltration and 
increased arterial pressure help to compensate for increased tubular 
reabsorption and homeostasis is maintained.  However, a subsequent 
increase in glomerular capillary wall stress, activation of neurohormonal 
systems, increased lipids and glucose intolerance, eventually lead to loss of 
nephron function (Hall, 1999).  Over time the compensatory increases in 
arterial pressure to maintain sodium balance results in hypertension which is 
difficult to resolve with anti-hypertensive therapy.   
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 Sodium intake has long been understood to be positively correlated with 
high blood pressure upon increasing age. To exemplify this, epidemiological 
research has shown that certain indigenous communities who survive on a 
low sodium diet, such as the Yanamamo Indians of the Brazilian Amazon, as 
a consequence do not suffer increasing blood pressure with age compared 
to people from developed countries who in contrast, consume on average 
twenty times more sodium per day (Takahashi et al, 2011). Furthermore, the 
obese and diabetic state exacerbates sodium retention by increasing sodium 
reabsorption at the kidney tubules (Defronzo, et al, 1975).  For example, 
during metabolic syndrome (obesity) and early stages of T2DM, 
hyperinsulinemia leads to metabolic insulin resistance.  Contrary to this, 
insulin resistance does not to occur in the kidney where insulin has been 
shown to enhance renal sodium reabsorption (Defronzo et al, 1975).  Of the 
sodium transporters involved the main regulators of sodium reabsorption are 
epithelial sodium channel (ENaC) in the distal portion of the nephron and 
sodium-proton exchanger type 3 (sodium-hydrogen exchanger 3, NHE3) in 
the proximal tubules (Horita et al, 2011). Similarly, hyperglycaemia and 
hyperaldosteronism which also occur during obesity and diabetes increase 
sodium reabsorption through similar mechanisms.  This effect is 
compounded by the “obesogenic” or modern day diet which is also low in 
potassium which under normal conditions enhances excretion of sodium by 
the kidneys (Takahashi et al, 2011).  Therefore, obesity and diabetes results 
in dysregulation of key sodium transport molecules exacerbating the impact 
of the western diet on blood pressure regulation.   
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Discovery of a severe monogenic form of hypertension, Liddle’s syndrome 
was an important breakthrough in our understanding of the critical role of 
ENaC in the pathogenesis of hypertension.  Liddle’s syndrome is 
characterised by severe hypertension and hyperkalaemia with negligible 
secretion of aldosterone.  Dysregulation of the sodium channel ENaC is able 
to independently produce severe and sustained hypertension (Bubein et al, 
2010).  Furthermore, obesity-related hypertension and Liddle’s syndrome, 
although physiologically distinct with regards to circulating insulin, glucose 
and aldosterone levels, display hyperactive ENaC and decreased plasma 
potassium levels.  Furthermore, both disorders are resistant to anti-
hypertensive agents, emphasizing the importance of increasing our 
understanding of the physiological role of ENaC in the pathogenesis of 
hypertension (Horita et al, 2011; Bubein et al, 2010).  
As already mentioned, extra-cellular fluid volume is maintained by regulation 
of Na+ by the kidney. This process is essential for maintaining fluid and 
electrolyte balance and regulation of blood pressure. The majority of sodium 
is reabsorbed in the proximal tubule (Figure, 1.3.1.1 The Renal 
Commission of the International Union of Physiological Sciences 
(IUPS) schema of the nephron).  However, the distal portion of the nephron 
(Figure, 1.3.1.1) is ultimately responsible for blood pressure regulation as a 
result of changes in urine flow and Na+ excretion (Petri-Pederdi et al, 2002). 
In the cortical collecting duct, sodium is transported across the apical 
membranes of salt- reabsorbing epithelia.  ENaC moves sodium ions into the 
cell by electrodiffusion and is sensitive to amiloride (and its analogues), a K+- 
sparing natriuretic and mild diuretic.  In the late distal convoluted tubule, 
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connecting tubule and collecting duct, sodium reabsorption is mainly 
controlled by aldosterone.  During this process, salt enters the epithelial cell 
via ENaC at the apical plasma membrane and sodium is expelled into the 
interstitial fluid via the basolateral Na+-K+-ATPase in exchange for potassium 
(Christensen et al, 2010).  It is well understood that aldosterone stimulates 
P13-K which promotes the activity of ENaC through upregulation of serum/ 
glucocorticoid regulated kinase-1 (SGK-1) (Thomas et al, 2007; 2008).  ERK 
activation has been shown to suppress ENaC activity and is dependent on 
activation of PKC (Thomas et al, 2008) and therefore, aldosterone is 
responsible for dual control of ENaC by both activating and suppressing its 
activity. Interestingly, recent evidence also suggests that another GPCR and 
component of RAAS, angiotensin II regulates ENaC and this effect has been 
found to be due to activation of PKC, independent of Ca2+ and which acts to 
activate NOX and consequent superoxide generation.  This effect is 
understood to be through activation of the angiotensin receptor AT1 (Petri-
Pederdi et al, 2002; Sun et al, 2011). 
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1. Renal corpuscle including Bowman’s capsule and the glomerulus 
(glomerular tuft). 
2. Proximal convoluted tubule 
3. Proximal straight tubule 
4. Descending thin limb 
5. Ascending thin limb 
6. Distal straight tubule (thick ascending limb) 
7. Macular densa located within the final portion of the thick ascending 
limb 
8. Distal convoluted tubule 
9. Connecting tubule 
10. Cortical collecting duct 
11. Outer medullary collecting duct 
12. Inner medullary collecting duct 
 
 
Figure, 1.3.1.1- The Renal Commission of the International Union of 
Physiological Sciences (IUPS) schema of the nephron: Depicts the 
short-looped and long-looped nephron as well as the collecting duct 
system. The dashed line within the cortex represents a medullary ray 
(from Kriz & Bankir, 1988).  
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Figure, 1.3.1.2 Aldosterone signalling in the kidney. Binding of
aldosterone to MR and a distinct non-genomic receptor is understood to
initiate rapid signalling events including activation of PKC family isoforms
which is central to rapid stimulation of membrane ion transport in the distal
nephron. ENaC activity is the rate-limiting step in Na+ reabsorption.
Trafficking and stability of pre-expressed ENaC is subject to delayed
regulation by SGK-1 expression. ERK1/2 activation and increasing
intracellular pH promotes basolateral recycling through activation of Ca2+ and
ATP-dependent K+ channels which is also dependent on PKC (From,
Thomas et al, 2007).
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ENaC is a member of the ENaC/ degenerin gene family (Kellenberger & 
Schild, 2002) and cloning has identified it to be composed of five ENaC 
subunits: α, β, γ, δ, and ε-ENaC (Ji et al, 2006). It is understood that β and γ 
subunits act as regulators of channel activity, whereas α, δ, ε- ENaC 
subunits are conductive and form heteromers in epithelial cells (Figure, 
1.3.1.3 Structure of ENaC and membrane topology)(Ji et al, 2006).  ENaC 
channels are understood to be selective for cations over anions and display 
a higher affinity for Na+ over other cations (Kucher et al, 2011).  Ji and co-
workers describe ENaC channels to vary in Na+ conductance, PNa/Pk and 
amiloride affinities depending on the tissues and species where the channels 
are located.  This is believed to be the consequence of differing heteromers 
of ENaC being present in the various types of epithelial cells (Ji et al, 2006).  
ENaC subunits share a common secondary and tertiary structure that 
consists of a large extracellular domain separated from shorter cytosolic 
NH2- and COOH-tails by two transmembrane domains (Kucher et al, 2011). 
Complex regulatory mechanisms exist for ENaC resulting in rapid responses 
by signalling cascades which occur within minutes and later transcriptional 
changes occurring within days (Thomas et al, 2007, 2008). Serum 
glucocorticoid kinase-1 (SGK-1) is known to be associated with the 
regulation of a wide variety of channels including ENaC, Na+ K+ ATPase and 
NaCl co-transporters (Lang et al, 2009). SGK-1 is also understood to be 
activated by a variety of mechanisms including insulin, and growth factors 
and its expression is stimulated by many mechanisms such as 
glucocorticoids, mineralocorticoids and hyperglycaemia (Lang et al, 2009). 
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The critical role of ENaC in sodium homeostasis has been exemplified by our 
understanding of Liddle’s syndrome which is caused by sodium retention 
resulting from mutations in the C-terminus of the β- or γ- subunit (Hansson et 
al, 1995).  Reports in the literature suggest that α- ENaC is vital for the 
functionality of the ENaC channel and that it is the availability of the α- 
subunit that influences the level of ENaC activity in the distal portion of the 
nephron (Thomas et al, 2008; Canessa et al, 1994; Snyder et al, 2000). It 
has been demonstrated that during co-expression of β- and/ or γ- subunits 
with α- ENaC there is a resultant increase in Na+ current (Canessa et al, 
1994; Snyder et al, 2000). The functional significance of α- ENaC required 
for Na+ transport can be further exemplified by Hummler and co-workers 
intricate studies in mice genetically lacking α- ENaC (Hummler et al, 1996).  
Hummler and co-workers describe mice lacking α- ENaC were born with 
morphologically normal lungs but were unable to clear fluid from the airways 
and died within the first two days after birth (Hummler et al, 1996). However, 
this lethal effect appears to highlight the importance of functional α-ENaC in 
the lung. Depletion of renal α-subunit results in metabolic acidosis but the 
renal pathology is not as severe as in β (-/-) or γ (-/-) mice (Bonny et al, 
2000). In contrast mice lacking β- and γ- ENaC subunits show a delay in lung 
water clearance and sodium reabsorption and subsequently die from an 
electrolyte imbalance as a consequence of abnormal renal function (Giallard 
et al, 2000).  
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Figure, 1.3.1.3 Structure of ENaC and membrane topology. ENaC is 
composed of three partly homologous subunits inserted into the membrane 
with a suggested topology of 2α: 1β: 1γ. Subunit α-ENaC is able to produce 
small amiloride sensitive Na+ currents which are greatly enhanced by β and 
γ-ENaC subunits (From Gormley et al, 2003).  
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1.4 Diagnosis of T2DM  
A diagnosis of diabetes is made by evidence of either recurrent or persistent 
hyperglycaemia, confirmed by one of the following blood plasma 
concentrations of glucose (WHO, 2006):  
1) Fasting plasma glucose (FPG) level of ≥7.0 mmol/l (whole blood, ≥6.0 
mmol/l). 
2) Two hour plasma glucose concentration of ≥11.1mM following ingestion of 
75g anhydrous glucose in an oral glucose tolerance test (OGTT)  
3) A random venous plasma glucose concentration of ≥11.1 mmol/l 
Pre-diabetes is confirmed by: 
1) Impaired fasting glucose (IFG) levels between 6.1 and 6.9mM and/ or 2h 
plasma glucose <7.8mM.  
2) Impaired glucose tolerance (IGT) of FPG <7.0mM and 2h plasma glucose 
>7.8mM (but <11.1mM).  
In addition to this the latest WHO guidelines state a cut-off value HbA1c of 
48 mmol/mol (6.5%) and that in asymptomatic patients a repeat laboratory 
test and if deemed to be high risk (<48 mmol/mol, 6.5%) repeat at 6 monthly 
intervals.  Patients with HbA1c less than 6.5% may still meet criteria for 
T2DM (high risk, 42-47 mmol/mol with the possibility that patients with 
HbA1c under this value may still be high risk) WHO, 2011. 
1.4.1 Treatment approaches and algorithms 
There are a number of algorithms which recommend haemoglobin A1C 
targets and clinical treatment of T2DM. These are developed by the 
regulatory authorities: American Diabetes Association, European Association 
for the Study of Diabetes, ADA/EASD (Figure, 1.4.1.1 ADA/ EASD 
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algorithm for the pharmacological management of type 2 diabetes), 
American Association of Clinical Endocrinologists (AACE), US Department of 
Veteran Affairs (VA/DoD), International Drug Federation (IDF) Canadian 
Diabetes Association (CDA) and National Institute for Health and Clinical 
Excellence (NICE). All of the proposed algorithms vary slightly in the 
approach to diabetes care and haemoglobin A1C targets. One of the 
important recent changes to the ADA/EASD algorithm is the initiation of drug 
therapy as well as lifestyle changes at start of treatment. Previously it was 
recommended that patients begin with lifestyle changes and after review be 
put on first line therapy such as metformin (Figure, 1.4.1.1). The AACE 
algorithm is more complex and features drugs such as colesevolam which is 
a bile acid sequestrant used to reduce low-density lipoprotein cholesterol, 
rather than an OAD.  The main strength of this algorithm is the 
recommendation that the approach to therapy is tailored to the individual 
depending on AIC levels at diagnosis (Rodbard et al, 2009).  Most algorithms 
are metformin based. The NICE guideline is unique in that its A1C targets 
are based on more achievable goals depending on success of initial 
treatment (from 6.5% in monotherapy to <7.5% in combination therapy). It 
may be argued that this is a logical approach for patients who are not able to 
reach glycaemic targets and to minimise the number of OADs prescribed in 
such circumstances (NICE, 2012).  Currently, newer agents such as the 
glucagon-like peptide agonists (GLP-1 agonists) are incorporated into 
combination therapy in patients who fail to maintain target values or who are 
not tolerant to other agents. 
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Figure, 1.4.1.1- ADA/ EASD algorithm for the pharmacological
management of type 2 diabetes. ADA/ EASD instruct to reinforce lifestyle
regimen during each clinical evaluation. “A) Consider beginning at this stage
in patients with very high HbA1c (e.g., ≥9%). B) Consider rapid-acting, non-
sulfonylurea secretagogues (meglitinides) in patients with irregular meal
schedules or who develop late postprandial hypoglycaemia on
sulfonylureas... D) Usually a basal insulin (NPH, glargine, detemir) in
combination with noninsulin agents. E) Certain noninsulin agents may be
continued with insulin”. (From, Inzucchi et al, 2012).
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2.0 From the identification of GLP-1 to the 
development of GLP-1 drugs 
Hormones secreted from the gastrointestinal tract after food intake act to 
stimulate insulin secretion from islet beta cells in response to glucose. This 
phenomena is coined the “incretin effect” and was first noticed during 
experiments whereby plasma insulin responses were compared in patients 
given either intravenous or oral glucose load.  It could be seen that insulin 
secretion is far less (≈40%) after intravenous administration than when given 
orally.  These findings indicate that mechanisms in addition to arterial blood 
glucose levels regulate insulin secretion (Perly & Kipnis, 1967).  The first 
incretin hormone was identified in the 1970s and named glucose-dependent 
insulinotropic polypeptide (GIP). GIP was shown to be a potent stimulator of 
glucose-dependent insulin secretion but removal of GIP from gut extracts did 
not abolish the incretin effect, indicating the existence of additional peptides 
with incretin-like activity. Many such hormones have been identified and 
include a superfamily of hormones such as, Glucagon-like peptides (GLP-1 
and GLP-2), secretin, glucagon, vasoactive intestinal peptide (VIP), glucose-
dependent insulinotropic peptide (GIP), glicentin and oxyntomodulin (Nancy 
et al, 2000; Manucci & Rotella, 2008).  
The novel Glucagon-Like Peptide- 1 (GLP-1) derivatives are a new class of 
type 2 diabetes drugs which are based on the incretin hormone. The primary 
action of these pharmacotherapies is significant improvement in postprandial 
glucose excursions and reduced incidence of hypoglycaemia (Grieve et al, 
2009).  Ceriello and colleagues propose management of postprandial 
glucose levels to be vital in reducing incidence of macrovascular and 
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microvascular complications as postprandial hyperglycaemia (plasma 
glucose > 7.8 mmol/l) is a common feature, despite sufficient overall 
metabolic control (Ceriello et al, 2008).  Endogenous GLP-1 secretion has 
been shown to be diminished in T2DM and obese patients (Muscilli et al, 
2007; Manucci et al, 2000; Holst & Gromada 2004; Vilsbøll et al, 2003).  
Perhaps, as mentioned in the introduction, a diet rich in high calorific foods 
but lacking the essential complex polysaccharides found in traditional ethnic 
diets, could be loosely speculated to reduce liberation of this gastro-intestinal 
hormone.  In particular, GLP-1 has not been found to be diminished in type 1 
diabetes the pathogenesis of which is not directly related to a westernised 
lifestyle (Huml et al, 2011; Visbøll et al, 2003).  
Exenatide (termed Exendin-4 at its developmental stage) which shares 53 
per cent homology with GLP-1 and Liraglutide, a GLP-1 analogue which 
shares 99 per cent homology are the primary GLP-1 drugs to enter the 
market, although other preparations including long-acting once-weekly 
formulations are now becoming available.  The main actions of this class of 
drug are to stimulate insulin secretion, increase β-cell neogenesis, inhibit β-
cell apoptosis, inhibit glucagon secretion, and slow gastric emptying and to 
increase satiety (Ceriello et al, 2008) (Figure 2.0.1- Biological functions of 
GLP-1). An exciting discovery is that GLP-1 derivatives have been reported 
to display beneficial effects on blood pressure and body weight, making 
these drugs extremely promising therapeutic agents (Nauck et al, 2009; 
Garber et al, 2008).  Importantly, it is suggested that the blood pressure 
effects reported in clinical trials might be independent of concurrent weight 
loss (Varanasi, et al, 2011), although this is yet to be confirmed.  
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Figure 2.0.1- Biological functions of GLP-1. GLP-1 acts directly on 
endocrine pancreas, GI- tract, heart and brain. (From: Drucker et al, (2006) 
Cell Metab. 3: 154). 
 
2.1 GLP-1 and the distribution and characterization of its 
receptor 
The polypeptide precursor of the glucagon gene, proglucagon encodes two 
glucagon-like peptides (GLP-1 and GLP-2) that shares roughly 50% amino 
acid homology to pancreatic glucagon (Figure 2.1.1 The proglucagon gene, 
localized on human chromosome 2q36eq37.). GLP-1 is a peptide which is 
synthesized in intestinal endocrine cells (namely, L- cells), in two chief 
molecular forms, GLP-1 (7-36) amide and GLP-1 (7-37).  In 1985, cloning of 
preproglucagon showed the full length N-terminal extended forms (GLP-1 (1-
36 amide) to display an insulinotropic effect but the truncated form GLP-1 (7-
36) produces a stronger effect (Schmidt et al, 1985).  By 1987 this had been 
demonstrated by several groups (Orskov et al, 1987; Kreymann et al, 1987). 
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Further to this, it was reported that GLP-1 (7-37) increases the intracellular 
messenger, cyclic AMP (cAMP) which is involved in a vast number of 
processes such as glycogen metabolism and regulation of Ca2+ through ion 
channels. This is supported by studies using cultured rat insulinoma cells 
and rat gastric glands where it was identified that GLP-1 receptors are 
coupled to a cAMP- dependent adenylate cyclase system (Goke et al, 1989; 
Uttenhal and Blazquez, 1990).  Characterization of the GLP-1 (7-37) receptor 
in various cells including rat lung membranes confirmed this. It was also 
demonstrated that specific binding of radio-labelled GLP-1(7-37) is 
dependent on pH, time and temperature and is proportional to membrane 
protein concentration.  In these experiments the addition of unlabelled GLP-1 
(7-36), inhibited binding in a linear fashion consistent with a single class of 
binding site (plots will be curvilinear in the presence of multiple binding sites 
on the protein or if it binds to multiple protein sites) (Richter et al, 1990). 
Cloning and functional experiments of the rat and human receptor revealed 
that it belongs to Class B of the seven transmembrane, G-protein coupled 
receptor superfamily (Van Eyll et al, 1994; Thorens et al, 1992; Dillon et al, 
1993; Grazanio, et al 1993; Richter et al, 1990; Goke et al, 1988).  
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Figure 2.1.1- The proglucagon gene, localized on human chromosome 
2q36eq37.  Proteolytic processing occurs in the intestine to yield GLP-1, 
over 70% of which is secreted from intestinal L-cells in its amidated form, 
and GLP-2.  Glucagon is secreted from the pancreas (From: Yabe & Seino, 
2011). 
 
Genetic susceptibility to mutations at the GLP-1 receptor has also been 
considered. Transfection experiments whereby a single point mutation within 
a non-conserved motif of the N-terminal, extracellular domain of GLP-1 
receptor, results in impaired receptor function (Van eyll et al, 1996).   
Previous analyses of GLP-1 receptor gene polymorphisms could not show 
linkage to T2DM (Van Eyll et al, 1996; Tanizawa et al, 1994; Zhang et al, 
1994).  However, Van Eyll and co-workers state that linkage analysis is not 
sensitive enough to locate single point mutations making this an important 
finding. More recently a GLP-1R missense polymorphism at position 149 
threonine has been identified with reduced binding affinities (60-fold for GLP-
1 and 5-fold for exendin-4 (exenatide) (Beinborn et al, 2005).  It may be 
postulated that due to GLP-1’s insulinotropic action, through glucose sensing 
pathways, receptor mutations might lead to impaired glucose tolerance, a 
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feature of T2DM. Going beyond glucose regulation, this may have 
implications with regards to blood pressure regulation as GLP-1R have been 
located in the heart, vascular smooth muscle, endocardium and coronary 
endothelium, suggesting GLP-1 may be involved in important cardiovascular 
actions (Wei & Mosjov, 1995; Grieve et al, 2009). Further to this, recent 
personal communication with Novo Nordisk researchers confirmed presence 
of GLP-1R in sinoatrial node tissue which suggests GLP-1 might directly 
modulate heart rhythm.    
It has been speculated that other receptors exist which bind exenatide as it 
has been shown to initiate effects not strictly related to GLP-1 such as 
activation of vagal afferent nerves (Grieve et al, 2009). Some studies also 
demonstrate that, despite the absence of the classical GLP-1R, exenatide 
GLP-1 and exendin (9-39) were able to initiate signalling components and 
transcription (Ban et al, 2010; Ban et al, 2008). Receptors for GLP-1 are 
expressed in a vast number of tissues including the GI tract, pancreatic islet 
cells, the lung, breast, heart, central nervous system and the kidney 
(Thorens et al, 1992; Wei and Mosjov, 1995; Yu et al, 2003; Körner et al, 
2007).  
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2.2 GLP-1 and glucose homeostasis 
The most widely studied area concerning the action of GLP-1 is in the β-cell.  
In brief, this is where GLP-1 acts to induce insulin secretion in response to 
glucose stimulation.  Activation of the GLP-1 receptor stimulates adenylyl 
cyclase and the generation of cyclic adenosine monophosphate (cAMP), 
leading to activation of second messenger pathways such as protein kinase 
A (PKA) and exchange proteins activated by cAMP (Epac).  Continuous 
GLP-1 receptor activation increases insulin synthesis and beta cell 
proliferation and neogenesis (Doyle and Egan, 2007).  Various factors 
contribute to the pathogenesis of hyperglycaemia in humans.  It is widely 
understood that GLP-1R contributes to the regulation of glucose in a variety 
of tissues and therefore the potential for dysregulation of GLP-1R signalling 
in each system highlighted in Table 2.2.1 GLP-1R- mediated effects on 
glucose homeostasis may contribute to metabolic abnormalities and hence 
T2DM.  Research is making great progress into piecing together GLP-1s 
actions in individual tissues. 
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Table 2.2.1 GLP-1R- mediated effects on glucose homeostasis. 
Tissue Defect Pathophysiological 
effect 
GLP-1R 
present? 
Role in 
glucose 
homeostasis 
Pancreas- 
β cells 
Decreased 
Insulin secretion 
Fasting and postprandial 
hyperglycaemia 
Y Increase insulin 
secretion 
Pancreas- 
α cells 
Increased 
glucagon 
secretion 
Excessive stimulation of 
hepatic glucose 
production 
N  
Liver Insulin 
resistance 
Increased 
hepatic glucose 
output 
Increased fasting and 
postprandial glucose 
Y Fatty acid 
oxidation, insulin 
sensitivity 
Muscle Insulin 
resistance 
Decreased 
glucose uptake 
Increased fasting and 
postprandial glucose 
Smooth 
muscle, 
cardiac 
Release GLP-1 
intestine in 
response to food; 
ANS; No affect 
on cardiac 
glucose uptake. 
Gut Decreased GLP-
1/ GIP secretion 
Β- cell glucose 
resistance to 
GLP-1/ GIP 
Reduced postprandial 
insulin secretion 
Y Post-prandial 
glucose 
homeostasis 
Satiety 
Adipose Increased 
lipolysis 
Increased plasma free 
fatty acids, exacerbating 
insulin resistance in 
muscle and liver and 
impairing β-cells 
Y Lipolysis/ 
lipogenesis 
Beneficial effects 
on body weight 
  
Brain Neurotransmitter 
dysfunction and 
insulin 
resistance 
Impaired satiety signals 
and impaired 
neurohormonal 
signalling 
Y Increase satiety 
Haemodynamics, 
CNS effects 
 
Kidney Increased 
glucose 
reabsorption 
Increased plasma 
glucose 
Y Poorly 
understood 
 
Adapted from Defronzo et al, 2011 
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2.3 Renal effects 
At the physiological level, there is a wealth of evidence to suggest that GLP-
1 derivatives are able to produce a dose dependent effect on sodium 
handling in renal tubules in animals and man and that this confers significant 
long term blood pressure reduction in patients prescribed GLP-1 agonists 
(Gutzwiller et al, 2004, 2006; Moreno et al, 2002; Bojanowska & Stempniak, 
2003; Hirata et al, 2009; Yu et al, 2003).  For instance, Moreno and co-
workers demonstrated that recombinant GLP-1 increased urine Na+ 
excretion 13-fold in kidneys of Sprague- Dawley rats (Moreno et al, 2002).  
Kidneys of the rats were denervated and compared to that of the innervated 
animals showing a greater increase in glomerular filtration in the innervated 
animals.  This might be explained if there was GLP-1 activation of the 
sympathetic outflow and consequent renin release.  Interestingly, increased 
Na+ excretion was not postulated to be the result of hemodynamic changes 
as no significant elevations of renal hydrostatic pressure were recorded 
between innervated and denervated rats despite a 39% increase in 
glomerular filtration rate in the innervated animals.  Moreover, the elevation 
of lithium clearance in these experiments was a strong indicator that sodium 
reabsorption was being inhibited in the tubules, mechanisms for this being 
inhibition of cellular sodium transport machinery (Moreno et al, 2002; 
Thomsen et al, 1981).  Furthermore, GLP-1 receptors have been located in 
the kidney (Körner et al, 2007) and renal GLP-1 receptors have been 
identified to be primarily located in the proximal tubular cells of the cortex 
(Moreno et al, 2002; Schlatter et al, 2007). Proximal tubule cells are 
concerned with regulating sodium-reabsorption as well other factors such as 
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excretion of drugs, recycling of proteins and other nutrients, and as 
discussed previously the kidney is the main controller of long-term blood 
pressure via regulation of BV. Therefore, a reduction in sodium reabsorption 
results in higher urinary output of sodium (natriuresis) and leads to 
decreased blood volume and hence decreased blood pressure.  Surprisingly, 
there is paucity in available literature to investigate whether GLP-1 is able to 
directly inhibit sodium reabsorption. In studies using porcine and opossum 
kidney cells, Schlatter and colleagues were unable to show GLP-1, exendin 
4 and the dipeptidyl peptidase IV (DPPIV) inhibitor P32/98 (Ile-thiazolidide) 
influenced the mRNA expression of the GLP-1R, DPPIV, or sodium 
transporter molecules: NHE3, sodium-dependent glucose transporter slc5al, 
slc5a2 (SGLT1,2).  However, there was a weak suggestion that sodium 
reabsorption is inhibited by GLP-1 but this effect was not replicated by 
Exendin-4.  These findings are not robust enough to conclude that there is 
an interaction of GLP-1 with active sodium transport mechanisms involved in 
blood pressure regulation in vivo.  A weakness in Schlatter’s results may 
have been due to varying species-specific expression patterns between 
isoforms of Na+/H+ exchangers (Schlatter et al, 2007). It may be worthwhile 
to remember that GLP-1 has been postulated to increase intracellular 
messenger, cyclic adenosine monophosphate (cAMP).  For instance in the 
glucoregulatory pathways of the beta cell GLP-1 has been postulated to 
increase cAMP dependent protein kinase A (PKA); the signalling cascade 
which is also implicated in the inhibition of NHE3 depending on the presence 
of co-regulators, most notably Na+ or H+ regulatory factor (NHERF) (Figure, 
2.3.1)   (Zizak et al, 1999; Weinman et al, 2001). (Thorens et al, 1993; 
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Shigeto et al, 2008). The inability of exendin-4 to inhibit sodium reabsorption 
in the porcine model may be due to its clearance being solely a result of 
glomerular filtration rate (GFR) as exemplified in a previous study (Simonsen 
et al, 2006).  In the same study, renal clearance of GLP-1 was shown to 
involve other but not identified mechanisms in conjunction with GFR.  The 
expression of GLP-1R in kidney proximal tubules is also closely associated 
with DPPIV and therefore it might be expected that this is the site where 
GLP-1 is broken down and the constituent amino acids recycled.   Exendin-4 
has recently been demonstrated to modulate NHE3 but these experiments 
utilised higher doses (500pM Exendin-4) (Carraro-Lacroix & Girardi, 2008).   
 
Figure, 2.3.1- Signal complex regulation of NHE3 by PKA. It is suggested 
that the complex of scaffolding proteins are required for activated PKA to 
phosphorylate specific residues in the c-terminus region of NHE3.  This leads 
to inhibition of NHE3 activity. (Taken from Weinman et al, (2001). Kidney Int.  
Aug; 60(2):450 
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Hirata and co-workers attempted to elucidate the effects of exendin-4 in type 
2 diabetic (db/db; C57BLK/s; BLKs) mice and after angiotensin II (ANG II) 
infusion in non-diabetic C57BLK/6J wild type littermates (Hirata et al, 2009).  
A characteristic of the BLKs mouse is a significant increase in blood 
pressure. Salt-induced hypertension was produced in the BLKs mice by 
infusion of ANG II, which is proposed to be a key mediator of hypertension in 
diabetes (Chin et al, 2005; Shibuya et al, 2005; Crowley et al, 2005). These 
experiments demonstrate that daily injection of exendin-4 significantly 
attenuates hypertension in BLKs mice at 12 weeks.  It was also shown that 
the blunted urinary excretion of sodium seen in the BLKs mouse model in 
response to salt-loading is significantly reduced after administration of 
exendin-4 conferring in this animal model the natriuresis described in man.  
Furthermore, exendin- 4 significantly increased natriuresis and attenuated 
high salt- sensitivity in mice with salt-induced hypertension. Exendin- 4 was 
also shown to inhibit ANG II phosphorylation of ERK1/2 (a mediator of 
intracellular ANG II signalling in renal cells) in a dose dependent manner. 
Real- time PCR confirmed the expression of GLP-1 receptor (GLP-1R) in 
tissues including the kidney and that urinary excretion of cAMP was also 
elevated, suggesting that exendin-4 functionally interacts with its receptor in 
the kidneys of these mice to direct inhibition of sodium at the tubules (Hirata 
et al, 2009).  
Interestingly and in agreement with previous studies in rodents and to 
develop Schlatter’s findings further, Crajoinas and colleagues have recently 
demonstrated GLP-1 infusions into rodents to increase glomerular filtration 
rate (GFR) and renal plasma flow (RPF).  These researchers also 
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demonstrated inhibition of proximal sodium, bicarbonate and water 
reabsorption in part by inhibiting NHE3-mediated Na+/H+ exchange.  
Crajoinas demonstrated inhibition of NHE3 to be via an increase in cAMP 
and phosphorylation of the exchangers COOH-terminal region at the PKA 
consensus sites, serines 552 and 605 (Crajoinas et al, 2010).  Interestingly 
urinary excretion of both sodium and potassium occurred suggesting 
involvement of the distal tubule and collecting duct although this research 
group failed to confirm the presence of GLP-1R in this portion of the nephron 
(Crajoinas et al, 2010).   
Various reports offer conflicting information with regards to blood pressure 
regulation by GLP-1 highlighting the limitations to using many different 
species in exploratory studies (Yamamoto et al, 2002; Barragan et al, 1999) 
For example, intravenous GLP-1 (7-37) has been reported to increase heart-
rate in calves, but not arterial blood pressure in this species (Edwards et al, 
1997).  However, the same research group also demonstrated that in fasted 
healthy human subjects subcutaneous injection of GLP-1 (7-37) increased 
both blood pressure and heart rate (Edwards et al, 1998).  With regards to 
this latter finding, there is much evidence in man to suggest that blood 
pressure is reduced but heart rate is increased (Gutzwiller et al, 2004; 
Madsbad, 2004; Buse et al, 2004). For instance, clinical trial data shows a 
statistically significant decrease in blood pressure from baseline (Apovian, 
2010; Derosa, 2010; Nauck, 2009; Russell & Jones, 2009; Diamant 2010).   
2.3.1    Central control of blood pressure homeostasis 
Interestingly, GLP-1 receptors (and secreted GLP-1) have been identified in 
the hypothalamus and there is strong supporting evidence to this effect.  A 
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provocative theory is that in rodents, GLP-1 is involved in the stress (fight or 
flight) response, linking taste aversion mechanisms with that of blood 
pressure control.  This contradicts findings whereby blood pressure is 
decreased upon administration of GLP-1 derivatives. Experimental 
techniques such as route of administration, use of anaesthesia and species 
differences, may hinder direct comparison of results.  It is likely that this 
hormone is also able to perform opposing roles via central and peripheral 
mechanisms or that there could be unidentified receptor types or 
metabolites. Often hormones display opposing or dual actions.   Moreno and 
co-workers demonstrated GLP-1 to exert dual effect on the kidney in 
experiments whereby the effects of GLP-1 and an antagonist were compared 
when administered either intravenously (I.V.) or intracerebroventricularly   
(I.C.V.) (Moreno et al, 2002).  
With regards to blood pressure centres, GLP-1 receptors have been located 
in hypothalamic magnocellular neurons (Bojanowska & Stempniak, 2002), 
and the neurohypophysis and neurons of the caudal region of nucleus of the 
solitary tract in rodents (Yamamoto et al, 2002). These brain centres are 
implicated in control of diuresis and the baroreflex.  Administration of GLP-1 
or Exendin-4 into these animals has been shown to increase Fos-like 
immunoreactivity (Fos-IR) in these and related brain centres indicating that 
certain GLP-1 derivatives activate these neurons. Areas of the brain which 
were activated included the paraventricular nucleus of the hypothalamus 
which is responsible for regulating diuretic responses by the kidney. 
Secretion of vasopressin by PVH acts on V2 receptors which are mainly 
located in the renal collecting ducts and initiates adenyl cyclase, resulting in 
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an increase of cytosolic cAMP.  Vasopressin acts as an antidiuretic hormone 
through the V2 receptor whereby it increases water permeability of the apical 
membrane of the distal nephron, hence increasing water absorption. This 
results in a decrease in plasma osmolarity causing an increase in atrial 
natriuretic peptide (ANP) secretion (Marunaka et al, 1997). Other areas 
involved in activation by GLP-1 are, the locus coeruleus and A5 
catecholamine group, responsible for synthesis of noradrenaline and hence 
initiation of the “fight or flight” response; and the rostral ventrolateral medulla, 
principally involved in regulation of blood pressure via innervation of the 
sympathetic nervous system and baroreceptors. Neurons containing 
corticotropin- releasing hormone in PVH are also stimulated, increasing 
plasma corticosterone and the chronotropic and pressor response. GLP-1 (7-
36) has been shown to increase basal levels of neurohypophysial hormones 
in normotensive rats and rats undergoing hypovolemia (Larson et al, 1997, 
Bojanowska & Stepniak 2000; Barragan et al, 1999). 
Yamamoto and co-workers showed that centrally and peripherally 
administered GLP-1 increases blood pressure and heart rate and appears to 
be mediated through sympathetic preganglionic neurons via activation of c-
fos expression in the adrenal medulla and catecholamine receptors in the rat 
brain.  These results suggest an adrenergic response to GLP-1 (Yamamoto 
et al, 2002).  However, contrary to this, Barragan and co-workers suggest a 
noradrenergic response (Barragan et al, 1994).  It was later proposed that 
GLP-1 may produce opposing effects because it was demonstrated in rats 
that vasoconstriction mediated by β-adrenoceptor and tachycardia occurs as 
a result of sympatho-adrenal activation. It was suggested that both α- and β-
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adrenoceptors are involved except during mesenteric vasoconstriction or the 
receptors for vasopressin or angiotensin (Gardiner et al, 2006). It is a strong 
possibility that GLP-1 displays a dual response and is able to contribute to a 
decrease blood pressure via the kidneys, and finely tune this action through 
the central nervous system responses.   In this way, blood pressure is 
regulated within a narrow index.  Considering this, it appears likely that 
contradictory findings in animals and humans are in part a result of 
limitations of animal models or experimental differences, such as condition or 
preparation of the subject or animal before the treatment or the effect of 
variables, not controlled for in the experiment. 
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3.0 Aims of the thesis 
The ability of GLP-1R agonists to normalise post-prandial blood glucose 
excursions, with a low incidence of hypoglycaemia offers great promise in 
the treatment of T2DM.  Of special interest is the potential for this class of 
agent to decrease body weight and blood pressure.  The aims of this thesis 
are to: 
1.  Explore the effects of GLP-1 agonists on blood pressure heart rate and 
body weight through conducting a meta-analysis of clinical trials. 
2. To evaluate the effects of obesity and diabetes- like conditions on GLP-1R 
expression in the murine kidney. 
3. To establish that GLP-1R is functional in human kidney cell lines. 
4. To ascertain whether hyperglycaemia influences renal GLP-1R in whole 
kidney and in human renal cells. 
5. Perform a mechanistic study to assess the effects of GLP-1 on α-ENaC 
mRNA and protein expression and signalling in cells of the human collecting 
duct.      
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4.0 Effects of Exenatide and Liraglutide on heart rate, 
blood pressure and body weight: Systematic review 
and meta-analysis 
4.1 Introduction 
In contrast to the weight increasing effects of several traditional anti-diabetic 
drug classes, GLP-1 analogues have been shown to reduce both body 
weight and blood pressure (Nathan et al, 2009; Vilsbøll et al, 2009). The 
mechanisms producing weight loss have been extensively investigated, and 
involve improved satiety and reduced calorie ingestion both through effects 
on the central nervous system and through delayed gastric emptying (Flint et 
al, 1998; MacDonald et al, 2001; Williams et al, 1996; Meier & Nauck, 2005). 
Mechanisms leading to reduced blood pressure are less adequately 
understood, but this effect has been shown to occur as early as two weeks 
after commencing therapy, preceding significant weight loss, suggesting that 
a direct hypotensive effect is at least partly responsible (Varanassi et al, 
2011). The blood pressure response to GLP-1 agonists is more modest than 
effects on weight loss but has been reported to be beneficial.   Experimental 
studies of GLP-1 analogues have also reported direct effects on blood 
pressure, possibly via interaction with the autonomic nervous system 
(Bojanowska & Stepniak, 2003).   
Whilst a number of studies have reported heart rate increases, the majority 
of published reports show only very small overall increases of up to 3 bpm 
and given the safety implications attributed to raised heart rate in other 
contexts, there is a surprising lack of concern over its possible implications in 
long-term treatment of diabetes patients (Levine, 1997; Aronow, 1996; 
Hozawa et al, 2004; Anselmino et al, 2010). A recent review of liraglutide by 
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Buse acknowledges the effect, but a meta-analysis on safety of incretin 
based therapies published in 2010 did not mention it, nor does an overview 
of the LEAD trials of liraglutide by Blonde and Russell-Jones (Bode et al, 
2012; Fakhoury et al, 2010; Blonde & Russell- Jones, 2009). A large 
nationwide audit of exenatide designed by the Association of British Clinical 
Diabetologists (ABCD) and supported by Eli Lilly did not include it as an 
outcome despite citing evidence for the effect in the main published report 
(Ryder et al, 2010; Gill et al, 2010). A subsequent (on-going) ABCD audit of 
liraglutide also aims to identify unknown safety issues but has similarly 
omitted this outcome from the protocol (ABCD audit, 2012). 
GLP-1 analogues are an expanding drug class, with recent development of 
longer acting agents including the once weekly form of exenatide, Bydureon. 
This drug has recently obtained approval from the National Institute of Health 
and Clinical Excellence for use in type 2 diabetes and its use is likely to 
increase (NICE, 2012). A review of trial data from five long acting GLP-1 
agonists (exenatide once weekly, taspoglutide, albiglutide, LY2189265 and 
CJC-1134-PC) concluded that they were more likely than shorter acting 
formulations to raise heart rate (Madsbad et al, 2011). A more recently 
published study of the long acting GLP-1 agent  PF-04603629 reported a 
substantial rise in heart rate (mean increase 23 bpm at 24 hours after 
injection of the higher dose studied), together with a rise in diastolic blood 
pressure (Gustarson et al, 2011).  Mechanisms to an increase in heart rate 
are not fully understood, but may be a direct result of autonomic activation 
with antagonism of vagus tone or secondary to metabolic and/ or blood 
pressure effects of the agents. 
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Whilst there is no evidence to date that these agents (short or long acting) 
increase cardiovascular event rates, safety data are limited by short follow up 
duration (Ratner et al, 2011). Longer term follow up is underway but will take 
a number of years to complete. 
We aimed to identify and synthesise all available heart rate data from both 
published and unpublished sources, to quantify the effect of GLP-1 
analogues on this outcome, as well as that on blood pressure and body 
weight.  
4.2 Methods 
4.2.1 Literature searches 
The following resources were systematically searched to identify completed, 
new or on-going controlled trials: Clinical Trials Gov (www.clinicaltrials.gov); 
Entertrials.co.uk; Clinicaltrialssearch.org; Centerwatch; Drugsontrial; 
WebMD; MEDLINE (1960- date); EMBASE (1960- date); The Cochrane 
Library Central Register of Controlled Trials (CENTRAL).  We used a search 
strategy to capture “exenatide”, “liraglutide” or “glucagon-like peptide-1” in 
any field, limited to “Randomised” or “Controlled Clinical Trial”. Conference 
proceedings (British Endocrinology Society, Diabetes UK European 
Association for the Study of Diabetes) and websites (American Diabetes 
Association, Federal Drug Agency and European Medicines Agency) were 
examined, and the reference lists of trials, meta-analyses and reviews were 
searched for further studies.  Novo Nordisk and Ely Lilly were contacted 
directly to request unpublished data. 
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4.2.2 Inclusion and exclusion criteria 
a) Participants 
We included only trials involving participants with type 2 diabetes. Diagnosis 
of T2DM should have been established using up-to-date standard diagnostic 
criteria from the beginning of the trial (e.g. ADA, 2008), evidence of HBA1c 
indicative of T2DM using standard diagnostic criteria, or patients using oral 
anti-diabetic therapy (OADs) for at least 3 months prior to screening. 
b) Study designs 
Randomised trials with >12 weeks.  Long term trials were excluded based on 
the design not comprising a comparator arm.  
c) Intervention(s) 
Trials of clinically relevant doses of liraglutide (1.2 or 1.8 mg daily), exenatide 
(5 or 10 µg twice a day), or exenatide once- weekly, either alone or in 
combination with an oral anti-diabetic drug (OAD) were included. 
c) Comparison groups(s) 
Comparators included placebo, continuous OAD, lifestyle intervention, or 
basal insulin. 
d) Outcomes  
We included all phase 2 and 3 studies (not including open-label extensions) 
reporting blood pressure, body weight and/or heart rate outcomes.  
4.2.3 Data extraction 
Studies were retrieved by two researchers independently and both 
researchers contacted trial organisers for missing data. We assessed studies 
for inclusion using the above criteria. Mean effect data from cross-over trials 
were extracted at the end of the initial phase.   
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4.2.4 Risk of Bias 
Risk of bias was assessed for each included study according to criteria 
described in Cochrane Handbook for Systematic reviews version 5 (Higgins, 
2011), below: 
A) Randomisation: A trial was considered to be of “low risk of bias”, if there 
was evidence of random sequence generation by a computer or web based 
automated system, or referring to a random number table.  The trial met the 
criteria of “high risk of bias” when random sequence generation was based 
on a series of laboratory tests or a rule based on treatment centre, clinician 
judgement or similar. 
B) Allocation concealment: Trials were assigned “low risk” when a central 
allocation method was used (a computer or web based automated system), 
opaque coded envelopes or other similar approach.  The trial met the criteria 
of “high risk of bias” when an open allocation schedule or other such method 
was employed.  
C) Blinding of participants/ investigators/ sponsors: Trials were 
considered to be of “low risk of bias” when blinding of the participants and 
investigators were described and it was considered unlikely that blinding had 
been broken; or when the study was not blinded but it was unlikely that the 
outcome was influenced by lack of blinding. Trials met the criteria of “high 
risk of bias” when no blinding or incomplete blinding occurred; there was a 
high risk of the outcome being influenced by lack of blinding or that blinding 
had been broken. 
 D) Blinding outcome assessment: Trials met the criteria of “low risk of 
bias” when blinding of outcome was described, or in trials where blinding did 
not occur, this was not considered to influence the outcome measurement. 
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Trials met the criteria of “high risk of bias” when no blinding occurred or there 
was evidence that blinding was broken. 
E) Incomplete outcome data: The trials met the criteria of “low risk of bias” 
when there were no missing outcome data, where attrition was well balanced 
between trial arms, and where effect size was not altered by the missing 
outcome (results of the trials were plausible) or that reasons for missing data 
were not related to true outcome.  The trial met the criteria of “high risk of 
bias” when reasons for the missing outcome data are related to true outcome 
(for example, participant drop-outs due to nausea when assessing the effects 
on patients’ tolerability), with an imbalance of numbers across groups; the 
effect size is directly related to missing outcome and introduces “favourable” 
results; application of an unsuitable imputation or other plausible reason for 
high risk criteria to be met.  
 F) Selective outcome reporting: The trials met the criteria of “low risk of 
bias” when the study protocols were available and all outcome data was 
reported within a pre-specified criteria; or a protocol was not available but it 
is clear that the trials report the outcomes of interest in a pre-specified way.  
The criteria of “high risk of bias” was met when the trials failed to report all 
pre-specified outcomes; the reported outcome measurement, analysis 
differed from those pre-specified; negative results or results lacking statistical 
significance were not reported or that data was incomplete, preventing 
assessment by meta-analysis.  
G) Other bias: Any other bias which I considered might influence the 
outcomes of the trials.  
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The criteria of “unclear risk of bias” was met when trial authors failed to 
describe the methods employed or the trials could not be classified as either 
“low” or “high” risk of bias. 
Where appropriate, the Cochrane risk of bias tool was used to assess risk of 
bias items at the level of the specific outcomes were performed. I assessed 
bias using funnel plots. A funnel plot is able to detect publication bias, poor 
methodological design of small studies or true heterogeneity of effect due to 
trial size which is depicted by asymmetry of the funnel plot (Higgins, 2011).  
Due to the subjective approach to the analysis, minimal emphasis was 
placed on findings from analysis of funnel plots.    Prior to undertaking the 
analysis, I planned to compare pooled mean differences and 95%CI of the 
completer groups against intention-to treat populations.  Intention-to treat 
group numbers will be shown in forest plots and described in the results 
section  
4.2.5 Analysis 
I undertook all data analyses. For our quantitative meta-analyses, we 
excluded ‘open-label’ extension studies of phase 3 trials because such trials 
are less well controlled and do not include a comparator arm. Means and 
standard deviations for baseline and outcome values for blood pressure, 
heart rate and body weight were extracted.  Where standard deviations for 
the outcome were not available they were imputed according to Cochrane 
Handbook for Systematic reviews version 5 (Higgins, 2011).  Where change 
from baseline measurements and the corresponding standard deviations 
were not available, these were calculated, taking into account the correlation 
of baseline to follow up measurements within individuals.  In instances where 
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the correlation coefficient could not be calculated, methods were employed 
as recommended by Follman (Follman, 1992).  
Study results were combined using RevMan version 5.2. Heterogeneity was 
estimated using the χ2- test and I2 statistic (95%CI) and repeated for 90%CI 
to enhance detection of heterogeneity. Interaction effects were evaluated 
using pre-specified subgroup analyses (comparing various doses of study 
drug to active control or placebo) and type of GLP-1 agonist (liraglutide once 
daily, exenatide twice daily and exenatide once weekly (ExLAR) 
preparations).  Sensitivity analyses were planned only to investigate clinical, 
methodological or statistical heterogeneity.  
A synthesis of all available studies for each outcome was conducted.  For 
these analyses, multiple comparison trials such as those featuring placebo 
and active control arms, data from placebo were preferentially entered into 
the analysis. Similarly, highest dose of GLP-1 agonist; and active 
comparators considered to be most “neutral” with respect to outcome were 
preferred.  
Initially, both the fixed and random effects models were applied using the 
inverse variance statistical approach for combining studies with 95% 
confidence intervals.  Results using the random effects model are reported.  
This approach was considered appropriate as high heterogeneity were 
expected due to differences in background therapy, patients’ characteristics 
and other clinical variables. If the results from random and fixed effects 
differed, results from fixed effects analyses are also described.  Where there 
was evidence of high inter-trial heterogeneity, pooled results are reported 
with appropriate caution. 
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4.3 Results 
We identified 520 articles through the initial searches.  Of these, 471 were 
excluded on the basis of the title or abstract being irrelevant to the aims of 
this review.  Forty-nine studies were examined full text. Out of these studies, 
8 studies were open-label extension trials, 6 were excluded either because 
the comparator was another form of GLP-1 (2 studies), the doses were not 
as specified in our inclusion criteria (2 studies), or because the study was a 
duplicate of an included trial, in which case we chose the primary source (2 
studies). This left 35 trials included in our review (Table 4.3.0.1 
Characteristics of included studies).  Of the included trial publications, the 
preferred method was to describe data which was derived using intention-to 
treat population with last observation carried forward (LOCF) with 2 studies 
describing per protocol or full analysis set.   Eleven of the thirty- five included 
trials measured heart rate as a primary or secondary outcome.  We were 
able to gain access to heart rate data from 5 Liraglutide studies (Lead 1-5) 
and also 4 Exenatide trials (equating to 82% of the total heart rate data), 
either through publication searches or direct contact with the trial organisers.  
Similarly, we obtained data from 85% (17 out of 20 studies) which measured 
systolic and diastolic blood pressure; and 19 studies measuring body weight.  
The majority of missing data was kindly supplied to us by trial coordinators.  
Heart rate and blood pressure data from a further 8 exenatide trials were 
kindly requested for the study (Barnett et al, 2007; Buse et al, 2004; Davies 
et al, 2009; Defronzo et al, 2005; Defronzo et al, 2010; Gao et al, 2009; 
Gallwitz et al, 2011; Kendall et al, 2005).  However, data had been collected 
as part of trial safety assessments, and were not designated primary or 
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secondary outcomes.  Appropriate power calculations had not been 
incorporated into the trial designs for these measurements. 
Of the included studies, there was a high amount of clinical heterogeneity 
(e.g. differences in patients’ characteristics, background OAD therapy) and 
methodological heterogeneity (e.g. blinding, allocation concealment) (Table 
4.3.0.1 PRISMA flow diagram; Table 4.3.0.2 Characteristics of included 
studies; Table 4.3.1.1 Risk of bias across included studies).  
 
 
Table 4.3.0.1 PRISMA flow diagram 
 
Table 4.3.0.2. Characteristics of included studies 
Study Comparisons Duration 
(weeks) 
Study 
population
/ethnicity 
Country 
 
Body weight 
groups 
included 
Balanced 
Male/ 
Female? 
Mean age Standardised 
diet/ exercise 
Background 
OAD 
Apovian, 
2010 
EX/PLAC 24 MR US OW >60% F 54.8 Y MET and/or 
SU 
Barnett, 
2007 
EX/IG 16 MR Multi-
national 
N/OW/ 
OB 
Y 54.9 N MET or SU 
Bergenst
al, 2009 
EX/BIAsp 24 MR US N/OW Y 52.6 N MET and 
SU 
Bergenst
al, 2010 
EX LAR vs 
PIO 
EX LAR vs 
SITA 
26 MR Multi-
national 
N/OW/ 
OB 
Y 52.3 N MET 
Buse, 
2004 
EX/PLAC 30 MR US OW/OB 60% M 55.3 N SU 
Buse, 
2011 
IG+EX/ 
IG+PLAC 
30 MR Multi-
national 
N/OW/ 
OB 
Y 59.0 N MET or PIO 
Davies, 
2009 
EX/IG 26 MR GB OW/OB >60% M 56.5 N Two or 
three 
OADS: 
MET, SU, or 
TZD 
Defronzo, 
2005 
EX/PLAC 30 MR US OW/OB Y 53.0 N MET 
Defronzo, 
2010 
EX vs ROSI 20 MR US OW/OB Y 56.0 N MET 
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Study Comparisons Duration 
(weeks) 
Study 
population
/ethnicity 
Country 
 
Body weight 
groups 
included 
Balanced 
Male/ 
Female? 
Mean age Standardised 
diet/ exercise 
Background 
OAD 
Derosa, 
2010 
EX/GLIB 52 W IT OW/OB Y 56.5 Y MET 
Derosa, 
2011 
EX/GLIM 52 CAUC IT OW/OB Y 55.5 Y MET 
Diamant, 
2010 
EX LAR/IG 26 MR Multi-
national 
OW/OB Y 58.0 N MET 
Gallwitz, 
2011 
EX/BIAsp 26 MR GER OW/OB Not reported 57.0 N MET 
Gallwitz 
2012 
EX/GLIM Up to 
4.5 
years 
MR Multi-
national 
OW/OB Y 56.0 N MET 
Gao, 
2009 
EX/PLAC 12 C/I/K/T Multi-
national 
N/OW/ 
OB 
Y 54.0 N MET and/or 
SU 
Garber, 
2009 
LIR/GLIM 52 MR US/ME
X 
N/OW/ 
OB 
Y 53.0 N Nil - 
previous 
OAD 
withdrawn 
Gill, 
2010 
EX/PLAC 12 MR CAN/N
L 
OW/OB Y 55.6 N MET and/or 
TZD 
Heine, 
2005 
EX/IG 26 MR Multi-
national 
OW/OB Y 58.9 N MET and 
SU 
Kadowaki
, 2009 
EX/PLAC 12 JP JP N/OW/ 
OB 
>60% M 60.3 N SU, with or 
without 
either BG or 
TZD 
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Study Comparisons Duration 
(weeks) 
Study 
population
/ethnicity 
Country 
 
Body weight 
groups 
included 
Balanced 
Male/ 
Female? 
Mean age Standardised 
diet/ exercise 
Background 
OAD 
Kendall, 
2005 
EX/PLAC 30 MR US OW/OB Y 55.3 Y MET and 
SU 
Kim, 
2007 
EX 
LAR/PLAC 
15 MR US OW/OB 60% M 53.7 Y MET 
Liutkus, 
2010 
EX/PLAC 26 MR Multi-
national 
OW/OB Y 54.7 N TZD with or 
without MET 
Marre, 
2009 
LIR/PLAC/RO
SI 
26 MR Multi-
national 
N/OW/ 
OB 
Y 56.0 N SU  
Moretto, 
2008 
EX/PLAC 24 MR Multi-
national 
OW/OB Y 54.0 Y DRUG 
NAIVE 
Nauck, 
2007 
EX/PIA 52 MR Multi-
national 
OW/OB Y 58.5 N SU and 
MET 
Nauck, 
2009 
LIR/GLIM/PL
AC 
26 MR Multi-
national 
N/OW/ 
OB 
Y 56.7 N MET 
Pratley, 
2010 
LIR/SIT 26 MR Multi-
national 
N- OW-OB Y 55.3 N MET 
Russell-
Jones, 
2009 
LIR/IG/PLAC 26 MR Multi-
national 
N/OW/ 
OB 
Y 57.5 N MET and 
SU 
Russell-
Jones, 
2012 
EX LAR/MET 
EX LAR/PIO 
EX LAR/SITA 
26 MR Multi-
national 
N/OW/ 
OB 
Y 54.0 N DRUG 
NAIVE 
Yang, 
2011 
LIR/GLIM 16 C/K/I Multi-
national 
N/OW/ 
OB 
Y 53.3 N MET 
Zinman, 
2007 
EX/PLAC 16 MR Multi-
national 
OW/OB Y 56.1 N TZD with or 
without MET 
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Study Comparisons Duration 
(weeks) 
Study 
population
/ethnicity 
Country 
 
Body weight 
groups 
included 
Balanced 
Male/ 
Female? 
Mean age Standardised 
diet/ exercise 
Background 
OAD 
Zinman, 
2009 
LIR/PLAC 26 MR  US/CA
N  
N/OW/ 
OB 
Y 55.0 N MET and 
ROSI 
EX, Exenatide; EX LAR, Exenatide long acting release; PLAC, placebo; IG, insulin glargine; BIAsp, biphasic insulin aspart; PIO, 
pioglitazone; SITA, sitagliptin; ROSI, rosiglitazone; GLIB, glibenclamide; GLIM, glimepiride; LIR, liraglutide; MET, metformin, BG, 
Biguanide. 
MR, Multi-racial; C, Chinese; K, Korean; I, Indian; T, Taiwanese; JP, Japanese; W, White; CAUC, Caucasian. 
GB, Great Britain; US, United States; GER, Germany; CAN, Canada; JP, Japan; NL, Netherlands; MEX, Mexico; IT, Italy. 
N, normal weight; OW, overweight; OB, obese.
4.3.1 Methodological quality and risk of bias 
The assessment of funnel plots showed satisfactory symmetry. Risk of bias 
for each of the included studies is shown in Table 4.3.1.1 Risk of bias 
across included studies. None of the trials were terminated prematurely 
and all trials included sample size calculations relevant to primary and/or 
secondary outcomes.  
Assessment of bias of the 32 included studies showed 31 studies to describe 
randomisation in sufficient detail and 1 study was allocated unclear risk; All 
studies reported allocation concealment in sufficient detail; 19 studies were 
blind and 13 studies were either partially blind (e.g. to investigator or 
statistician) or open label.  Of these studies, blinding of outcome assessment 
was adequate for 20 but not sufficiently described for 12 studies; Losses to 
follow up were adequately described for 23 studies,  9 studies were 
considered “unclear risk” due to attrition rates being higher than the generally 
accepted value of 20%; 23 studies reported all outcomes numerically.  A 
further 9 studies either did not report all outcomes, for instance, those which 
were not significant or the trial arms were not balanced; 3 studies showed 
potential for “other biases” which were, changes to maximum dose regimes 
due to country where the investigation took place, higher weight loss due to 
nausea and diet and exercise regime not standardised. 
 
 
 
Table 4.3.1.1 Risk of bias across included studies. 
 
Included studies were assessed using the Cochrane Risk of Bias Tool for factors which may cause bias in the trial outcomes and 
subsequent evaluation by meta-analysis: A) Randomisation, B) Allocation concealment, C) Blinding of 
participants/investigators/sponsors, D) Blinding outcome assessment, E) Incomplete outcome data, F) Selective outcome reporting, 
G) Other bias. 
No.  Study A B C D E F G Comments 
1 Apovian, 
2010ǂ 
-------- -------- -------- -------- -------  -------- -------- Greater than 20% attrition. 
2 Barnett, 
2007*ǂ 
-------- -------- ------- -------- -------- -------- -------- Open label cross-over study.  
3 Bergenstal, 
2009*ǂ 
-------- -------- ------- ------- ------- ------- -------- Open label. Greater than 20% attrition and higher 
attrition in exenatide group. 
4 Bergenstal, 
2010ǂ 
-------- -------- -------- -------- ------- -------- ------- Greater than 20% attrition. Blinding removed after 
finalisation of analysis plan. 
5 Buse, 2004 -------- -------- -------- -------- ------- ------- --------  Greater than 20% attrition. Higher attrition in the 
placebo arm. 
6 Buse, 
2011ǂ 
------- -------- -------- -------- -------- -------- -------- Groups not balanced for sex and concomitant 
medication. 
7 Davies, 
2009* 
-------- -------- ------- ------- -------- -------- -------- Open label. 
8 Defronzo, 
2005 
-------- -------- -------- -------- -------- -------- --------  
9 Defronzo, 
2010*ǂ 
-------- -------- ------- ------- ------- -------- -------- Open label. Greater than 20% attrition. 
Page 68 of 192 
 
No.  Study A B C D E F G Comments 
10 Derosa, 
2010 
-------- -------- ------- ------- -------- -------- -------- Single blind. 
11 Derosa, 
2011ŧ 
-------- -------- ------- ------- -------- -------- -------- Single blind.  
12 Diamant, 
2010*Ȣ 
-------- -------- ------- ------- -------- ------- -------- Open label. Higher attrition in the exenatide arm. 
13 Gallwitz, 
2011* 
-------- -------- ------- ------- -------- -------- -------- Open label. 
14 Gallwitz 
2012* 
-------- -------- ------- ------- ------- ------- -------- Open label. Greater than 20% attrition. Higher 
attrition in the exenatide arm. 
15 Gao, 2009ǂ -------- -------- -------- -------- -------- -------- --------  
16 Garber, 
2009ǂ 
-------- -------- -------- -------- ------- -------- -------- Greater than 20% attrition. 
17 Gill, 2010 -------- -------- -------- -------- -------- -------- --------  
18 Heine, 
2005* 
-------- -------- ------- ------- -------- ------- -------- Open label. Higher attrition in the exenatide arm. 
19 Kadowaki,¥ 
2009 
-------- -------- -------- -------- -------- -------- --------  
20 Kendall, 
2005 
-------- -------- -------- -------- -------- -------- --------  
21 Kim, 2007 -------- -------- -------- -------- -------- -------- --------  
22 Liutkus, 
2010¥ 
-------- -------- -------- -------- -------- -------- --------  
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No.  Study A B C D E F G Comments 
23 Marre, 
2009 
-------- -------- -------- -------- -------- ------- ------- Higher attrition in the placebo arm. Restriction of 
glimipiride and rosiglitazone in some countries 
precluded maximal dose regimes.  
24 Moretto, 
2008 
-------- -------- ------------ -------- -------- -------- ------- Diet and exercise regimes not standardised. 
25 Nauck, 
2007*ǂ 
-------- -------- ------- ------- -------- -------- -------- Open label. 
26 Nauck, 
2009ǂ 
-------- -------- ------------ ------------ ------------ ------- -------- Higher attrition in Liraglutide 1.8 mg and placebo 
arms. 
27 Pratley, 
2010* 
-------- -------- ------- -------- -------- -------- -------- Open label, but statistician was masked to the 
allocation.  
28 Russell-
Jones, 
2009*ǂ 
-------- -------- ------- ------- -------- -------- -------- Insulin glargine arm-open label.  
29 Russell-
Jones 
2012ǂ 
-------- -------- -------- -------- -------- -------- --------  
30 Yang, 2011 -------- -------- ------------ ------------ ------------ ------- -------- Higher attrition in the liraglutide groups.  
31 Zinman, 
2007 
-------- -------- ------------ ------------ ------- ------- -------- Greater than 20% attrition. Higher attrition in 
exenatide group. 
32 Zinman, 
2009 
-------- -------- ------------ ------------ ------- ------- ------------ Greater than 20% attrition. Higher attrition in 
placebo group. 
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* Open label; ǂ method of randomisation/allocation concealment consisted of a computer random-number generator and voice-response or 
telephone system; Ȣ permuted block randomisation; ¥ randomised according to baseline biochemical values or background pharmacological 
agent; ŧ randomised according to coded envelopes designed by a statistician – high risk; -- low risk; -- unclear risk. 
 
4.3.2 Blood pressure and heart rate 
We were able to obtain heart rate data directly from Novo Nordisk for 5 out of 
8 liraglutide studies (62.5% of trials) (Garber et al, 2009; Marre et al, 2010; 
Nauck et al, 2009; Russell-Jones et al, 2009; Zinman et al, 2009; Feinglos et 
al, 2005; Yang et al, 2011; Pratley et al, 2010).  It is not known whether the 
remainder of the studies measured a significant heart rate effect. Novo 
Nordisk provided the data grouped into quartiles of baseline heart rate 
(Figure 4.3.2.1 Effect of GLP-1 agonists on heart rate in patients with 
type 2 diabetes).  Pooled results show liraglutide to produce an increase in 
heart-rate versus placebo, weighted mean difference 2.71 beats per minute 
[N= 2056, 95% CI, 1.45, 3.97], heterogeneity, random effects: Chi² = 13.34, 
df = 6 (P = 0.04); I² = 55%, versus placebo.  Heterogeneity was reduced to 
acceptable limits when Marre, 2009 (Lead 1) was removed from the analysis.  
However, removal of this study did not significantly alter the strength or 
direction of effect.  
Similarly, and although sponsors were very willing to assist this meta-
analysis, we were only able to obtain data from 88% of trials measuring the 
effects of exenatide on heart rate.  Pooling of exenatide trials did not result in 
a significant increase in heart rate, -0.88 bpm [N= 1652, 95%CI, -0.47, 2.22; 
I2= 40%], versus placebo.  Slight statistically significant increases were seen 
compared to active control, 1.36 bpm [N= 4803, 95%CI, 0.57, 2.14, I2= 37%], 
with exenatide once- weekly formulations (ExLAR) showing the highest 
increases in heart rate, 2.14 bpm [N=1776, 95%CI, 1.11, 3.17] (Figure 
4.3.2.1 Effect of GLP-1 agonists on heart rate in patients with type 2 
diabetes).  
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Overall, GLP-1 agonists’ raised heart rate by a small but statistically 
significant extent, 1.86 bpm [N=3708, 95%CI, 0.85, 2.87, I2= 57%], versus 
placebo.  No effect on pooled mean differences or confidence intervals were 
observed due to patients lost- to- follow- up, and also when fixed effects 
approach was employed. 
We included 25 (90%) of trials reporting systolic blood pressure and 22 
(78%) of trials reporting diastolic blood pressure outcomes.  GLP-1 agonists 
show a favourable effect on blood pressure.  Liraglutide and exenatide 
produced comparable reductions in systolic blood pressure of 2-4 mmHg. 
Heterogeneity was fairly high (I2=45%, I2=57% GLP-1 agonists’ vs placebo 
and active control groups respectively.  In the GLP-1 agonists’ versus 
placebo group inter-trial heterogeneity was reduced to acceptable levels after 
removal of Gao, 2009 and Kadowaki, 2009. Similarly, the source of 
heterogeneity in the GLP-1 agonists’ versus active control groups appeared 
to be Barnett, 2007 and Defronzo, 2010.    Removal of these studies did not 
significantly alter the strength or direction of the effect. (Figure 4.3.2.2 GLP-
1 agonists’ effect on systolic blood pressure in patients with type 2 
diabetes).  
Sensitivity analysis to assess inclusion of included studies whereby blood 
pressure and heart rate was measured for patient safety did not alter the 
strength or direction of these outcomes (Barnett, 2007; Buse, 2004; Davies, 
2009; Defronzo, 2005; Gao, 2009; Gallwitz, 2011; Kendall, 2005). 
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Figure 4.3.2.1 Effect of GLP-1 agonists on heart rate in patients 
with type 2 diabetes: 
 
i) Heart rate change from baseline to endpoint in patients undergoing 
Liraglutide therapy for <30 weeks, stratified by baseline blood pressure 
(from Novo Nordisk) 
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a) Liraglutide versus placebo using a random effects model 
ii) Data from Lead1-5 studies: Liraglutide versus placebo in T2DM 
patients stratified by baseline heart rate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study or Subgroup
1.1.1 Liraglutide 1.2 mg vs placebo
Q1 Baseline HR ≤ 68 b.p.m
Q2 68 < Baseline HR ≤ 74
Q3 74 Baseline HR ≤ 80
Q4 Baseline HR > 80
Subtotal (95% CI)
Heterogeneity: Tau² = 1.09; Chi² = 4.72, df = 3 (P = 0.19); I² = 36%
Test for overall effect: Z = 2.74 (P = 0.006)
1.1.2 Liraglutide 1.8 mg vs placebo
Q1 Baseline HR ≤ 68 b.p.m
Q2 68 < Baseline HR ≤ 74
Q3 74 Baseline HR ≤ 80
Q4 Baseline HR > 80
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.10, df = 3 (P = 0.55); I² = 0%
Test for overall effect: Z = 4.57 (P < 0.00001)
Total (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 7.28, df = 7 (P = 0.40); I² = 4%
Test for overall effect: Z = 5.59 (P < 0.00001)
Test for subgroup differences: Chi² = 0.39, df = 1 (P = 0.53), I² = 0%
Mean
8.5
3.5
0.4
-5.5
8.2
4.2
0.9
-3.4
SD
8.9
8.9
8.9
8.9
8.4
8.4
8.4
8.4
Total
233
168
192
149
742
284
220
234
192
930
1672
Mean
3.7
1.7
-1.1
-6.6
3.7
1.7
-1.1
-6.6
SD
8.3
8.3
8.3
8.3
8.3
8.3
8.3
8.3
Total
50
50
50
38
188
49
50
49
38
186
374
Weight
13.4%
12.5%
12.8%
9.9%
48.6%
13.9%
13.5%
13.4%
10.6%
51.4%
100.0%
IV, Random, 95% CI
4.80 [2.23, 7.37]
1.80 [-0.87, 4.47]
1.50 [-1.12, 4.12]
1.10 [-1.90, 4.10]
2.37 [0.67, 4.07]
4.50 [1.98, 7.02]
2.50 [-0.05, 5.05]
2.00 [-0.56, 4.56]
3.20 [0.31, 6.09]
3.05 [1.74, 4.36]
2.74 [1.78, 3.70]
Liraglutide Placebo Mean Difference Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Placebo Liraglutide
Page 75 of 192 
 
iii) Liraglutide versus placebo including dose subgroups 
 
 
iv) Exenatide versus placebo including dose subgroups 
 
 
 
 
Study or Subgroup
1.2.1 Liraglutide 1.2 mg vs placebo
Marre, 2009
Nauck 2009
Zinman 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.69; Chi² = 2.98, df = 2 (P = 0.23); I² = 33%
Test for overall effect: Z = 2.86 (P = 0.004)
1.2.2 Liraglutide 1.8 mg vs placebo
Marre, 2009
Nauck 2009
Russell- Jones, 2009
Zinman 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 2.90; Chi² = 10.09, df = 3 (P = 0.02); I² = 70%
Test for overall effect: Z = 2.90 (P = 0.004)
Total (95% CI)
Heterogeneity: Tau² = 1.58; Chi² = 13.34, df = 6 (P = 0.04); I² = 55%
Test for overall effect: Z = 4.22 (P < 0.0001)
Test for subgroup differences: Chi² = 0.18, df = 1 (P = 0.67), I² = 0%
Mean [bpm]
2.49
2.13
2.4
4.54
2.07
2.21
3.12
SD [bpm]
8.9
8.9
8.9
8.4
8.4
8.4
8.4
Total
228
240
178
646
234
242
230
178
884
1530
Mean [bpm]
-1.55
1.06
0.25
-1.55
1.06
0.19
0.25
SD [bpm]
8.3
8.3
8.3
8.3
8.3
8.3
8.3
Total
57
60
89
206
57
61
114
88
320
526
Weight
13.2%
13.5%
14.7%
41.4%
13.4%
13.7%
16.6%
15.0%
58.6%
100.0%
IV, Random, 95% CI [bpm]
4.04 [1.60, 6.48]
1.07 [-1.31, 3.45]
2.15 [-0.01, 4.31]
2.39 [0.75, 4.03]
6.09 [3.68, 8.50]
1.01 [-1.33, 3.35]
2.02 [0.15, 3.89]
2.87 [0.74, 5.00]
2.95 [0.96, 4.94]
2.71 [1.45, 3.97]
Liraglutide Placebo Mean Difference Mean Difference
IV, Random, 95% CI [bpm]
-10 -5 0 5 10
Placebo Liraglutide
Study or Subgroup
1.3.1 Exenatide 5mcg vs placebo
Buse, 2004
DeFronzo, 2005
Subtotal (95% CI)
Heterogeneity: Tau² = 5.89; Chi² = 3.64, df = 1 (P = 0.06); I² = 73%
Test for overall effect: Z = 0.64 (P = 0.52)
1.3.2 Exenatide 10 mcg vs placebo
Buse, 2004
Buse, 2011
DeFronzo, 2005
Gao, 2009
Gill, 2010
Liutkus, 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 1.32; Chi² = 8.02, df = 5 (P = 0.16); I² = 38%
Test for overall effect: Z = 0.98 (P = 0.33)
Total (95% CI)
Heterogeneity: Tau² = 1.46; Chi² = 11.76, df = 7 (P = 0.11); I² = 40%
Test for overall effect: Z = 1.28 (P = 0.20)
Test for subgroup differences: Chi² = 0.06, df = 1 (P = 0.81), I² = 0%
Mean [bpm]
0.47
2.89
-0.8
2.3
1.06
0.1
2.14
0.5
SD [bpm]
9.054
9.573
9.201
13.16
10.746
9.82
6.52
13.72
Total
125
110
235
129
137
113
234
26
111
750
985
Mean [bpm]
1.12
-0.49
1.12
-0.7
-0.49
-0.7
-0.71
1.8
SD [bpm]
8.911
9.815
8.911
13.42
9.815
9.5
6.81
11.31
Total
62
57
119
61
122
56
230
25
54
548
667
Weight
13.8%
11.7%
25.5%
13.7%
11.1%
11.1%
20.6%
9.4%
8.5%
74.5%
100.0%
IV, Random, 95% CI [bpm]
-0.65 [-3.38, 2.08]
3.38 [0.27, 6.49]
1.29 [-2.65, 5.24]
-1.92 [-4.66, 0.82]
3.00 [-0.24, 6.24]
1.55 [-1.70, 4.80]
0.80 [-0.96, 2.56]
2.85 [-0.81, 6.51]
-1.30 [-5.25, 2.65]
0.76 [-0.76, 2.28]
0.88 [-0.47, 2.22]
Exenatide Placebo Mean Difference Mean Difference
IV, Random, 95% CI [bpm]
-10 -5 0 5 10
Placebo Exenatide
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v) GLP-1 agonists versus placebo 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study or Subgroup
Buse, 2004
Buse, 2004
Buse, 2011
DeFronzo, 2005
DeFronzo, 2005
Gao, 2009
Gill, 2010
Liutkus, 2010
Marre, 2009
Marre, 2009
Nauck 2009
Nauck 2009
Russell- Jones, 2009
Zinman 2009
Zinman 2009
Total (95% CI)
Heterogeneity: Tau² = 2.19; Chi² = 32.90, df = 14 (P = 0.003); I² = 57%
Test for overall effect: Z = 3.61 (P = 0.0003)
Mean
0.47
-0.8
2.3
2.89
1.06
0.1
2.14
0.5
2.49
4.54
2.13
2.07
2.21
2.4
3.12
SD
9.054
9.201
13.16
9.573
10.746
9.82
6.52
13.72
8.9
8.4
8.9
8.4
8.4
8.9
8.4
Total
125
129
137
110
113
234
26
111
228
234
240
242
230
178
178
2515
Mean
1.12
1.12
-0.7
-0.49
-0.49
-0.7
-0.71
1.8
-1.55
-1.55
1.06
1.06
0.19
0.25
0.25
SD
8.911
8.911
13.42
9.815
9.815
9.5
6.81
11.31
8.3
8.3
8.3
8.3
8.3
8.3
8.3
Total
62
61
122
57
56
230
25
54
57
57
60
61
114
89
88
1193
Weight
6.4%
6.4%
5.4%
5.6%
5.4%
8.9%
4.7%
4.2%
7.1%
7.2%
7.2%
7.3%
8.6%
7.8%
7.9%
100.0%
IV, Random, 95% CI
-0.65 [-3.38, 2.08]
-1.92 [-4.66, 0.82]
3.00 [-0.24, 6.24]
3.38 [0.27, 6.49]
1.55 [-1.70, 4.80]
0.80 [-0.96, 2.56]
2.85 [-0.81, 6.51]
-1.30 [-5.25, 2.65]
4.04 [1.60, 6.48]
6.09 [3.68, 8.50]
1.07 [-1.31, 3.45]
1.01 [-1.33, 3.35]
2.02 [0.15, 3.89]
2.15 [-0.01, 4.31]
2.87 [0.74, 5.00]
1.86 [0.85, 2.87]
GLP-1 agonists Placebo Mean Difference Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Placebo GLP-1 agonists
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b) Effect of GLP-1 versus active control on heart rate in patients 
with type 2 diabetes using a random effects model 
 
i) Data from Lead1-5 studies: Liraglutide versus active control in T2DM 
patients, stratified by baseline heart rate 
 
 
 
 
 
 
 
 
 
 
 
 
Study or Subgroup
1.5.1 Liraglutide 1.2 mg vs active control
Q1 Baseline HR ≤ 68 b.p.m
Q2 68 < Baseline HR ≤ 74
Q3 74 Baseline HR ≤ 80
Q4 Baseline HR > 80
Subtotal (95% CI)
Heterogeneity: Tau² = 0.05; Chi² = 3.13, df = 3 (P = 0.37); I² = 4%
Test for overall effect: Z = 2.36 (P = 0.02)
1.5.2 Liraglutide 1.8 mg vs active control
Q1 Baseline HR ≤ 68 b.p.m
Q2 68 < Baseline HR ≤ 74
Q3 74 Baseline HR ≤ 80
Q4 Baseline HR > 80
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 0.87, df = 3 (P = 0.83); I² = 0%
Test for overall effect: Z = 3.90 (P < 0.0001)
Total (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 4.84, df = 7 (P = 0.68); I² = 0%
Test for overall effect: Z = 4.49 (P < 0.00001)
Test for subgroup differences: Chi² = 0.83, df = 1 (P = 0.36), I² = 0%
Mean
8.5
3.5
0.4
-5.5
8.2
4.2
0.9
-3.4
SD
8.9
8.9
8.9
8.9
8.4
8.4
8.4
8.4
Total
223
168
192
149
732
284
220
234
192
930
1662
Mean
5.9
2
-0.3
-5.6
5.9
2
-0.3
-5.6
SD
8.3
8.3
8.3
8.3
8.3
8.3
8.3
8.3
Total
103
92
116
87
398
103
92
116
87
398
796
Weight
12.9%
10.9%
13.2%
10.0%
47.0%
14.4%
12.4%
14.8%
11.4%
53.0%
100.0%
IV, Random, 95% CI
2.60 [0.62, 4.58]
1.50 [-0.67, 3.67]
0.70 [-1.27, 2.67]
0.10 [-2.15, 2.35]
1.28 [0.22, 2.34]
2.30 [0.42, 4.18]
2.20 [0.17, 4.23]
1.20 [-0.65, 3.05]
2.20 [0.09, 4.31]
1.95 [0.97, 2.93]
1.63 [0.92, 2.35]
Liraglutide Active control Mean Difference Mean Difference
IV, Random, 95% CI
-10 -5 0 5 10
Active control Liraglutide
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ii) Liraglutide versus active control displaying dose subgroups  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study or Subgroup
1.6.1 Liraglutide 1.2 mg vs active control
Garber, 2009
Marre, 2009
Nauck 2009
Pratley, 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.33, df = 3 (P = 0.51); I² = 0%
Test for overall effect: Z = 4.89 (P < 0.00001)
1.6.2 Liraglutide 1.8 mg vs active control
Garber, 2009
Marre, 2009
Nauck 2009
Pratley, 2010
Russell- Jones, 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 1.01; Chi² = 8.96, df = 4 (P = 0.06); I² = 55%
Test for overall effect: Z = 4.49 (P < 0.00001)
Total (95% CI)
Heterogeneity: Tau² = 0.40; Chi² = 11.88, df = 8 (P = 0.16); I² = 33%
Test for overall effect: Z = 6.75 (P < 0.00001)
Test for subgroup differences: Chi² = 0.40, df = 1 (P = 0.53), I² = 0%
Mean [bpm]
3.17
2.49
2.13
2.32
1.6
4.54
2.07
3.94
2.21
SD [bpm]
8.9
8.9
8.9
8.9
8.4
8.4
8.4
8.4
8.4
Total
251
228
240
225
944
246
234
242
221
230
1173
2117
Mean [bpm]
0.43
1.09
0.58
-0.64
0.43
1.09
0.58
-0.64
-0.75
SD [bpm]
8.3
8.3
8.3
8.3
8.3
8.3
8.3
8.3
8.3
Total
124
116
121
209
570
124
116
121
110
232
703
1273
Weight
10.7%
10.2%
10.5%
12.6%
44.0%
11.0%
10.5%
10.8%
10.1%
13.6%
56.0%
100.0%
IV, Random, 95% CI [bpm]
2.74 [0.91, 4.57]
1.40 [-0.50, 3.30]
1.55 [-0.31, 3.41]
2.96 [1.34, 4.58]
2.23 [1.34, 3.13]
1.17 [-0.63, 2.97]
3.45 [1.60, 5.30]
1.49 [-0.33, 3.31]
4.58 [2.67, 6.49]
2.96 [1.44, 4.48]
2.72 [1.53, 3.90]
2.49 [1.77, 3.21]
Liraglutide Active control Mean Difference Mean Difference
IV, Random, 95% CI [bpm]
-10 -5 0 5 10
Active control Liraglutide
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iii) Exenatide versus active control displaying dose subgroups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study or Subgroup
1.7.1 Exenatide 10 mcg vs active control
Barnett, 2007
Bunck, 2009
Buse, 2011
DeFronzo, 2010
Gallwitz, 2011
Gallwitz, 2012
Heine, 2005
Nauck, 2007
Subtotal (95% CI)
Heterogeneity: Tau² = 0.64; Chi² = 10.83, df = 7 (P = 0.15); I² = 35%
Test for overall effect: Z = 1.66 (P = 0.10)
1.7.2 Exenatide LAR 2.0 mg vs active control
Bergenstal, 2010 (Piogl)
Bergenstal, 2010 (sita)
Diamant, 2010
Russell-Jones,2012 (MET)
Russell-Jones,2012 (Sita)
Russell-Jones,2012(Piogl)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 4.66, df = 5 (P = 0.46); I² = 0%
Test for overall effect: Z = 4.09 (P < 0.0001)
Total (95% CI)
Heterogeneity: Tau² = 0.76; Chi² = 20.48, df = 13 (P = 0.08); I² = 37%
Test for overall effect: Z = 3.40 (P = 0.0007)
Test for subgroup differences: Chi² = 3.36, df = 1 (P = 0.07), I² = 70.3%
Mean [bpm]
-1.29
4.6
2.3
-0.6
-0.5
1.2
-0.31
1.53
1.6
1.6
4
1.5
1.5
1.5
SD [bpm]
8.7
10.02
17.25
9.34
11
10.6
9.6
10.27
9.27
9.27
14.46
10
10
10
Total
68
36
137
73
181
504
282
253
1534
80
80
233
82
82
83
640
2174
Mean [bpm]
-0.93
-2.2
-0.7
-1.67
0.1
0.6
-1.2
1.19
-0.9
0.5
0
0.3
0.5
-1.7
SD [bpm]
8.95
9.82
7.14
10.03
9.1
10.5
9.52
9.17
8.75
8.93
14.46
9.5
9.7
8.7
Total
70
33
122
79
173
501
267
248
1493
165
166
233
246
163
163
1136
2629
Weight
5.3%
2.5%
4.7%
4.9%
8.3%
13.2%
11.1%
10.5%
60.5%
6.9%
6.9%
6.2%
6.8%
6.2%
6.5%
39.5%
100.0%
IV, Random, 95% CI [bpm]
-0.36 [-3.30, 2.58]
6.80 [2.12, 11.48]
3.00 [-0.15, 6.15]
1.07 [-2.01, 4.15]
-0.60 [-2.70, 1.50]
0.60 [-0.70, 1.90]
0.89 [-0.71, 2.49]
0.34 [-1.36, 2.04]
0.82 [-0.15, 1.79]
2.50 [0.07, 4.93]
1.10 [-1.34, 3.54]
4.00 [1.37, 6.63]
1.20 [-1.27, 3.67]
1.00 [-1.63, 3.63]
3.20 [0.67, 5.73]
2.14 [1.11, 3.17]
1.36 [0.57, 2.14]
Exenatide Active control Mean Difference Mean Difference
IV, Random, 95% CI [bpm]
-10 -5 0 5 10
Active control Exenatide
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iv) GLP-1 versus active control 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study or Subgroup
Barnett, 2007
Bergenstal, 2010 (Piogl)
Bergenstal, 2010 (sita)
Bunck, 2009
Buse, 2011
DeFronzo, 2010
Diamant, 2010
Gallwitz, 2011
Gallwitz, 2012
Garber, 2009
Garber, 2009
Heine, 2005
Marre, 2009
Marre, 2009
Nauck 2009
Nauck 2009
Nauck, 2007
Pratley, 2010
Pratley, 2010
Russell- Jones, 2009
Russell-Jones,2012 (MET)
Russell-Jones,2012 (Sita)
Russell-Jones,2012(Piogl)
Total (95% CI)
Heterogeneity: Tau² = 0.96; Chi² = 41.85, df = 22 (P = 0.007); I² = 47%
Test for overall effect: Z = 6.23 (P < 0.00001)
Mean [bpm]
-1.29
1.6
1.6
4.6
2.3
-0.6
4
-0.5
1.2
3.17
1.6
-0.31
4.54
2.49
2.13
2.07
1.53
2.32
3.94
2.21
1.5
1.5
1.5
SD [bpm]
8.7
9.27
9.27
10.02
17.25
9.34
14.46
11
10.6
8.9
8.4
9.6
8.4
8.9
8.9
8.4
10.27
8.9
8.4
8.4
10
10
10
Total
68
80
80
36
137
73
233
181
504
251
246
282
234
228
240
242
253
225
221
230
82
82
83
4291
Mean [bpm]
-0.93
-0.9
0.5
-2.2
-0.7
-1.67
0
0.1
0.6
0.43
0.43
-1.2
1.09
1.09
0.58
0.58
1.19
-0.64
-0.64
-0.75
0.3
0.5
-1.7
SD [bpm]
8.95
8.75
8.93
9.82
7.14
10.03
14.46
9.1
10.5
8.3
8.3
9.52
8.3
8.3
8.3
8.3
9.17
8.3
8.3
8.3
9.5
9.7
8.7
Total
70
165
166
33
122
79
233
173
501
124
124
267
116
116
121
121
248
209
110
232
246
163
163
3902
Weight
2.9%
3.7%
3.7%
1.4%
2.6%
2.7%
3.4%
4.4%
6.6%
5.1%
5.2%
5.7%
5.0%
4.9%
5.0%
5.1%
5.4%
5.7%
4.9%
6.0%
3.7%
3.4%
3.5%
100.0%
IV, Random, 95% CI [bpm]
-0.36 [-3.30, 2.58]
2.50 [0.07, 4.93]
1.10 [-1.34, 3.54]
6.80 [2.12, 11.48]
3.00 [-0.15, 6.15]
1.07 [-2.01, 4.15]
4.00 [1.37, 6.63]
-0.60 [-2.70, 1.50]
0.60 [-0.70, 1.90]
2.74 [0.91, 4.57]
1.17 [-0.63, 2.97]
0.89 [-0.71, 2.49]
3.45 [1.60, 5.30]
1.40 [-0.50, 3.30]
1.55 [-0.31, 3.41]
1.49 [-0.33, 3.31]
0.34 [-1.36, 2.04]
2.96 [1.34, 4.58]
4.58 [2.67, 6.49]
2.96 [1.44, 4.48]
1.20 [-1.27, 3.67]
1.00 [-1.63, 3.63]
3.20 [0.67, 5.73]
1.90 [1.30, 2.50]
GLP-1 agonists Active control Mean Difference Mean Difference
IV, Random, 95% CI [bpm]
-10 -5 0 5 10
Active control GLP-1 agonists
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Figure 4.3.2.2 GLP-1 agonists’ effect on systolic blood pressure in 
patients with type 2 diabetes: 
 
a) Effect of GLP-1 versus placebo on systolic blood pressure in 
patients with type 2 diabetes using a random effects model 
 
i) Liraglutide versus placebo including dose subgroups  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study or Subgroup
2.1.1 Liraglutide 1.2 mg vs placebo
Nauck 2009
Zinman 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 7.08; Chi² = 3.02, df = 1 (P = 0.08); I² = 67%
Test for overall effect: Z = 1.38 (P = 0.17)
2.1.2 Liraglutide 1.8 mg vs Placebo
Nauck 2009
Russell- Jones, 2009
Zinman 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 0.51; Chi² = 2.32, df = 2 (P = 0.31); I² = 14%
Test for overall effect: Z = 2.13 (P = 0.03)
Total (95% CI)
Heterogeneity: Tau² = 1.20; Chi² = 5.47, df = 4 (P = 0.24); I² = 27%
Test for overall effect: Z = 2.78 (P = 0.005)
Test for subgroup differences: Chi² = 0.10, df = 1 (P = 0.75), I² = 0%
Mean [mmHg]
-2.8
-6.7
-2.3
-4
-5.6
SD [mmHg]
14
14.68
14
15
14.7
Total
242
177
419
242
230
178
650
1069
Mean [mmHg]
-1.8
-1.1
-1.8
-1.4
-1.1
SD [mmHg]
16
15.96
16
14
16
Total
121
89
210
121
114
89
324
534
Weight
21.6%
16.9%
38.6%
21.6%
22.9%
16.9%
61.4%
100.0%
IV, Random, 95% CI [mmHg]
-1.00 [-4.35, 2.35]
-5.60 [-9.56, -1.64]
-3.17 [-7.68, 1.33]
-0.50 [-3.85, 2.85]
-2.60 [-5.82, 0.62]
-4.50 [-8.46, -0.54]
-2.36 [-4.52, -0.19]
-2.63 [-4.48, -0.78]
Liraglutide Placebo Mean Difference Mean Difference
IV, Random, 95% CI [mmHg]
-10 -5 0 5 10
Liraglutide Placebo
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ii) Exenatide versus placebo including dose subgroups 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study or Subgroup
2.2.1 Exenatide 5 mcg vs placebo
Buse, 2004
DeFronzo, 2005
Kadowaki, 2009
Kendall 2005
Moretto, 2008
Subtotal (95% CI)
Heterogeneity: Tau² = 0.99; Chi² = 4.79, df = 4 (P = 0.31); I² = 17%
Test for overall effect: Z = 0.84 (P = 0.40)
2.2.2 Exenatide 10 mcg vs placebo
Apovian, 2010
Buse, 2004
Buse, 2011
DeFronzo, 2005
Gao, 2009
Gill, 2010
Kadowaki, 2009
Kendall 2005
Liutkus, 2010
Moretto, 2008
Zinman, 2007
Subtotal (95% CI)
Heterogeneity: Tau² = 6.27; Chi² = 27.57, df = 10 (P = 0.002); I² = 64%
Test for overall effect: Z = 1.67 (P = 0.09)
2.2.3 Exenatide LAR 0.8 mg vs placebo
Kim, 2007
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.09 (P = 0.93)
2.2.4 Exenatide LAR 2.0 mg vs placebo
Kim, 2007
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.66 (P = 0.51)
Total (95% CI)
Heterogeneity: Tau² = 4.03; Chi² = 32.97, df = 17 (P = 0.01); I² = 48%
Test for overall effect: Z = 1.99 (P = 0.05)
Test for subgroup differences: Chi² = 0.49, df = 3 (P = 0.92), I² = 0%
Mean [mmHg]
-2.24
1.04
0
-0.42
-3.56
-9.44
0.82
-2.7
-1.29
0.8
-0.81
-2
-2
-0.6
-3.7
-2.17
-0.3
-4.1
SD [mmHg]
15.34
14.29
11.8
13.92
11.68
13.72
15.71
14.04
14.26
14.44
13.61
13.3
14.98
21.07
13.32
9.07
10.83
16.21
Total
125
110
37
245
77
594
96
129
137
113
234
26
37
241
111
78
121
1323
15
15
16
16
1948
Mean [mmHg]
-1.61
1.73
-5
1.14
0.08
-1.97
-1.61
1.7
1.73
-1.4
-0.34
-5
1.14
-1.1
-0.3
-0.7
0.2
0.2
SD [mmHg]
14.29
13.22
11.7
14.72
12.33
13.86
14.29
9.38
13.22
14.76
13.6
11.7
14.72
16.9
12.33
7.92
13.52
13.52
Total
61
57
20
124
39
301
98
62
122
56
230
25
20
124
54
38
112
941
7
7
7
7
1256
Weight
5.7%
5.9%
3.6%
8.0%
5.4%
28.6%
6.6%
5.7%
8.5%
5.9%
9.0%
2.8%
3.4%
7.9%
4.0%
5.1%
10.0%
68.8%
1.4%
1.4%
1.1%
1.1%
100.0%
IV, Random, 95% CI [mmHg]
-0.63 [-5.11, 3.85]
-0.69 [-5.04, 3.66]
5.00 [-1.38, 11.38]
-1.56 [-4.68, 1.56]
-3.64 [-8.31, 1.03]
-0.91 [-3.04, 1.21]
-7.47 [-11.35, -3.59]
2.43 [-2.04, 6.90]
-4.40 [-7.28, -1.52]
-3.02 [-7.37, 1.33]
2.20 [-0.46, 4.86]
-0.47 [-7.94, 7.00]
3.00 [-3.68, 9.68]
-3.14 [-6.35, 0.07]
0.50 [-5.47, 6.47]
-3.40 [-8.31, 1.51]
-1.47 [-3.65, 0.71]
-1.67 [-3.62, 0.28]
-0.50 [-11.92, 10.92]
-0.50 [-11.92, 10.92]
-4.30 [-17.08, 8.48]
-4.30 [-17.08, 8.48]
-1.45 [-2.87, -0.02]
Exenatide Placebo Mean Difference Mean Difference
IV, Random, 95% CI [mmHg]
-10 -5 0 5 10
Exenatide Placebo
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iii) GLP-1 agonists versus placebo 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study or Subgroup
Apovian, 2010
Buse, 2004
Buse, 2004
Buse, 2011
DeFronzo, 2005
DeFronzo, 2005
Gao, 2009
Gill, 2010
Kadowaki, 2009
Kadowaki, 2009
Kendall 2005
Kendall 2005
Kim, 2007
Kim, 2007
Liutkus, 2010
Moretto, 2008
Moretto, 2008
Nauck 2009
Nauck 2009
Russell- Jones, 2009
Zinman 2009
Zinman 2009
Zinman, 2007
Total (95% CI)
Heterogeneity: Tau² = 3.19; Chi² = 39.65, df = 22 (P = 0.01); I² = 45%
Test for overall effect: Z = 3.05 (P = 0.002)
Mean [mmHg]
-9.44
-2.24
0.82
-2.7
1.04
-1.29
0.8
-0.81
-2
0
-2
-0.42
-4.1
-0.3
-0.6
-3.7
-3.56
-2.3
-2.8
-4
-5.6
-6.7
-2.17
SD [mmHg]
13.72
15.34
15.71
14.04
14.29
14.26
14.44
13.61
13.3
11.8
14.98
13.92
16.21
10.83
21.07
13.32
11.68
14
14
15
14.7
14.68
9.07
Total
96
125
129
137
110
113
234
26
37
37
241
245
16
15
111
78
77
242
242
230
178
177
121
3017
Mean [mmHg]
-1.97
-1.61
-1.61
1.7
1.73
1.73
-1.4
-0.34
-5
-5
1.14
1.14
0.2
0.2
-1.1
-0.3
0.08
-1.8
-1.8
-1.4
-1.1
-1.1
-0.7
SD [mmHg]
13.86
14.29
14.29
9.38
13.22
13.22
14.76
13.6
11.7
11.7
14.72
14.72
13.52
13.52
16.9
12.33
12.33
16
16
14
16
15.96
7.92
Total
98
61
62
122
57
56
230
25
20
20
124
124
7
7
54
38
39
121
121
114
89
89
112
1790
Weight
4.9%
4.1%
4.1%
6.5%
4.3%
4.3%
6.9%
1.9%
2.3%
2.5%
5.9%
6.0%
0.8%
0.9%
2.8%
3.6%
3.9%
5.6%
5.6%
5.9%
4.7%
4.7%
7.8%
100.0%
IV, Random, 95% CI [mmHg]
-7.47 [-11.35, -3.59]
-0.63 [-5.11, 3.85]
2.43 [-2.04, 6.90]
-4.40 [-7.28, -1.52]
-0.69 [-5.04, 3.66]
-3.02 [-7.37, 1.33]
2.20 [-0.46, 4.86]
-0.47 [-7.94, 7.00]
3.00 [-3.68, 9.68]
5.00 [-1.38, 11.38]
-3.14 [-6.35, 0.07]
-1.56 [-4.68, 1.56]
-4.30 [-17.08, 8.48]
-0.50 [-11.92, 10.92]
0.50 [-5.47, 6.47]
-3.40 [-8.31, 1.51]
-3.64 [-8.31, 1.03]
-0.50 [-3.85, 2.85]
-1.00 [-4.35, 2.35]
-2.60 [-5.82, 0.62]
-4.50 [-8.46, -0.54]
-5.60 [-9.56, -1.64]
-1.47 [-3.65, 0.71]
-1.79 [-2.94, -0.64]
GLP-1 agonists Placebo Mean Difference Mean Difference
IV, Random, 95% CI [mmHg]
-10 -5 0 5 10
GLP-1 agonist Placebo
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b) Effect of GLP-1 versus active control on systolic blood 
pressure in patients with type 2 diabetes using a random effects 
model 
 
 
 
ii) Exenatide versus active control displaying dose subgroups 
 
 
 
 
 
 
 
 
Study or Subgroup
2.4.1 Liraglutide 1.2 mg vs active control
Garber, 2009
Nauck 2009
Pratley, 2010
Subtotal (95% CI)
Heterogeneity: Tau² = 1.43; Chi² = 3.46, df = 2 (P = 0.18); I² = 42%
Test for overall effect: Z = 1.00 (P = 0.32)
2.4.2 Liraglutide 1.8 mg vs active control
Garber, 2009
Nauck 2009
Pratley, 2010
Russell- Jones, 2009
Subtotal (95% CI)
Heterogeneity: Tau² = 3.05; Chi² = 7.54, df = 3 (P = 0.06); I² = 60%
Test for overall effect: Z = 2.10 (P = 0.04)
Total (95% CI)
Heterogeneity: Tau² = 2.15; Chi² = 12.76, df = 6 (P = 0.05); I² = 53%
Test for overall effect: Z = 2.35 (P = 0.02)
Test for subgroup differences: Chi² = 0.72, df = 1 (P = 0.40), I² = 0%
Mean [mmHg]
-2.1
-2.8
-0.55
-3.6
-2.3
-0.72
-4
SD [mmHg]
14.25
14
4.79
14.1
14
9.01
15
Total
251
242
225
718
247
242
218
230
937
1655
Mean [mmHg]
-0.7
0.4
-0.94
-0.7
0.4
-0.94
0.54
SD [mmHg]
13.7
16
10.25
13.7
16
10.25
14.7
Total
124
121
110
355
124
121
109
232
586
941
Weight
13.3%
11.7%
18.5%
43.4%
13.3%
11.7%
17.0%
14.6%
56.6%
100.0%
IV, Random, 95% CI [mmHg]
-1.40 [-4.39, 1.59]
-3.20 [-6.55, 0.15]
0.39 [-1.63, 2.41]
-1.06 [-3.13, 1.01]
-2.90 [-5.88, 0.08]
-2.70 [-6.05, 0.65]
0.22 [-2.05, 2.49]
-4.54 [-7.25, -1.83]
-2.37 [-4.59, -0.16]
-1.81 [-3.32, -0.30]
Liraglutide Active Control Mean Difference Mean Difference
IV, Random, 95% CI [mmHg]
-10 -5 0 5 10
Liraglutide Active control
Study or Subgroup
2.5.1 Exenatide 10 mcg vs active control
Barnett, 2007
Bunck, 2009
Davies, 2009
DeFronzo, 2010
Gallwitz, 2011
Gallwitz, 2012
Heine, 2005
Nauck, 2007
Subtotal (95% CI)
Heterogeneity: Tau² = 3.21; Chi² = 16.12, df = 7 (P = 0.02); I² = 57%
Test for overall effect: Z = 3.83 (P = 0.0001)
2.5.2 Exenatide LAR vs active control
Bergenstal, 2010 (Piogl)
Bergenstal, 2010 (sita)
Diamant, 2010
Russell-Jones,2012 (MET)
Russell-Jones,2012 (Sita)
Russell-Jones,2012(Piogl)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 2.75, df = 5 (P = 0.74); I² = 0%
Test for overall effect: Z = 2.15 (P = 0.03)
Total (95% CI)
Heterogeneity: Tau² = 2.07; Chi² = 22.46, df = 13 (P = 0.05); I² = 42%
Test for overall effect: Z = 4.48 (P < 0.00001)
Test for subgroup differences: Chi² = 2.03, df = 1 (P = 0.15), I² = 50.7%
Mean [mmHg]
-3.96
-3.5
-2.9
-0.8
-4.3
-1.9
-4.12
-5
-4
-4
-3
-1.3
-1.3
-1.3
SD [mmHg]
17.34
12.8
13
10.24
16.6
16.3
17.77
15.15
32.27
32.27
16.6
12.6
12.6
12.6
Total
136
36
118
73
246
505
282
253
1649
80
80
233
82
82
83
640
2289
Mean [mmHg]
-3.28
0.9
0.7
-2.12
1.8
1.1
-0.57
1
-1.8
0.2
-1
-0.03
1.8
-1.7
SD [mmHg]
15.86
18
13
11.33
16.1
15.9
16.01
15.6
11.8
12.9
14.93
13.77
12.77
12.77
Total
127
33
116
79
233
501
267
248
1604
165
160
223
246
163
163
1120
2724
Weight
6.1%
2.3%
7.7%
7.4%
8.8%
12.2%
9.1%
9.6%
63.2%
2.4%
2.4%
8.9%
7.9%
7.6%
7.6%
36.8%
100.0%
IV, Random, 95% CI [mmHg]
-0.68 [-4.69, 3.33]
-4.40 [-11.83, 3.03]
-3.60 [-6.93, -0.27]
1.32 [-2.11, 4.75]
-6.10 [-9.03, -3.17]
-3.00 [-4.99, -1.01]
-3.55 [-6.38, -0.72]
-6.00 [-8.69, -3.31]
-3.33 [-5.04, -1.63]
-2.20 [-9.50, 5.10]
-4.20 [-11.55, 3.15]
-2.00 [-4.90, 0.90]
-1.27 [-4.49, 1.95]
-3.10 [-6.46, 0.26]
0.40 [-2.95, 3.75]
-1.67 [-3.19, -0.15]
-2.76 [-3.97, -1.55]
Exenatide Active Control Mean Difference Mean Difference
IV, Random, 95% CI [mmHg]
-10 -5 0 5 10
Exenatide Active control
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iii) GLP-1 agonists’ versus active control 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study or Subgroup
Barnett, 2007
Bergenstal, 2010 (Piogl)
Bergenstal, 2010 (sita)
Bunck, 2009
Davies, 2009
DeFronzo, 2010
Diamant, 2010
Gallwitz, 2011
Gallwitz, 2012
Garber, 2009
Garber, 2009
Heine, 2005
Nauck 2009
Nauck 2009
Nauck, 2007
Pratley, 2010
Pratley, 2010
Russell- Jones, 2009
Russell-Jones,2012 (MET)
Russell-Jones,2012 (Sita)
Russell-Jones,2012(Piogl)
Total (95% CI)
Heterogeneity: Tau² = 2.32; Chi² = 39.21, df = 20 (P = 0.006); I² = 49%
Test for overall effect: Z = 4.85 (P < 0.00001)
Mean [mmHg]
-3.96
-4
-4
-3.5
-2.9
-0.8
-3
-4.3
-1.9
-3.6
-2.1
-4.12
-2.8
-2.3
-5
-0.55
-0.72
-4
-1.3
-1.3
-1.3
SD [mmHg]
17.34
32.27
32.27
12.8
13
10.24
16.6
16.6
16.3
14.1
14.25
17.77
14
14
15.15
4.79
9.01
15
12.6
12.6
12.6
Total
136
80
80
36
118
73
233
246
505
247
251
282
242
242
253
225
218
230
82
82
83
3944
Mean [mmHg]
-3.28
-1.8
0.2
0.9
0.7
-2.12
-1
1.8
1.1
-0.7
-0.7
-0.57
0.4
0.4
1
-0.94
-0.94
0.54
-0.03
1.8
-1.7
SD [mmHg]
15.86
11.8
12.9
18
13
11.33
14.93
16.1
15.9
13.7
13.7
16.01
16
16
15.6
10.25
10.25
14.7
13.77
12.77
12.77
Total
127
165
160
33
116
79
223
233
501
124
124
267
121
121
248
110
109
232
246
163
163
3665
Weight
3.7%
1.5%
1.5%
1.5%
4.7%
4.5%
5.4%
5.3%
7.2%
5.2%
5.2%
5.5%
4.6%
4.6%
5.8%
7.2%
6.6%
5.7%
4.8%
4.6%
4.6%
100.0%
IV, Random, 95% CI [mmHg]
-0.68 [-4.69, 3.33]
-2.20 [-9.50, 5.10]
-4.20 [-11.55, 3.15]
-4.40 [-11.83, 3.03]
-3.60 [-6.93, -0.27]
1.32 [-2.11, 4.75]
-2.00 [-4.90, 0.90]
-6.10 [-9.03, -3.17]
-3.00 [-4.99, -1.01]
-2.90 [-5.88, 0.08]
-1.40 [-4.39, 1.59]
-3.55 [-6.38, -0.72]
-3.20 [-6.55, 0.15]
-2.70 [-6.05, 0.65]
-6.00 [-8.69, -3.31]
0.39 [-1.63, 2.41]
0.22 [-2.05, 2.49]
-4.54 [-7.25, -1.83]
-1.27 [-4.49, 1.95]
-3.10 [-6.46, 0.26]
0.40 [-2.95, 3.75]
-2.39 [-3.35, -1.42]
GLP-1 agonist Active Control Mean Difference Mean Difference
IV, Random, 95% CI [mmHg]
-10 -5 0 5 10
GLP-1 agonist Active control
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Figure 4.3.2.3 GLP-1 agonists’ effect on diastolic blood pressure 
in patients with type 2 diabetes: 
 
a) Effect of GLP-1 versus active control on diastolic blood 
pressure in patients with type 2 diabetes using a random effects 
model 
 
i) Exenatide versus placebo displaying dose subgroups 
 
 
 
 
 
 
Study or Subgroup
3.2.1 Exenatide 5 mcg vs placebo
Buse, 2004
DeFronzo, 2005
Kadowaki, 2009
Kendall 2005
Moretto, 2008
Subtotal (95% CI)
Heterogeneity: Tau² = 0.00; Chi² = 1.04, df = 4 (P = 0.90); I² = 0%
Test for overall effect: Z = 0.76 (P = 0.45)
3.2.2 Exenatide 10 mcg vs placebo
Apovian, 2010
Buse, 2004
Buse, 2011
DeFronzo, 2005
Gao, 2009
Gill, 2010
Kadowaki, 2009
Kendall 2005
Liutkus, 2010
Moretto, 2008
Zinman, 2007
Subtotal (95% CI)
Heterogeneity: Tau² = 1.21; Chi² = 16.55, df = 10 (P = 0.08); I² = 40%
Test for overall effect: Z = 0.94 (P = 0.35)
3.2.3 Exenatide LAR 0.8mg vs placebo
Kim, 2007
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 0.43 (P = 0.67)
3.2.4 Exenatide LAR 2.0 mg vs placebo
Kim, 2007
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Z = 1.05 (P = 0.29)
Total (95% CI)
Heterogeneity: Tau² = 0.21; Chi² = 18.81, df = 17 (P = 0.34); I² = 10%
Test for overall effect: Z = 1.16 (P = 0.25)
Test for subgroup differences: Chi² = 1.16, df = 3 (P = 0.76), I² = 0%
Mean [mmHg]
-1.96
-1
-1
-0.73
-0.8
-2.22
-0.47
-1.7
-1
0.7
-0.6
-1
-0.41
-2.9
-2.3
-2.4
-0.1
-5.1
SD [mmHg]
9.05
7.4
7.4
8.58
5.69
9.8
9.38
14.08
7.7
8.55
6.99
7.7
8.9
10.78
5.77
14.41
7.89
7.08
Total
125
37
37
245
77
521
96
129
137
37
234
26
37
241
111
78
121
1247
15
15
16
16
1799
Mean [mmHg]
-0.63
-1
-1
-0.85
-0.3
0.47
-0.63
1.7
-1
-0.5
-2.34
-1
-0.85
-3.6
-0.3
1.01
-1.6
-1.6
SD [mmHg]
8.62
8
8
9
5.81
9.8
8.62
14.37
8
8.9
7.29
8
9
9.19
5.81
14.14
7.46
7.46
Total
123
20
20
124
39
326
98
123
122
20
230
25
20
123
54
39
112
966
7
7
7
7
1306
Weight
8.4%
2.5%
2.5%
10.6%
8.2%
32.2%
5.6%
8.2%
3.7%
2.5%
14.2%
2.9%
2.5%
10.3%
4.4%
8.2%
3.3%
65.7%
1.0%
1.0%
1.1%
1.1%
100.0%
IV, Random, 95% CI [mmHg]
-1.33 [-3.53, 0.87]
0.00 [-4.24, 4.24]
0.00 [-4.24, 4.24]
0.12 [-1.79, 2.03]
-0.50 [-2.72, 1.72]
-0.43 [-1.56, 0.69]
-2.69 [-5.45, 0.07]
0.16 [-2.06, 2.38]
-3.40 [-6.87, 0.07]
0.00 [-4.30, 4.30]
1.20 [-0.39, 2.79]
1.74 [-2.18, 5.66]
0.00 [-4.30, 4.30]
0.44 [-1.51, 2.39]
0.70 [-2.47, 3.87]
-2.00 [-4.23, 0.23]
-3.41 [-7.08, 0.26]
-0.52 [-1.59, 0.56]
1.50 [-5.32, 8.32]
1.50 [-5.32, 8.32]
-3.50 [-10.02, 3.02]
-3.50 [-10.02, 3.02]
-0.41 [-1.09, 0.28]
Exenatide Placebo Mean Difference Mean Difference
IV, Random, 95% CI [mmHg]
-10 -5 0 5 10
Exenatide Placebo
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ii) GLP-1 agonists’ versus placebo 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study or Subgroup
Apovian, 2010
Buse, 2004
Buse, 2004
Buse, 2011
DeFronzo, 2005
DeFronzo, 2005
Gao, 2009
Gill, 2010
Kadowaki, 2009
Kadowaki, 2009
Kendall 2005
Kendall 2005
Kim, 2007
Kim, 2007
Liutkus, 2010
Moretto, 2008
Moretto, 2008
Zinman 2009
Zinman 2009
Zinman, 2007
Total (95% CI)
Heterogeneity: Tau² = 0.12; Chi² = 20.27, df = 19 (P = 0.38); I² = 6%
Test for overall effect: Z = 1.72 (P = 0.08)
Mean [mmHg]
-2.22
-1.96
-0.47
-1.7
-1
-1
0.7
-0.6
-1
-1
-0.73
-0.41
-0.1
-5.1
-2.9
-0.8
-2.3
-1.9
-2.3
-2.4
SD [mmHg]
9.8
9.05
9.38
14.08
7.4
7.7
8.55
6.99
7.4
7.7
8.58
8.9
7.89
7.08
10.78
5.69
5.77
8.07
8.66
14.41
Total
96
125
129
137
37
37
234
26
37
37
245
241
15
16
111
77
78
178
178
121
2155
Mean [mmHg]
0.47
-0.63
-0.63
1.7
-1
-1
-0.5
-2.34
-1
-1
-0.85
-0.85
-1.6
-1.6
-3.6
-0.3
-0.3
-0.8
-0.8
1.01
SD [mmHg]
9.8
8.62
8.62
14.37
8
8
8.9
7.29
8
8
9
9
7.46
7.46
9.19
5.81
5.81
7.7
7.7
14.14
Total
98
123
123
122
20
20
230
25
20
20
124
123
7
7
54
39
39
88
89
112
1483
Weight
4.6%
7.0%
6.9%
3.0%
2.0%
2.0%
12.5%
2.3%
2.0%
2.0%
9.0%
8.7%
0.8%
0.9%
3.5%
6.9%
6.9%
8.3%
8.0%
2.7%
100.0%
IV, Random, 95% CI [mmHg]
-2.69 [-5.45, 0.07]
-1.33 [-3.53, 0.87]
0.16 [-2.06, 2.38]
-3.40 [-6.87, 0.07]
0.00 [-4.24, 4.24]
0.00 [-4.30, 4.30]
1.20 [-0.39, 2.79]
1.74 [-2.18, 5.66]
0.00 [-4.24, 4.24]
0.00 [-4.30, 4.30]
0.12 [-1.79, 2.03]
0.44 [-1.51, 2.39]
1.50 [-5.32, 8.32]
-3.50 [-10.02, 3.02]
0.70 [-2.47, 3.87]
-0.50 [-2.72, 1.72]
-2.00 [-4.23, 0.23]
-1.10 [-3.10, 0.90]
-1.50 [-3.54, 0.54]
-3.41 [-7.08, 0.26]
-0.54 [-1.15, 0.07]
GLP-1 agonists Placebo Mean Difference Mean Difference
IV, Random, 95% CI [mmHg]
-10 -5 0 5 10
GLP-1 agonist Placebo
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b) Effect of GLP-1 versus active control on diastolic blood 
pressure in patients with type 2 diabetes using a random effects 
model 
 
i) Exenatide versus active control displaying dose subgroups 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study or Subgroup
3.6.1 Exenatide 10 mcg vs active control
Barnett, 2007
Bunck, 2009
Davies, 2009
DeFronzo, 2010
Gallwitz, 2011
Gallwitz, 2012
Heine, 2005
Nauck, 2007
Subtotal (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 7.84, df = 7 (P = 0.35); I² = 11%
Test for overall effect: Z = 5.82 (P < 0.00001)
3.6.2 Exenatide LAR 2.0 mg vs active control
Bergenstal, 2010 (Piogl)
Bergenstal, 2010 (sita)
Diamant, 2010
Russell-Jones,2012 (MET)
Russell-Jones,2012 (Sita)
Russell-Jones,2012(Piogl)
Subtotal (95% CI)
Heterogeneity: Tau² = 0.14; Chi² = 5.58, df = 5 (P = 0.35); I² = 10%
Test for overall effect: Z = 0.61 (P = 0.54)
Total (95% CI)
Heterogeneity: Tau² = 0.88; Chi² = 28.76, df = 13 (P = 0.007); I² = 55%
Test for overall effect: Z = 2.30 (P = 0.02)
Test for subgroup differences: Chi² = 12.37, df = 1 (P = 0.0004), I² = 91.9%
Mean [mmHg]
-2
-0.3
-0.5
-1.17
-1.7
-1.3
-1.18
-1.8
-1.6
-1.6
-1
-0.65
-0.65
-0.65
SD [mmHg]
9.17
1.4
7.6
9.48
9.9
10
10.33
9.68
7.46
7.46
14.46
8.55
8.55
8.55
Total
136
30
118
73
246
505
282
253
1643
80
80
233
82
82
83
640
2283
Mean [mmHg]
-0.93
1.7
0.9
-2.24
0.5
0.3
-0.77
0.6
-2.6
-0.2
-1
-0.6
-0.51
-2.67
SD [mmHg]
9.23
1.53
7.14
8.65
8.8
10.3
9.76
10.13
0.6
8.12
14.46
8.47
7.76
9.15
Total
127
33
117
79
233
501
267
248
1605
137
137
223
246
162
163
1068
2673
Weight
5.9%
12.6%
7.1%
4.2%
7.9%
9.9%
7.9%
7.7%
63.2%
8.1%
6.2%
4.7%
6.2%
6.0%
5.6%
36.8%
100.0%
IV, Random, 95% CI [mmHg]
-1.07 [-3.30, 1.16]
-2.00 [-2.72, -1.28]
-1.40 [-3.29, 0.49]
1.07 [-1.82, 3.96]
-2.20 [-3.88, -0.52]
-1.60 [-2.85, -0.35]
-0.41 [-2.09, 1.27]
-2.40 [-4.14, -0.66]
-1.63 [-2.18, -1.08]
1.00 [-0.64, 2.64]
-1.40 [-3.53, 0.73]
0.00 [-2.66, 2.66]
-0.05 [-2.18, 2.08]
-0.14 [-2.34, 2.06]
2.02 [-0.29, 4.33]
0.29 [-0.63, 1.20]
-0.82 [-1.52, -0.12]
Exenatide Active control Mean Difference Mean Difference
IV, Random, 95% CI [mmHg]
-10 -5 0 5 10
Exenatide Active control
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ii) GLP-1 agonists’ versus active control 
 
 
 
 
 
Study or Subgroup
Barnett, 2007
Bergenstal, 2010 (Piogl)
Bergenstal, 2010 (sita)
Bunck, 2009
Davies, 2009
DeFronzo, 2010
Diamant, 2010
Gallwitz, 2011
Gallwitz, 2012
Heine, 2005
Nauck, 2007
Pratley, 2010
Pratley, 2010
Russell-Jones,2012 (MET)
Russell-Jones,2012 (Sita)
Russell-Jones,2012(Piogl)
Total (95% CI)
Heterogeneity: Tau² = 1.35; Chi² = 42.27, df = 15 (P = 0.0002); I² = 65%
Test for overall effect: Z = 1.33 (P = 0.18)
Mean [mmHg]
-2
-1.6
-1.6
-0.3
-0.5
-1.17
-1
-1.7
-1.3
-1.18
-1.8
0.07
-0.71
-0.65
-0.65
-0.65
SD [mmHg]
9.17
7.46
7.46
1.4
7.6
9.48
14.46
9.9
10
10.33
9.68
8.84
5.43
8.55
8.55
8.55
Total
136
80
80
30
118
73
233
246
505
282
253
221
225
82
82
83
2729
Mean [mmHg]
-0.93
-2.6
-0.2
1.7
0.9
-2.24
-1
0.5
0.3
-0.77
0.6
-1.78
-1.78
-0.6
-0.51
-2.67
SD [mmHg]
9.23
0.6
8.12
1.53
7.14
8.65
14.46
8.8
10.3
9.76
10.13
8.83
8.83
8.47
7.76
9.15
Total
127
137
137
33
117
79
223
233
501
267
248
109
110
246
162
163
2892
Weight
5.4%
7.0%
5.7%
9.6%
6.3%
4.1%
4.5%
6.9%
8.1%
6.9%
6.7%
5.9%
6.5%
5.7%
5.5%
5.2%
100.0%
IV, Random, 95% CI [mmHg]
-1.07 [-3.30, 1.16]
1.00 [-0.64, 2.64]
-1.40 [-3.53, 0.73]
-2.00 [-2.72, -1.28]
-1.40 [-3.29, 0.49]
1.07 [-1.82, 3.96]
0.00 [-2.66, 2.66]
-2.20 [-3.88, -0.52]
-1.60 [-2.85, -0.35]
-0.41 [-2.09, 1.27]
-2.40 [-4.14, -0.66]
1.85 [-0.18, 3.88]
1.07 [-0.73, 2.87]
-0.05 [-2.18, 2.08]
-0.14 [-2.34, 2.06]
2.02 [-0.29, 4.33]
-0.50 [-1.24, 0.24]
GLP-1 agonists Active control Mean Difference Mean Difference
IV, Random, 95% CI [mmHg]
-10 -5 0 5 10
GLP-1 agonist Active control
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4.3.3 Body weight 
This study confirms GLP-1 agonists to display a clinically beneficial effect on 
body weight, WMD -1.22 kg [N=3128, 95%CI -0.93, -1.51, I2= 26%] versus 
placebo.  Liraglutide reduced body weight by -2.46 kg [N=1825, 95%CI, -
2.04, -2.87, I2= 65%] compared to active control.  Removal of Russell-Jones, 
2009 from this analyses abolished heterogeneity in the Liraglutide 1.8 mg 
subgroup and brought the overall inter-trial heterogeneity to acceptable 
limits. Heterogeneity was I2= ≥95% for trials comparing exenatide versus 
active control. Results were unchanged when using a fixed effects model or 
examining the number of completers rather than ITT.  Overall, mean (SD) 
body weight decreased by between -0.39 kg (2.38) and -6.22 kg (5.09) 
(Figure 4.3.3.1 GLP-1 agonists’ effects on weight loss in type 2 diabetes 
patients).  
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Figure 4.3.3.1 GLP-1 agonists effects on weight loss in type 2 
diabetes patients: 
 
a) GLP-1 agonists versus placebo for included studies using the 
random effects model 
 
i) Exenatide versus placebo displaying dose subgroups 
 
 
 
 
Study or Subgroup
4.2.1 Exenatide 5 mcg vs placebo
Buse, 2004
Kadowaki, 2009
Kendall 2005
Moretto, 2008
Subtotal (95% CI)
Heterogeneity: Tau² = 0.22; Chi² = 5.85, df = 3 (P = 0.12); I² = 49%
Test for overall effect: Z = 3.01 (P = 0.003)
4.2.2 Exenatide 10 mcg vs placebo
Apovian, 2010
Buse, 2004
Buse, 2011
Kadowaki, 2009
Kendall 2005
Liutkus, 2010
Moretto, 2008
Zinman, 2007
Subtotal (95% CI)
Heterogeneity: Tau² = 0.13; Chi² = 10.00, df = 7 (P = 0.19); I² = 30%
Test for overall effect: Z = 5.52 (P < 0.00001)
Total (95% CI)
Heterogeneity: Tau² = 0.15; Chi² = 17.04, df = 11 (P = 0.11); I² = 35%
Test for overall effect: Z = 6.28 (P < 0.00001)
Test for subgroup differences: Chi² = 0.55, df = 1 (P = 0.46), I² = 0%
Mean [kg]
-0.9
-1.54
-1.6
-2.8
-6.22
-1.6
-1.78
-0.39
-1.6
-1.4
-3.1
-2.12
SD [kg]
3.35
2.31
3.13
2.63
5.09
3.4
8.31
2.38
3.1
6.32
2.65
2.75
Total
125
73
245
77
520
96
129
137
72
241
111
78
121
985
1505
Mean [kg]
-0.6
0.47
-0.9
-1.4
-4.08
-0.6
0.96
0.47
-0.9
-0.8
-1.4
-0.24
SD [kg]
3.3
2.34
3.14
2.63
5.15
3.3
8.28
2.34
3.14
5.14
2.7
2.75
Total
62
18
124
39
243
98
61
122
18
123
54
38
60
574
817
Weight
8.9%
7.0%
13.8%
8.9%
38.7%
5.4%
8.9%
3.0%
7.0%
13.8%
3.7%
8.6%
11.0%
61.3%
100.0%
IV, Random, 95% CI [kg]
-0.30 [-1.31, 0.71]
-2.01 [-3.21, -0.81]
-0.70 [-1.38, -0.02]
-1.40 [-2.41, -0.39]
-1.02 [-1.69, -0.36]
-2.14 [-3.58, -0.70]
-1.00 [-2.01, 0.01]
-2.74 [-4.76, -0.72]
-0.86 [-2.07, 0.35]
-0.70 [-1.38, -0.02]
-0.60 [-2.41, 1.21]
-1.70 [-2.74, -0.66]
-1.88 [-2.73, -1.03]
-1.33 [-1.80, -0.86]
-1.21 [-1.58, -0.83]
Exenatide Placebo Mean Difference Mean Difference
IV, Random, 95% CI [kg]
-10 -5 0 5 10
Exenatide Placebo
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ii) GLP-1 agonists’ versus placebo (includes 2 liraglutide studies: 
Russell-Jones, 2009, Nauck, 2009) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Study or Subgroup
Apovian, 2010
Buse, 2004
Buse, 2004
Buse, 2011
Kadowaki, 2009
Kadowaki, 2009
Kendall 2005
Kendall 2005
Liutkus, 2010
Moretto, 2008
Moretto, 2008
Nauck 2009
Russell- Jones, 2009
Zinman, 2007
Total (95% CI)
Heterogeneity: Tau² = 0.07; Chi² = 17.54, df = 13 (P = 0.18); I² = 26%
Test for overall effect: Z = 8.20 (P < 0.00001)
Mean [kg]
-6.22
-0.9
-1.6
-1.78
-1.54
-0.39
-1.6
-1.6
-1.4
-2.8
-3.1
-2.8
-1.8
-2.12
SD [kg]
5.09
3.35
3.4
8.31
2.31
2.38
3.13
3.1
6.32
2.63
2.65
2.76
4.75
2.75
Total
96
125
129
137
73
72
245
241
111
77
78
230
230
121
1965
Mean [kg]
-4.08
-0.6
-0.6
0.96
0.47
0.47
-0.9
-0.9
-0.8
-1.4
-1.4
-1.5
-0.42
-0.24
SD [kg]
5.15
3.3
3.3
8.28
2.34
2.34
3.14
3.14
5.14
2.63
2.7
1.72
4.1
2.75
Total
98
62
61
122
18
18
124
123
54
39
38
232
114
60
1163
Weight
3.6%
6.5%
6.5%
1.9%
4.9%
4.8%
11.4%
11.4%
2.4%
6.5%
6.2%
18.5%
6.9%
8.4%
100.0%
IV, Random, 95% CI [kg]
-2.14 [-3.58, -0.70]
-0.30 [-1.31, 0.71]
-1.00 [-2.01, 0.01]
-2.74 [-4.76, -0.72]
-2.01 [-3.21, -0.81]
-0.86 [-2.07, 0.35]
-0.70 [-1.38, -0.02]
-0.70 [-1.38, -0.02]
-0.60 [-2.41, 1.21]
-1.40 [-2.41, -0.39]
-1.70 [-2.74, -0.66]
-1.30 [-1.72, -0.88]
-1.38 [-2.35, -0.41]
-1.88 [-2.73, -1.03]
-1.22 [-1.51, -0.93]
GLP-1 agonist Placebo Mean Difference Mean Difference
IV, Random, 95% CI [kg]
-10 -5 0 5 10
GLP-1 agonist Placebo
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b) GLP-1 agonists versus active control for included studies using the 
random effects model (95%CI) 
 
ii) Liraglutide versus active control effects on body weight, displaying 
dose subgroups 
 
 
 
ii) Exenatide versus active control effects on body weight, displaying 
dose subgroups 
 
 
 
 
 
 
Study or Subgroup
4.5.1 Liraglutide 1.2 mg vs active control
Pratley, 2010
Yang, 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.06; Chi² = 1.93, df = 1 (P = 0.17); I² = 48%
Test for overall effect: Z = 8.54 (P < 0.00001)
4.5.2 Liraglutide 1.8 mg vs active control
Pratley, 2010
Russell- Jones, 2009
Yang, 2011
Subtotal (95% CI)
Heterogeneity: Tau² = 0.12; Chi² = 4.55, df = 2 (P = 0.10); I² = 56%
Test for overall effect: Z = 10.19 (P < 0.00001)
Total (95% CI)
Heterogeneity: Tau² = 0.14; Chi² = 11.38, df = 4 (P = 0.02); I² = 65%
Test for overall effect: Z = 11.66 (P < 0.00001)
Test for subgroup differences: Chi² = 2.55, df = 1 (P = 0.11), I² = 60.7%
Mean [kg]
-2.86
-2.3
-3.38
-1.8
-2.4
SD [kg]
2.1
3
3
4.75
2.6
Total
225
233
458
221
230
234
685
1143
Mean [kg]
-0.96
0.1
-0.96
1.6
0.1
SD [kg]
1.8
2.2
1.8
3.82
2.2
Total
110
115
225
109
232
116
457
682
Weight
23.3%
20.0%
43.4%
21.0%
14.7%
21.0%
56.6%
100.0%
IV, Random, 95% CI [kg]
-1.90 [-2.33, -1.47]
-2.40 [-2.96, -1.84]
-2.12 [-2.60, -1.63]
-2.42 [-2.94, -1.90]
-3.40 [-4.19, -2.61]
-2.50 [-3.02, -1.98]
-2.70 [-3.22, -2.18]
-2.46 [-2.87, -2.04]
Liraglutide Active Control Mean Difference Mean Difference
IV, Random, 95% CI [kg]
-10 -5 0 5 10
Liraglutide Active control
Study or Subgroup
4.6.1 Exenatide 10 mcg vs active control
Barnett, 2007
Davies, 2009
DeFronzo, 2010
Gallwitz, 2011
Gallwitz, 2012
4.6.2 Exenatide LAR 2.0mg vs active control
Bergenstal, 2009
Bergenstal, 2010 (Piogl)
Bergenstal, 2010 (sita)
Diamant, 2010
Russell-Jones,2012 (MET)
Russell-Jones,2012 (Sita)
Russell-Jones,2012(Piogl)
Mean [kg]
-2
-2.73
-2.82
-4.1
-3.3
-1.9
-2.3
-2.3
-2.6
-2
-2
-2
SD [kg]
3.3
3.4
3.67
3.46
5.5
3.8
7.72
7.72
3.05
3.15
3.15
3.15
Total
68
118
45
248
504
124
80
80
233
82
82
83
Mean [kg]
1
2.98
1.48
1.02
1.2
4.1
2.8
-0.8
1.4
-2
-0.8
1.5
SD [kg]
3.35
3.4
3.67
3.36
4.2
3.6
7.84
8.5
2.99
3.14
3.83
3.83
Total
70
117
45
233
501
124
165
166
223
246
163
163
IV, Random, 95% CI [kg]
-3.00 [-4.11, -1.89]
-5.71 [-6.58, -4.84]
-4.30 [-5.82, -2.78]
-5.12 [-5.73, -4.51]
-4.50 [-5.10, -3.90]
-6.00 [-6.92, -5.08]
-5.10 [-7.17, -3.03]
-1.50 [-3.63, 0.63]
-4.00 [-4.55, -3.45]
0.00 [-0.79, 0.79]
-1.20 [-2.10, -0.30]
-3.50 [-4.40, -2.60]
Exenatide Active Control Mean Difference Mean Difference
IV, Random, 95% CI [kg]
-10 -5 0 5 10
Exenatide Active control
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iii) GLP-1 agonists’ versus active control 
 
 
Study or Subgroup
Barnett, 2007
Bergenstal, 2009
Bergenstal, 2010 (Piogl)
Bergenstal, 2010 (sita)
Davies, 2009
DeFronzo, 2010
Diamant, 2010
Gallwitz, 2011
Gallwitz, 2012
Pratley, 2010
Pratley, 2010
Russell- Jones, 2009
Russell-Jones,2012 (MET)
Russell-Jones,2012 (Sita)
Russell-Jones,2012(Piogl)
Yang, 2011
Yang, 2011
Mean [kg]
-2
-1.9
-2.3
-2.3
-2.73
-2.82
-2.6
-4.1
-3.3
-3.38
-2.86
-1.8
-2
-2
-2
-2.4
-2.3
SD [kg]
3.3
3.8
7.72
7.72
3.4
3.67
3.05
3.46
5.5
3
2.1
4.75
3.15
3.15
3.15
2.6
3
Total
68
124
80
80
118
45
233
248
504
221
225
230
82
82
83
234
233
Mean [kg]
1
4.1
2.8
-0.8
2.98
1.48
1.4
1.02
1.2
-0.96
-0.96
1.6
-2
-0.8
1.5
0.1
0.1
SD [kg]
3.35
3.6
7.84
8.5
3.4
3.67
2.99
3.36
4.2
1.8
1.8
3.82
3.14
3.83
3.83
2.2
2.2
Total
70
124
165
166
117
45
223
233
501
109
110
232
246
163
163
116
115
IV, Random, 95% CI [kg]
-3.00 [-4.11, -1.89]
-6.00 [-6.92, -5.08]
-5.10 [-7.17, -3.03]
-1.50 [-3.63, 0.63]
-5.71 [-6.58, -4.84]
-4.30 [-5.82, -2.78]
-4.00 [-4.55, -3.45]
-5.12 [-5.73, -4.51]
-4.50 [-5.10, -3.90]
-2.42 [-2.94, -1.90]
-1.90 [-2.33, -1.47]
-3.40 [-4.19, -2.61]
0.00 [-0.79, 0.79]
-1.20 [-2.10, -0.30]
-3.50 [-4.40, -2.60]
-2.50 [-3.02, -1.98]
-2.40 [-2.96, -1.84]
GLP-1 agonists Active Control Mean Difference Mean Difference
IV, Random, 95% CI [kg]
-10 -5 0 5 10
GLP-1 agonists Active control
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4.4 Discussion 
In agreement with recent literature, GLP-1 agonists’ display a beneficial 
effect on blood pressure and also a clinically significant reduction in body 
weight (Vilsbøll, 2012).   The effectiveness of GLP-1 agonists in improving 
diabetes co-morbidities such as raised blood pressure and body weight is 
clearly of importance in clinical decision making.  This small but favourable 
effect on blood pressure might confer significant clinical benefit evident at the 
population level, particularly in patients with diabetes and associated 
cardiovascular morbidity (Stäessen & Wang, 2001).  Studies in these high 
risk patients show that as little as a 2-5mmHg lowering of blood pressure can 
reduce the relative risk of cardiovascular events by 20-40 % (Stäessen & 
Wang, 2001). This assumes that the mechanism behind this change in blood 
pressure, which is not yet understood, is itself beneficial. Interestingly, this 
meta-analysis highlights that inter-trial heterogeneity was reduced to 
acceptable limits (I2 <20%) when Gao, 2009 and Kadowaki, 2009 were 
removed from the GLP-1 agonists versus placebo groups.  This suggests 
that there might be ethnic differences in systolic blood pressure response as 
the patients from these trials were of Asian descent.  Possible reasons for 
heterogeneity in other comparisons were not identified. However, it could be 
argued that statistical heterogeneity will always exist in a meta-analysis as it 
is not possible to fully account for such differences.  Identification of the 
sources of heterogeneity and subsequent removal did not alter the strength 
or direction of the effects for blood pressure and heart rate and so further 
exploration using meta-regression was not deemed appropriate.  However, it 
would have been interesting to compare further the potential ethnic 
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differences had there been a higher number of trials using Asian patients.  
Interestingly, patients undergoing therapy with exenatide long acting release 
formulations displayed slightly less blood pressure reductions over all than 
patients administered shorter-acting GLP-1 agonists compared to active 
comparators.  The suggestion of reduced blood pressure gains and 
increased pulse rate is of clear concern for the safety evaluation of these 
long-acting formulations.  Further explorations into the possible mechanisms 
behind this effect would be beneficial.   
The inclusion of trials consisting of active comparators impacted on the 
strength and direction of effect on body weight and also led to substantial 
between-trial heterogeneity, which is at least in- part due to the tendency for 
traditional oral antidiabetic agents to increase body weight. However, I am 
able to demonstrate the reduction of body weight by GLP-1 agonists remain 
apparent when the control arm consisted of patients receiving placebo.  
Reports in the literature show a large variation in response to exenatide with 
roughly 30% of patients displaying high response to short term treatment 
(>5% weight loss), 39% being moderate responders (<5% weight loss) and 
31% being non responders (Dushay et al, 2012; Ryder et al, 2010) which 
may have contributed to heterogeneity seen in this study.  Physiological 
actions of GLP-1 agonists leading to body weight reduction are understood 
to be through activation of taste aversion via GLP-1s actions in the 
amygdala, decreased gastric emptying and development of conditioned taste 
aversion as well as increased energy expenditure (Grieve, 2009).   
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While there is indication that these drugs improve blood pressure as well as 
to offer clinically significant reductions in body weight, clinicians need to 
continue to be cautious and careful about the potential harm that a drug that 
increases heart rate might produce.  It is likely that the increased heart rate 
responses to GLP-1 agonists are produced via similar neuronal mechanisms 
to those which regulate glycaemia and body weight.  GLP-1R has been 
located in vagal afferent fibers, pancreatic β-cells and within CNS neurons 
(Hayes, 2012; Griffion et al, 2011; Cabou et al, 2008), the significance of 
which is GLP-1’s involvement in the co-ordinated control of metabolic and 
cardiovascular function (Hayes, 2012; Griffion et al, 2011; Cabou et al, 
2008). Recently, personal communications with Novo Nordisk researchers 
highlight the presence of GLP-1R on sino-atrial tissue.  This might prove to 
be a significant side effect for individuals sensitive to heart rate effects of 
GLP-1 agonists.   
Interpretation of the impact of GLP-1 agonists’ on heart rate is limited due to 
the paucity of available data.  The tendency for reports to only publish 
significant data could result in (reporting) bias towards an increase in overall 
heart rate for patients taking liraglutide.  The inclusion of unpublished data 
for exenatide enables some indication of the effect this drug has on heart 
rate. However, differences in the included trial designs with respect to this 
particular outcome might potentially weaken the findings of this meta-
analysis.   In keeping with current reports, liraglutide displayed a slightly 
more pronounced increase in heart rate to exenatide but was comparable to 
exenatide once weekly suggesting that the prolonged half life of exenatide 
long acting release formulation increases the risk of chronotropic side 
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effects.  Interestingly, NovoNordisk quartile data highlight the possibility that 
liraglutide causes greater heart rate increases in T2DM patients with a lower 
baseline heart rate and one assumes higher vagal tone.  Although this data 
could be interpreted as being biased statistically by the regression to the 
mean phenomenon, a physiological mechanism is another valid explanation 
particularly as this effect is being reported as enhanced in the longer acting 
agents.   
GLP-1R has been located in a variety of extra-pancreatic tissues including 
vascular smooth muscle, cardiomyocytes, endocardium and coronary 
endothelium/ smooth muscle suggestive of direct cardiovascular action of 
GLP-1 (Grieve, 2009).  As mentioned, GLP-1R has also been discovered in 
autonomic nervous tissue (vagal and sympathetic) and GLP-1R exists in the 
cardiac sinus node.  Supportive studies in animals indicate that GLP-1 acts 
as a neuropeptide and has been shown consistently to raise heart rate and 
also blood pressure in rodents within the picomolar and nanomolar range, 
but disparity exists in studies of large animals and humans. Furthermore, 
these effects have not yet been clearly demonstrated to be species- specific 
(Hirata et al, 2009; Bojanowska & Stempniak, 2000; 2003; Barragan et al, 
1999). Interestingly, and which has been highlighted in a comprehensive 
review by Grieve (Grieve, 2009), studies in animals and humans show a 
biphasic response to infusions of GLP-1(7-36) with an initial rise in blood 
pressure followed by a prolonged hypotensive effect which could be the 
result of the action of DPPIV truncated GLP-1(9-36) (Barragan, 1994; 
Bojanowska & Stepniak, 2000; Edwards, 1998).   Liraglutide is also 
understood to be converted to truncated GLP-1 (9-36) but after a prolonged 
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half-life due to resistance to DPPIV (Malm-Erjefalt, 2010). However, this 
study confirms comparable blood pressure reductions in patients taking 
exenatide suggestive that more complex mechanisms relating to blood 
pressure reduction exist.  With regards to heart rate both animal and human 
studies suggest that this is a GLP-1R-mediated action and thus might be 
expected to be a consequence of action of GLP-1(7-36) and GLP-1(7-37) 
and exenatide.  It might be valuable to conduct clinical trials into the effects 
of other GLP-1 metabolites such as GLP-1(9-36) as there is increasing 
evidence that this metabolite might play a beneficial role in the 
cardiovascular system as has been shown to display vasorelaxant effects as 
well as to improve LV, systolic and diastolic function (Grieve et al, 2009).         
A limitation to this meta-analysis is that I was not able to compare GLP-1 
agonists to specific oral antidiabetic drugs (OADs) due to the limited number 
of trials with similar therapeutic strategies to directly compare.  Furthermore, 
meta-regression could not be conducted for all comparisons due to some 
comparisons having less than 10 trials to compare.  A minimum of 10 trials is 
needed for meta-regression to increase statistical power. Therefore, we 
chose not to perform meta-regression for this study.  Other types of meta-
analyses such as network meta-analysis would not have been appropriate 
due to limited number of trials with multiple intervention and comparator 
arms.  We therefore chose a simpler approach that allowed for stratification 
of the different drugs and doses allowing the potential differences in effect to 
be easily compared.    Further research needs to be conducted to improve 
our understanding of the physiological mechanisms through which these 
drugs act and this particularly needs to be addressed for the long acting 
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GLP-1 agonists, whilst the results of longer term safety studies are awaited. 
There is also a clear need to improve the comprehensive reporting of all 
outcome data measured during clinical trials of anti-diabetic agents, 
particularly those relevant to cardiovascular outcomes. 
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5.0 Reversible glucotoxicity as a possible causal 
mechanism for blunted GLP-1R    expression in 
diabetic and obese transgenic mice 
5.1 Introduction  
The presence of GLP-1R in renal tissue suggests that GLP-1 might play an 
important role in either renal control of glucose or sodium.  GLP-1 has been 
shown to inhibit hepatic gluconeogenesis and so it is logical that GLP-1 
might regulate renal glucose by similar mechanisms (Tomas & Habener, 
2009).  As previously discussed GLP-1 has been shown to increase 
natriuresis and hence is speculated to inhibit renal sodium reabsorption 
(Hirata et al, 2009). Therefore, it might be pertinent to elucidate and dissect 
possible involvement of renal GLP-1R -dependent and -independent 
regulation of core metabolic processes.  I hypothesize that extended 
exposure to high glucose (such as during the metabolic syndrome (obesity) 
and T2DM), will result in blunted renal GLP-1R expression in models of 
obesity and diabetes.        
Circulating GLP-1 has been shown to be reduced in obesity and T2DM in 
humans (Muscilli et al, 2007; Manucci et al, 2000; Holst & Gromada 2004; 
Vilsbøll et al, 2003; Vaag et al, 1996). Furthermore, Xu and co-workers have 
shown that gene expression of GLP-1R to be significantly reduced in islets of 
90% pancreatectomised hyperglycaemic rats.  This effect was reversed 
when glucose levels were normalised by sodium glucose transporter (SGLT) 
inhibitor, phlorizin which prevents both intestinal glucose absorption and 
induces glycosuria.  GLP-1 receptor expression was also shown to be 
blunted in rats using the hyperglycaemic clamp technique for 96 hours and 
further replicated in cells cultured with high glucose for 48 hours (Xu et al, 
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2007). In addition, Cheong and colleagues describe fluctuating exposure to 
high glucose to result in blunted GLP-1R expression in cultured cells 
(Cheong et al, 2011).  GLP-1R mediated insulinotropic effects are highly 
dependent on ambient glucose which can be exemplified by the protection of 
GLP-1 agonists against hypoglycaemia (Grieve et al, 2009). GLP-1R is 
dependent on ambient glucose concentrations and is present in the kidney. It 
is thus possible that GLP-1R-mediated actions could contribute to renal 
glucose regulation and sodium transport under normal conditions and that 
during pathological states GLP-1R signalling is disrupted. The following 
study shows GLP-1R expression to be altered in the kidneys of ob/ob 
(C57BL/6; BL/6), db/db (C57BLK/s; BLK/s) and Tamoxifen-induced diabetic 
mice (MycER) animal models of obesity and T2DM; and that hyperglycaemia 
might, at least in part, be a driving force behind abnormal GLP-1R 
expression in these mice.  
5.1 Materials and methods 
5.1.1 Transgenic mice 
Ob/ob and db/db mice: Adult Db/db mice with a genetic background 
C57BL/Ks and ob/ob transgenic mouse strains with genetic background 
C57BLK/6 as well as wild-type C57BLK/6J controls (n=9) were obtained from 
Harlan Ltd (Loughborough, UK). Both mice strains were congenic mutants 
and were maintained as an inbred model via full sib matings at the Harlen 
facility before the mice were passed to researchers at the University of 
Warwick.  Animal husbandry and sacrifice described herein was performed 
by post doctoral researchers at University of Warwick.  All mice were housed 
individually and maintained under pathogen-free conditions with controlled 
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lighting (0700- 1900 h), 12 hr dark (1900- 0700 h) cycle with controlled 
temperature and humidity.  Mice had free access to standard laboratory 
chow consisting of 70% carbohydrate, 10% fat, and 20% protein with an 
energy density of 3.85 kcal/ g. At 11 weeks, mice were killed by CO2 
exposure for 10 minutes and kidneys dissected, ensuring complete removal 
of encapsulating adipose tissue.  The overall weights for all mice used in this 
study were C57BL/6J: 30 ± 5g; C57BL/6 ob/ob; 55 ± 5g; C57BL/Ks db/db: 48 
± 4g.  
Tamoxifen- induced diabetic mice:  Whole kidneys from the right hand side of 
heterozygous transgenic pIns-c-MycERTAM+/– (MycER) mice were kindly 
donated by Professor Michael Kahn (University of Warwick). Dr. Manjunath 
Ramanjanaya killed and I subsequently dissected kidneys from matched 
control (wild type) mice.  I performed this procedure under the kind 
supervision of Dr. Manjunath Ramanjanaya, University of Warwick. Kidneys 
from these mice were transferred immediately to storage at -80 C until use. 
 
pIns-c-MycERTAM mice express, under the control of the Ppi promoter, 
human c-MYC fused to the hormone binding domain of 4-OH-tamoxifen 
(TAM)-responsive mutant oestrogen receptor (Littlewood, 1995). Pascal and 
co-workers have previously described their characteristics and the effect of in 
vivo activation and deactivation of the MycERTAM construct on β-cell 
apoptosis and proliferation, β-cell mass, and glucose tolerance (Pascal, 
2008). Professor Mike Khan’s research group maintained these mice on a 
mixed genetic background (C57BL/6J x CBA F1 mice) and genotyped by 
PCR analysis (using MycERTAM-specific primers (sense 5'-CCA AAG GTT 
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GGC AGC CCT CAT GTC-3'; antisense 5'-AGG GTC AAG TTG GAC AGT 
GTC AGA GT-3')). All mice (N = 12) had previously been housed under 
controlled lighting (12:12-h light-dark cycle) and temperature conditions and 
received a common laboratory chow (Carfil Quality; Pavan, Oud-Turnhout, 
Belgium) and water ad libitum. Professor Michael Khan’s group subsequently 
killed the mice by cervical dislocation and decapitation and measured their 
body weight and blood glucose concentration in the fed state (Ascensia Elite 
glucometer; Bayer Healthcare, Leverkusen, Germany), before excision of 
organs and storage in -80 C.  The whole kidneys from the right hand sides of 
the animals were then kindly donated to me for analysis.  All animal 
procedures had been performed under UK guidance on the Operation of 
Animals Scientific Procedures) Act (1986).  
5.1.2 Preparation of kidney homogenates 
For the analyses and regulation of GLP-1R protein, kidneys were removed 
from -80 C storage and thawed at room temperature. A coronal section of 
each kidney was removed and homogenised.  All fresh kidney samples were 
kept on ice to minimise degradation. Samples were separated and prepared 
either for analysis by RT-PCR or western blot. 
5.1.3 RT-PCR. 
Primers against murine GLP-1R were purchased from Primer design (Figure 
5.1.3.1). Quantitative PCR of murine GLP-1 receptor were performed on an 
ABI 7000 system (Applied Biosystems).  PCRs were carried out in a reaction 
mixture consisting of 10 µl PrecisionTM master mix containing syber green 
and ROX (Primerdesign, UK), 1.0 µl of each primer (300 nM per 20 µl 
reaction), 5 µl cDNA (≈5 ng/ µl), and 4 µl RNAse/DNAse free water. Protocol 
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conditions consisted of denaturation for 95 C for 10 minutes, followed by 40 
cycles of 95 C for 15 sec, 57 C for 60 sec, followed by melting curve 
analysis. The RNA levels were expressed as a ratio, using δ-δ method which 
is an approximation method for comparing relative expression results 
between measurements in real-time PCR (Pfaffl, 2001). Ten microlitres of 
the reaction mixture were subsequently eletrophoresed on a 1% agarose gel 
and visualised by ethidium bromide, using a 1-kb DNA ladder (Invitrogen) to 
estimate band sizes.   RNAs were assayed from three independent biological 
replicates.   
Table 5.1.3.1 
Gene Forward primer Reverse Primer Size (bp) 
Mus musculus 
GLP-1R* 
5-
TGGGGTACGCACTTTCTTTC-3 
5’-
GCAAACAGGTTCAGGTGGAT-3 
106  
*, Pre-validated primers, patent protection (Primer Design, UK) 
5.1.4 Western blot 
Protein lysates were prepared by mixing equal amounts of Laemmli buffer [5 
M urea, 0.17 M sodium dodecyl sulphate, 0.4 M dithiothreitol, and 50 mM 
Tris-HCL (pH 8.0)] and placing on a hot plate at 95 Celsius for 5 minutes.  All 
samples were then allowed to cool at room temperature. The proteins in 
protein lysates (35 µg/lane) were separated by SDS-PAGE (10% resolving 
gel) and transferred to polyvinylidene diflouride (PVDF) membranes at 100 V 
for 1 h in a transfer buffer containing 20 mM Tris, 150 mM glycine, and 20% 
methanol. PVDF membranes were then blocked in tris-buffered saline 
containing 0.1% Tween 20 and 5% BSA overnight.  Membranes were then 
incubated in primary murine GLP-1R antibody or murine GLP-1 peptide 
antibody (1:2000 +0.5% B.S.A TBST) for 1 hr before undergoing 5 
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consecutive 15 minute washes under gentle agitation. Membranes were then 
incubated in secondary anti-rabbit peroxidise (1:8000 +0.5% BSA TBST) or 
secondary anti-mouse peroxidise (1:2000 +0.5% BSA, TBST) for GLP-1R 
and GLP-1 respectively before a further 5, 15 minute washes and 
subsequent visualisation by ECL chemiluminescence.  
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5.2 Results 
5.2.1 Decreased GLP-1R mRNA expression in the kidneys of 
obese (db/db and ob/ob) mice 
I initially examined GLP-1R mRNA expression in whole kidneys from wild-
type (WT) BL/6J, obese BL/6 and diabetic BLK/s male mice.  The kidneys 
were separated according to the three comparator groups before preparation 
of cDNA and subsequent analysis by PCR. One- way analysis of variance 
showed an approximate 4-fold decrease in GLP-1R mRNA expression in 
BL/6 (P = 0.05) and 5-fold decrease in GLP-1R expression in BLK/s mice (P 
= 0.001) compared to wild-type littermates (Figure, 5.2.1.1 Differences in 
GLP-1R mRNA expression in kidneys of wild-type (C57BL/6J), ob/ob 
(C57BL/6) and db/db (C57BL/Ks) mice).  Evaluation of the GLP-1R 
expression on the protein level by western blot showed a corresponding 2-
fold decrease in GLP-1R expression in the kidneys of these mice (P= 0.01) 
(Figure 5.2.1.2 Differences in GLP-1R protein expression in kidneys of 
wild-type (C57BL/6J), ob/ob (C57BL/6) and db/db (C57BL/Ks) mice).  
Protein characteristic of GLP-1 peptide was not found to be present in 
murine renal tissue.  Results confirm my hypothesis that GLP-1 R mRNA 
expression is down-regulated in obesity and diabetes. 
 
5.2.2 Decreased GLP-1R mRNA expression in kidneys from 
tamoxifen-induced hyperglycaemic mice 
To dissociate obesity and leptin mediated factors and to assess the influence 
of hyperglycaemia on renal GLP-1 receptor expression in vivo, I then 
explored GLP-1R expression in Tamoxifen-induced diabetic mice.  Kidneys 
were separated according to stage of hyperglycaemia initiated by activation 
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of the beta-cell c-myc promoter by tamoxifen, (Day 0: baseline 
normoglycaemia (mean ± S.E.M glucose levels: 77.48 ± 8.83 mg/dL), Day 7: 
severe hyperglycaemia (426.49 ± 22.88 mg/dL) and recovery day 6 showing 
a reduction of hyperglycaemia towards normal levels (285.23 ± 95.32 
mg/dL).  Statistical analysis showed the overall effect to be an inverse 
relationship of GLP-1R mRNA expression with circulating glucose levels in 
these mice.  A 3- fold reduction of GLP-1R expression was seen at day 7 
hyperglycaemia compared to day 0 control (P= 0.021) and this returned 
towards normal values by day 6 of the recovery phase (P= N.S.) (Figure, 
5.2.2.1 GLP-1R mRNA expression in tamoxifen-induced hyperglycaemic 
mice).  
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Figure 5.2.1.1- Differences in GLP-1R mRNA expression in kidneys of 
wild-type (C57BL/6J), ob/ob (C57BL/6) and db/db (C57BL/Ks) mice. 
Coronal sections from the kidneys of BL/6J, BL/6 and BL/Ks transgenic 
mouse strains (N=9) were homogenised and extracted for total RNA as 
described previously. Complimentary cDNA was then prepared before 
analysis by RT-PCR for GLP-1R mRNA expression. Ubiquitously expressed 
GapDH was used as control. Data are expressed as relative difference of 
median of control (WT). Nine independent experiments were performed and 
each experiment was carried out in three replicates. Results were analysed 
using ANOVA and expressed as means ± S.E.M. 
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Figure 5.2.1.2- Differences in GLP-1R protein expression in kidneys of
wild-type (C57BL/6J), ob/ob (C57BL/6) and db/db (C57BL/Ks) mice.
BL/6J, BL/6 and BL/Ks transgenic mouse strains were culled at 11 weeks.
Right kidneys from each animal (N=9) were homogenised and proteins
separated by western blot and probed for anti-GLP-1R antibody. Glucagon-
like peptide receptor (GLP-1R) protein levels relative to β actin were 
significantly decreased in BL/6 and BL/Ks mice compared to WT using
western blotting. Data are expressed relative to median of control (WT). Nine
independent experiments were performed and each experiment was carried
out in three replicates. Group comparison were analysed using ANOVA with
Dunnett’s Multiple Comparison test. Results are expressed as means ±
S.E.M.
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Figure 5.2.2.1- GLP-1R mRNA expression in tamoxifen-induced 
hyperglycaemic mice (MycER). Blood glucose was measured at baseline 
(D0), and during hyperglycaemia (D7) and recovery phase (R6) in tamoxifen-
induced MycER mice.  GLP-1R mRNA was quantified using RT-PCR at 
corresponding days to show 3-fold decrease in GLP-1R mRNA expression 
with a corresponding rise in glucose levels (above graph). Data are 
expressed relative to median of control (WT). Twelve independent 
experiments were carried out and each experiment was performed in three 
replicates. Group comparison by repeated measures ANOVA with Tukey’s 
Multiple Comparisons test.  
 
 
 
 
5.3 Discussion 
GLP-1 signalling pathways are well understood to be influenced by plasma 
glucose concentrations.  That is to say that GLP-1 is secreted in response to 
glucose and plays a role in glucose regulation and insulin secretion as well 
as certain GLP-1 metabolites displaying insulin-like action in peripheral 
tissues (Thomas & Habener, 2009).  Furthermore, insulinotropic actions of 
GLP-1 are dependent on ambient glucose concentrations which can be 
exemplified by the inability of GLP-1 agonists to induce hypoglycaemia 
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(Grieve et al, 2009).  A release of GLP-1 in response to increasing glucose 
levels stimulates insulin, an effect which is halted subsequent to 
normalisation of ambient glucose concentrations by insulin.  This 
phenomenon is of clinical benefit in the treatment of T2DM by GLP-1 
agonists which, unlike traditional anti-diabetes therapy protects against 
hypoglycaemic episodes.   
The animals in the following chapter were chosen primarily to assess GLP-
1R expression in response to differing levels of derangement in insulin 
signalling, with consequent hyperglycaemia.  Following this, I planned to 
focus specifically on GLP-1R expression during hyperglycaemia after 
reversible Ppi gene knock-out and hence, β-cell apoptosis and depletion of 
insulin secretion.  Benefits of the latter mouse model, MycER (Tamoxifen- 
induced diabetes mouse), is that the direct effects of insulin depletion and 
subsequent marked hyperglycaemia can be observed in vivo with 
dissociation of obesity and leptin factors which are present in the other 
experimental models.  The use of spontaneous or genetically derived T2DM 
mice such as ob/ob (C57BL/6; BL/6) and db/db (C57BLK/s; BLK/s) mice 
have various advantages and disadvantages over nutrient or chemically 
induced species (e.g. C57BL/6J mouse, similar to BL/6 strain but which are 
normal weights until administered high fat feed; or GTG treated obese mice).  
These mice are genetically homogenous and thus only a small number of 
animals are required for experimentation and environmental factors are 
easily controlled making it simpler to tease out genetic influences from this 
multifactoral disease (Srinivasan & Ramarao, 2007).  However, these mice 
are not similar to human obesity-induced diabetes which is highly 
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heterogenous.  Transgenic/knock-out diabetic mice such as the MycER mice 
are also highly homogenous but the complexity of this experimental model 
means that it is a highly costly option.  Nevertheless, these animal models 
were chosen due to their genomic constitutions being derived from BL/6 
which makes these mice highly comparable despite differing physiological 
profiles.  This enabled me to study the effects of moderate to frank 
hyperglycaemia (and hence the corresponding relationship of insulin 
secretion and β-cell function) in the BL/6 and BLK/s mice against their wild 
type litter mates.  I was then able to look closely at the pattern of response of 
renal GLP-1R expression to hyperglycaemia (with respect to insulin depletion 
and feedback to the gut-brain axis) in the MycERTAM model without the 
associated factors related to obesity and leptin signalling.  
Renal disease is more pronounced in the BLK/s than in the BL/6 mice 
possibly due to high circulating leptin levels and the ability of leptin to 
stimulate matrix production (BL/6 mice display reduced leptin secretion as a 
core mechanism in the development of obesity whereas BLK/s metabolic 
dysfunction arises from disrupted leptin receptor signalling). Renal disease 
may also be dependent on genetic background and hence the marked 
hyperglycaemia seen in this mouse strain (Sharma et al, 2003).  GLP-1R 
mRNA and protein expression are markedly lower in BLK/s mice as 
compared to WT and BL/6 strains which may be in part, a reflection of more 
severe hyperglycaemia and hence diabetes in these mice or deregulated 
insulin secretion and β-cell apoptosis.  However, before any inferences can 
be made as to whether disrupted neuronal signalling from pancreatic β-cells 
to the CNS and/ or subsequent hyperglycaemia is the driving force behind 
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the blunted receptor expression, we must first consider other factors that 
might lead to disruption of GLP-1R signalling in the kidney. Leptin and GLP-1 
share interrelated actions, both opposing and complimentary, with respect to 
glucose homeostasis and satiety regulation.  For instance, GLP-1 has been 
demonstrated to reside downstream of leptin action in the CNS pathways 
regulating food intake (Goldstone et al, 1997).  GLP-1R antagonist exendin 
(9-39), has been shown to inhibit the leptin-induced reduction of food intake 
and weight loss (Goldstone et al, 1997) and leptin is understood to 
upregulate brainstem proglucagon RNA and hypothalamic GLP-1 content in 
rats (Goldstone et al, 2000). Furthermore, GLP-1 and leptin both activate c-
fos expression in a subset of neurons in the nucleus of the solitary tract of 
the brain stem (Elias et al, 2000) and leptin up-regulates the GLP-1 receptor 
(Sanz et al, 2008; Schrocchi et al, 2000).  Despite the ability of leptin to 
influence central GLP-1 production and brain GLP-1R expression it is 
unlikely that in BLK/s, circulating leptin directly down-regulates peripheral 
GLP-1R such as that in the kidney because the BL/6 model is deficient in 
leptin but also displayed down-regulation of renal GLP-1R.  
 
 It might therefore be hypothesized that down-regulation of renal GLP-1R 
might be correlated with the degree of β-cell destruction and hence insulin 
signalling to the hypothalamus via the gut-brain axis or a direct down-
regulation by chronic hyperglycaemia.  Hyperglycaemia is much greater and 
sustained in BLKs mice than in the BL/6 strain which might contribute to the 
more pronounced inhibition of GLP-1R in the BLK/s mice as compared to the 
BL/6 mice.   
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To explore the contribution of β-cell destruction and subsequent depletion of 
insulin/ hyperglycaemia to the down-regulation of renal GLP-1R I assessed 
GLP-1R mRNA expression in an in vivo model of hyperglycaemia. MycER 
mice were utilised in this part of the study.  These mice are genetically 
manipulated to upregulate c-MYC after treatment with tamoxifen triggering 
cell apoptosis and decreased preproinsulin gene expression in c-MYC islets.  
This results in marked β-cell destruction, depletion of insulin secretion and 
hyperglycaemia while upon withdrawal of tamoxifen the glycaemic response 
returns to normal values.  Mice were mostly male and were treated with 
tamoxifen for 7 days. Tamoxifen was then withdrawn and the mice were 
monitored for 50 days.  Results show an inverse relationship between GLP-
1R mRNA expression and circulating glucose levels which is indicative that 
these changes may be due to the effect of hyperglycaemia on GLP-1R 
expression.  However, it might also be postulated that renal GLP-1R mRNA 
expression would also correlate with the degree of β-cell destruction and 
insulin secretion.  Therefore, hypothalamic-regulatory neurons might relay 
signals from CNS to renal GLP-1R to down regulate the receptor. When 
considering this from the perspective of feedback from the brain to the 
periphery, it is highly unlikely that chronic hyperglycaemia per se would down 
regulate brain GLP-1R and subsequently relay messages to down-regulate 
renal GLP-1R. It would be more likely that, in order to protect the brain 
against pathologically high levels of glucose, chronically high brain glucose 
would “switch on” GLP-1R response and subsequently lead to 
hyperinsulinemia via CNS and vagal efferents for pancreatic β-cells.  
However, the reduction of brain insulin due to advanced diabetes and hence 
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β-cell destruction might trigger feedback to the periphery to down-regulate 
GLP-1R and also during advanced uncontrolled hyperglycaemia, GLP-1R 
might be directly influenced by glucose generation of reactive oxygen 
species and glycation end products in both the brain regions and also the 
kidney.  This might subsequently be reversed by generation of nitric oxide 
(NO) and other free radical scavenging molecules by restoration of insulin 
signalling and GLP-1R response (Cabou et al, 2008; Ojima et al, 2013). 
The MycERTAM model reduces Ppi mRNA expression as a consequence of 
interaction with tamoxifen and therefore is important to consider whether 
tamoxifen administration interacts directly with GLP-1R function as well as 
the preproinsulin promoter and thus directly inhibits GLP-1R mRNA 
expression.  As mentioned previously, activation of the MycERTAM construct 
interferes with glucose homeostasis via disruption of insulin secretion and 
beta cell apoptosis (Pascal et al, 2008). GLP-1 is involved in glucose- 
dependent insulin secretion and stimulates pro-insulin biosynthesis and has 
been shown to increase insulin mRNA levels and insulin content (Doyle et al, 
2007). GLP-1R activation is also understood to be involved in β-cell growth 
and proliferation through induction of WNT signalling in pancreatic β-cells, 
isolated islets and in INS-1 cells.  Basal and GLP-1 agonist- induced 
proliferation of β-cells requires active WNT signalling cascade via GLP-1R- 
mediated activation of Akt and beta-cell independent GSK3β (Lui et al, 
2008). This process involves activation of c-Myc (Lui et al, 2008) and so it is 
logical to consider that inactivation of c-Myc by tamoxifen might indirectly 
down-regulate GLP-1R by disruption of the GLP-1 signalling system.  This 
may be tested by administering the animals with both tamoxifen and insulin 
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to restore glucose levels to normal values without restoring Ppi gene function 
and hence insulin secretion.  This will allow more information as to whether 
hyperglycaemia is in fact a driving force for GLP-1R down-regulation and 
help to tease out the effects of direct neuronal feedback from pancreatic 
islets and insulin signalling to the hypothalamus.  These results suggest that 
hyperglycaemia influences inhibition of the GLP-1R.  The possible interaction 
between tamoxifen and pancreatic GLP-1R needs to be clarified.  
Teasing out the relationship between dysregulated metabolic effects and the 
effects on GLP-1R expression is not an easy task and much research needs 
to be conducted to deduce what effects certain regulatory factors have on 
GLP-1 signalling and how restoration of GLP-1R activation by GLP-1 
agonists might restore homeostatic mechanisms. Primarily there are two 
lines of thought when considering the reason as to why renal GLP-1R 
expression might be down-regulated in the animals utilised in this study, 1) 
Direct feedback from β-cells as a consequence of apoptosis and reduced 
insulin signalling, possibly due to neuronal feedback via the vagal nerve to 
the brain 2) direct glucose-dependent effects and possible disruption of GLP-
1R signalling through generation of ROS.  The following chapter will assess 
the latter hypothesis using isolated cells of the renal and proximal tubule.  
Further research is warranted into the neuropeptide effects of GLP-1 which 
links GLP-1 signalling to body weight, blood pressure and heart rate 
responses as will be discussed in the final chapter.  
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6.0 GLP-1R expression in human collecting duct and 
proximal tubule cells during hyperglycaemia-like 
conditions 
6.1 Introduction 
The primary purpose of the following chapter was to assess whether GLP-1R 
is present and functional in cells of the kidney in preparation for mechanistic 
studies into the effect of GLP-1 on α-ENaC expression studies (a surrogate 
marker for blood pressure regulation). The aim was also to continue work 
from the previous chapter to confirm whether high ambient glucose 
concentrations will down-regulate human GLP-1R expression.  My rationale 
was to explore whether I could replicate down-regulation of GLP-1R in the 
absence of confounding factors present in vivo such as obesity- related leptin 
deficiency/ resistance and associated hypothalamic factors or insulin/ beta 
cell depletion seen in the animal models.  I also wanted to assess whether 
my previous findings could be species specific and whether this effect can be 
replicated in human renal cells expressing GLP-1R.  Information is scarce 
regarding mechanisms which influence GLP-1R in the kidney.  I therefore 
mimicked hyperglycaemia in cell lines of the human kidney proximal tubule 
and collecting duct to assess the influence of high glucose on renal GLP-1R 
expression.    
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6.2 Materials and methods 
6.1.1 Cell culture  
Human collecting duct (HCD) and human proximal tubule (HKC8) cells were 
kindly donated by Dr. Rose Bland, University of Warwick.  Cells were 
previously characterised and cloned and this is described elsewhere (Prie, 
1995).  Cells (passages 15-23) were maintained in DMEM/ Hams F-12 
medium (GIBCO, Invitrogen), supplemented with 2% foetal calf serum (FCS), 
glutamine (2 mmol), 15 mmol/l HEPES, transferring (5 µg/ml), Na2SeO3 (5 
ng/ml), insulin (5 µg/ml), and dexamethasone (5 x 10-8 M), 2 mL pen/strep. 
Normal growth media for HKC8 cells consisted of DMEM/Hams-F12 
containing 5% foetal calf serum and 2 mL pen/strep. Subculturing and fasting 
media incorporated the same method for both cell lines (see ‘appendix’). 
Cells were grown to 80% confluence at 37oC in a humidified atmosphere of 
5% CO2 in air.   
My initial concern was in deciding upon glucose concentrations that 
constituted ‘normal’ and ‘hyperglycaemia-like’ conditions for HCD and HKC8 
cell lines.  In humans, two hour plasma glucose concentration of ≥11.1mM/L 
following ingestion of 75g anhydrous glucose in an oral glucose tolerance 
test (OGTT) is classed as (post-prandial) hyperglycaemia.  Normal growth 
media for both HCD and HKC8 immortalised cell lines consisted of DMEM- 
F12 containing supraphysiological concentrations of approximately 18 mM/ L 
glucose. Therefore, the cell lines normal growth conditions consisted of 
ambient glucose concentrations which exceeded what would be considered 
pathological concentrations in humans.  This highlighted several potential 
problems, a) What concentration would be considered to parallel human 
hyperglycaemia in these cells? b) How similar to human physiological 
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conditions are these cells? c) How do I control for the effects of background 
glucose levels on my experimental results? d) If I acclimatize the cells in low 
glucose containing media before performing my experiments, will this affect 
cellular integrity or viability?    However, a common approach by researchers 
is to incubate the cells in serum-free media containing baseline values of 5 
mM/ L D-glucose before subsequent experimentation (Hills, 2006).  This 
baseline concentration is considered sufficient to maintain cell viability but 
also low enough to reduce the likelihood that baseline glucose will mask the 
effects of additive glucose levels on GLP-1R expression.  To ensure that cell 
growth was not inhibited, a trypan blue assay was performed (data not 
shown).  Subsequent concentrations of 10 mM/ L, 15 mM/ L and 25 mM/ L 
D-glucose were considered to be synonymous to varying degrees of 
hyperglycaemia for these cells. 
 Cells were seeded into 25 mL flasks until 80-90% confluence and passaged 
1-2 times into 75 mL flasks before being aliquotted onto 6-well plates 
containing 2 mL media.  Media was then replaced with serum-free media 
containing 5 mM/L D-glucose and fasted over night before subsequent 
incubation with 5 (no supplement), 10, 15, or 25 mM/ L D-glucose for either 4 
or 24 hours. In separate samples, cells were incubated in 5 mM/L D-glucose 
plus 10, 15 or 25 mL D-Mannitol to control for osmotic effects. After 4h and 
24 h respectively media was removed and replaced with ice cold PBS buffer 
to stop the cellular processes. Cells were kept on ice while removing PBS 
buffer and preparing cells for subsequent analysis by either RT-PCR or 
western blot.   
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6.1.2 Total RNA isolation and cDNA synthesis 
Total cellular RNA was extracted from HCD and HKC8 cells using the 
RNeasy Mini Kit (Qiagen Ltd., UK) and first strand DNA synthesis was 
performed using qScriptTM reverse transcription kit (Primer Design, UK) 
according to the manufacturer’s instructions. 
6.1.3 RT-PCR 
Quantitative PCR of human GLP-1 receptor were performed on an ABI 7000 
system (Applied Biosystems).  PCRs were carried out in a reaction mixture 
consisting of 10 µl PrecisionTM master mix containing syber green and ROX 
(Primerdesign, UK), 1.0 µl of each primer (300 nM per 20 µl reaction), 5 µl 
cDNA (≈5 ng/ µl), and 4 µl RNAse/DNAse free water. Protocol conditions 
consisted of denaturation for 95 C for 10 minutes, followed by 40 cycles of 95 
C for 15 sec, 57 C for 60 sec, followed by melting curve analysis. The RNA 
levels were expressed as a ratio, using δ-δ method for comparing relative 
expression results between measurements in real-time PCR (Pfaffl, 2001). 
Ten microlitres of the reaction mixture were subsequently eletrophoresed on 
a 1% agarose gel and visualised by ethidium bromide, using a 1-kb DNA 
ladder (Invitrogen) to estimate band sizes. As a negative control preparations 
lacking reverse transcriptase or water (blanks) were used in place of the 
cDNA. RNAs were assayed from three independent biological replicates.  
Quality of cDNA was assessed by electrophoresis using 1% agarose gel. 
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Table 6.1.3.1 Primer sequences 
Gene Forward primer Reverse Primer Size (bp) 
Human 
GLP-1R* 
5’-
GTTTCTGGAAATGGCTGTAGGT-3 
5’-
CAGGCACCAAAACAACTCAAAT-3 
94  
Human 
GLP-1R 
5’-GTTCCCCTGCTGTTTGTTGT-3 5’-CTTGGCAAGTCTGCATTTGA-3 227 
*, Pre-validated primers, patent protection (Primer Design, UK) 
6.1.4 Western blot analysis 
For the analyses and regulation of GLP-1R protein, media was removed and 
protein lysates were prepared by mixing equal amounts of RIPA buffer and 
consequently adding Laemmli buffer [5 M urea, 0.17 M sodium dodecyl 
sulphate, 0.4 M dithiothreitol, and 50 mM Tris-HCL (pH 8.0)], mixed, and 
placed on a hot plate at 95 Celsius for 5 minutes.  All samples were then 
allowed to cool at room temperature. The proteins in protein lysates (35 
µg/lane) were separated by SDS-PAGE (10% resolving gel) and transferred 
to polyvinylidene diflouride (PVDF) membranes at 100 V for 1 h in a transfer 
buffer containing 20 mM Tris, 150 mM glycine, and 20% methanol. PVDF 
membranes were then blocked in tris-buffered saline containing 0.1% Tween 
20 and 5% BSA overnight. 
The PVDF membranes were incubated with primary GLP-1R antibody 
(dilution 1:2000) (Santa Cruz biotechnology, Middlesex, UK) for 1 h. The 
membranes were washed thoroughly for 60 min with TBS- 0.1% Tween 20 
before incubation with the secondary antibody, anti-rabbit horseradish-
peroxidase-conjugated Ig (1:10,000) (Dako Ltd., Cambridge, UK) for 1 h at 
room temperature.  Membranes were also re-probed with the β-actin 
antibody (Cell Signalling Technology Inc., Beverly, MA, USA; 1 in 8000 
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dilution) to determine equal protein loading. Antibody complexes were 
visualised using chemiluminescence (ECL+; Amersham, Little Chalfont, UK). 
Membranes were subsequently re-probed with inclusion of antagonist 
Exendin (9-39) to confirm selectivity of primary antibody. 
6.1.5 Statistical analysis 
Data in the present study are expressed as means ± SEM. Comparisons 
among groups were made by repeated measures ANOVA. When 
significance (P < 0.05) was detected, a post hoc Dunnett’s multiple-
comparison test or Tukey’s multiple comparison test was performed (Graph 
Pad software (version 4.0)). 
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6.2 Results 
6.2.1 Expression of GLP-1 receptor in HCD and HKC8 cells 
Preparations of both HKC8 and HCD samples underwent gel electrolysis 
which revealed the presence of PCR product which was characteristic of 
human GLP-1R mRNA. Specificity of primers to human GLP-1R was also 
confirmed using mouse kidney homogenates. Initially, primers were designed 
for end-point PCR with a product size of 227 bp (IDT Technology, UK).  For 
quantitative RT-PCR separate pre-validated primers were purchased from 
Primer Design, UK with a product size of 95 bp. Standard deviations for RT-
PCR Ct values ranged between 0.1- 1.  To confirm that human GLP-1R 
mRNA was appropriately translated, protein expression was quantified using 
western blot analysis, revealing band at approximately 53 kDa. Addition of 
antagonist GLP-1(9-39) successfully blocked binding of GLP-1R antibody 
and hence confirmed its specificity to GLP-1R. 
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6.2.3 Human collecting duct cells  
Timed experiments suggest that mRNA expression is down- regulated at 24 
hrs by GLP-1R protein. One way ANOVA showed an overall decrease in 
GLP-1R mRNA expression [HCD, P= 0.001 (5 mM/ L versus 10 mM/ L, P= 
0.005 and 5 mM/ L versus 25 mM/ L P= 0.013); HKC8, P= 0.001 (5 mM/ L 
versus 10 mM/ L, P= 0.001 and 5 mM/ L versus 15 mM/ L, P= 0.012)].  GLP-
1R mRNA was observed to be up-regulated 1.5- fold at 4 hrs in HCD cells (5 
mM/ L versus 25 mM/ L D-glucose, P= 0.026).  In HCD cells a concentration- 
dependent increase in GLP-1R expression was observed. This corresponded 
to a 3-fold increase (P= 0.053) in protein at 24 hours. Similarly, at 4hrs a 2-
fold increase in GLP-1R mRNA was seen in HKC8 cells after incubation in 
25 mM/ L D-glucose (P= 0.007). A corresponding 2-fold increase was seen 
for GLP-1R protein at 24 hrs (25 mM/ L, P= 0.041).  No osmotic effects were 
observed for mRNA or protein expression in either cell line.  Results show 
that GLP-1R expression is regulated by D-glucose in cells of the human 
collecting duct and proximal tubule. Figure 6.2.3.1 Concentration- 
dependent effects of D-Glucose on GLP-1 mRNA expression in HCD 
cells A-D and Figure 6.2.3.2 Concentration- dependent effects of D-
Glucose on GLP-1 protein expression A-B shows the relative fold 
expression of GLP-1R with baseline (5 mM D-glucose) given an arbitrary 
value of 1.  
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Figure 6.2.3.1 - Concentration- dependent effects of D-Glucose on GLP-
1 mRNA expression in HCD cells after a) 4 hr, b) 24 hr and in HKC8 cells 
after c) 4 hr and d) 24 hr, were assessed by RT-PCR, compared with basal 
(5 mM/ L Glucose). Ubiquitously expressed GapDH was used as control. 
Data are expressed as relative difference of median of basal. A minimum of 
three independent experiments were performed and each experiment was 
carried out in triplicates. No osmotic effects were observed in cells incubated 
in D-mannitol (+ 5 mM/ L glucose). Results are analysed using repeated 
measures ANOVA and Dunnett's multiple comparisons test. Data is 
expressed as mean ± S.E.M.  
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b) HCD cells incubated for 24 hours in various concentrations of 
glucose 
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c) HKC8 cells incubated for 4 hours in various concentrations of 
glucose 
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d) HKC8 cells incubated for 24 hours in various concentrations of 
glucose 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 5- Glucose 10- Glucose 10- Mannitol 15- Glucose 15- Mannitol
0.0
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
1.1
1.2
P= 0.013
P= 0.005
24 hrs
(mM)
G
L
P
-1
R
 m
R
N
A
 e
xp
re
ss
io
n
(a
rb
itr
ar
y 
u
n
its
)
Page 130 of 192 
 
Figure 6.2.3.2- Concentration- dependent effects of D-Glucose on GLP-
1 protein expression in a) HCD and b) HKC8 cells after 24 h incubation 
were assessed by western blot, compared with basal (5 mM/ L Glucose). 
Ubiquitously expressed GapDH was used as control. Data are expressed as 
relative difference of median of basal. Three independent experiments were 
performed and each experiment was carried out in triplicates. No osmotic 
effects were observed in cells incubated in D-mannitol (+ 5 mM/ L glucose). 
Results are analysed using repeated measures ANOVA and Dunnett’s 
multiple comparisons test. Data is expressed as means ± S.E.M.   
 
a) GLP-1R protein expression in HCD cells at 24 hours 
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b) GLP-1R protein expression in HKC8 cells at 24 hours 
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6.3 Discussion 
I show for the first time that GLP-1R is present in human cortical collecting 
duct cells, which is contrary to studies in rodents suggesting species 
differences in renal GLP-1R expression.  Furthermore, GLP-1R is functional 
in both human proximal tubule and collecting duct cells.  I was not able to 
demonstrate inhibition of GLP-1R expression on mRNA or protein level due 
to chronic hyperglycaemia-like conditions. A limitation to this study is that the 
timing of my experiments might not have mimicked chronic hyperglycaemia 
(other studies assessing similar responses use 48h incubation times while 
cells described herein were incubated for 24 hrs).   
    
Glucose absorption through the gastro-intestinal tract is well understood to 
stimulate GLP-1 release from L-cells (Gribble et al, 2003; Reinman & 
Gribble, 2002; Grieve, 2009).  This phenomenon is dependent on the 
concentration of glucose and hence the amount of food ingested.  It might be 
speculated that in renal cells, rises in ambient glucose might directly 
stimulate secretion of GLP-1. However, I was not able to detect secreted 
GLP-1 in renal cells by western blot. The increased renal GLP-1R expression 
seen in HCD and HKC8 cells might indicate that GLP-1R might be involved 
in the kidney regulation of glucose because the kidney regulates glucose by 
releasing glucose into the circulation (gluconeogenesis), uptake of glucose 
from the circulation to use as energy and reabsorption of glucose from 
glomerular filtrate to conserve glucose carbon (Gerich, 2009). It might also 
be speculated that GLP-1R activation might stimulate renal glucose uptake 
as approximately 10% of glucose is utilized by the kidney during the post-
prandial glycaemic state (Gerich, 2009).   
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It would be interesting to assess GLP-1’s effects on facilitated glucose 
uptake and sodium reabsorption hence, GLP-1R-mediated action on glucose 
transporters in the kidney, for example GLUT, and sodium-glucose co-
transporter (SGLT 1/2), respectively. Previous research did not show GLP-1 
to up-regulate renal glucose transporters in porcine proximal tubule cells but 
this may highlight species differences and so should be repeated in human 
cells (Schlatter, 2009). Further research into the possibility that GLP-1 might 
activate renal gluconeogenesis during post-prandial hyperglycaemia would 
be beneficial.  GLP-1 is reported to suppress hepatic gluconeogenesis but it 
is not clear whether this is a direct GLP-1R-mediated action or non-GLP-1R- 
mediated action by GLP-1(9-36) or an indirect effect by suppression of 
insulin and glucagon (Larsson et al, 1997; Grieve, 2009).  It is possible that 
GLP-1 might contribute to regulation of gluconeogenesis through hepatic 
renal glucoreciprocity and therefore future research is necessary to evaluate 
this and also to evaluate whether this is a GLP-1R-directed action.   
I have been able to show GLP-1R expression to be down-regulated in 
diabetes and obesity in rodents and that the down-regulation of GLP-1R 
correlates with hyperglycaemia in vivo.  This is the first study to show GLP-
1R to be present and functional in cells of the human collecting duct.  This 
study also shows GLP-1R expression to be up-regulated during acute 
hyperglycaemia-like conditions in both human proximal tubule and collecting 
duct cells.  The significance of this in humans can only be speculated at this 
stage and further research is necessary.  It might be postulated that 
restoration of GLP-1R expression in patients undergoing therapy with GLP-1 
agonists might improve diabetes- related manifestations with regards to 
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sodium and glucose dysregulation and slow or prevent renal disease in 
susceptible individuals. Recently, GLP-1 and exendin-4 has been shown to 
reduce oxidative stress, improve histologic changes and suppress advanced 
glycation end product receptor (RAGE) gene expression in the human 
proximal tubule of streptozotocin- induced diabetic rats through GLP-1R 
activation of cAMP pathways (Ojima et al, 2013). However, studies into the 
effects of GLP-1 agonists in renal disease are lacking and further research is 
warranted. The significance of possible dysregulated GLP-1R during 
diabetes begs further research into the action of GLP-1 with regards to 
glucose regulation by the kidney.  If GLP-1R does mediate glucose 
reabsorption and gluconeogenesis this would be of great importance in 
developing treatments to focus on slowing or improving diabetic nephropathy 
as many traditional oral anti-diabetes drugs are not suitable or contra-
indicated in patients with renal disease.  Presence of GLP-1R in renal cells 
might also highlight a beneficial pleiotropic action of GLP-1 agonists on the 
kidney.  
It might be speculated that a down-regulation of GLP-1R expression in renal 
cells was not replicated in isolated cells of the proximal tubule and collecting 
duct due to the lack interaction with central autonomic control and the 
absence of insulin.  It is necessary to perform further research into the 
effects of GLP-1R restoration through use of GLP-1 agonists with special 
focus on regulation by neural circuits and from the perspective of GLP-1 as a 
neuropeptide as this might be a primary factor linking the weight reducing, 
blood pressure and heart rate responses to GLP-1 agonists seen in clinical 
studies.  It would be interesting to add to the work from the previous chapter 
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and to perform new experiments to study 1) the effects of bilateral vagotomy 
on renal GLP-1R expression in the MycERTAM model before and after 
administration of endogenous insulin to assess whether central autonomic or 
hormonal influences are directly involved in the down regulation of renal 
GLP-1R and 2) how ablation of Ppi gene expression might affect free radical 
scavenging molecules in the renal tissue and 3) whether administration of 
insulin to isolated human kidney cells directly affects GLP-1R expression in 
the presence of glucose. 
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7.0 GLP-1 effects on Epithelial sodium channel –
alpha in human collecting duct cells 
The distal portion of the nephron is ultimately responsible for the rate of urine 
volume and composition, and also BP-induced changes in urine flow and Na+ 
excretion via pressure natriuresis and diuresis (Peti-Peterdi, 2002).  
Furthermore, as I have already discussed, ENaC is strongly implicated in 
treatment-resistant hypertension commonly observed in obese and T2DM 
patients as it is dysregulated by hyperglycaemia, hyperinsulinemia and 
hyperaldosteronism.  Research into the actions of GLP-1 on blood pressure 
has thus far focussed on renal and central nervous system effects using 
animal models and clinical findings from human trials (Hirata et al, 2009; 
Edwards, 1998). A small number of mechanistic studies have also been 
performed on a cellular level in the renal proximal tubule (Schlatter, 2006).  
In animals and man there is strong suggestion that GLP-1 increases 
natriuresis at the kidney tubules (Yu, 2003; Gutzwiller, 2006).   Thus far I 
have shown that renal GLP-1R expression is dependent on ambient glucose 
levels and might be down-regulated by prolonged hyperglycaemia.  Sodium 
transport molecules such as ENaC are known to be “hyper”-activated by 
hyperglycaemia, hyperinsulinemia and hyperaldosteronism seen in the 
metabolic syndrome (obesity) and T2DM.  I hypothesize that GLP-1 may play 
a role in regulating blood pressure through inhibition of ENaC in the renal 
tubules.  Therefore, in the following chapter, I explore the effects of GLP-1 on 
SCNN1A (α- ENaC) mRNA and protein expression and potential involvement 
of rapid signalling cascades in cells of the human collecting duct. 
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7.1 Materials and Methods 
7.1.1 Cell culture  
HCD cells (passages 15-21) were used for this set of experiments. A detailed 
account of cell culture conditions is described in the ‘appendix’ section of 
this document.  The active metabolite of GLP-1 (GLP-1 (7-36) amide) is 
understood to have an IC50 of 0.5- 0.78 nM/ L (Greischel, 2010; Deacon, 
1998).   However, I planned to assess the effect of various concentrations of 
GLP-1 on α-ENaC and its’ corresponding signalling molecules.  Therefore, 
cells were treated with 0.1 nM/ L, 1 nM/ L, 10 nM/ L and 100 nM/ L GLP-1 (7-
36) amide (Bachem, France) for 2 hr, 4 hr, 12 hr and 24 hrs after overnight 
fasting in the presence of unsupplemented DMEM/ Hams F-12 without FCS.   
GLP-1 (7-36) is understood to initiate mitogen- activated protein kinases and 
extracellular- regulated kinases (MAPK/ ERK pathway) which is mediated by 
protein kinases (PKA and PKC)  (Portha, 2011). Furthermore, these 
signalling cascades and also serum- glucocorticoid- regulated kinase (SGK-
1) are associated with regulation of SCNN1A/ ENaC expression in the 
collecting duct (Thomas, 2008). I assessed the responses of SGK-1 gene 
and protein to concentrations of GLP-1 (7-36). I then used the same 
experimental design to assess the response of ERK1/2 phosphorylation to 
GLP-1 (7-36). I subsequently assessed the involvement of PKA and PKC on 
ERK1/2 activation. HCD cells were treated in a time and concentration 
dependent fashion with various concentrations of GLP-1 (7-36) for 2, 5, 15, 
30 60 minutes. Extreme care was taken to avoid excessive movement/ 
causing stress to the cells during this process.  Angiotensin II at a 
concentration of 10 nM/ L was used as positive control to ERK1/2 activation.  
In separate experiments, cells were cultured in the presence of PKC and 
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PKA inhibitors for appropriate incubation periods prior to treatment with GLP-
1 (7-36).  For these experiments ERK1/2 inhibitor was used as control to 
ensure the correct protein bands were being visualised.   
7.1.2 RT-PCR 
Total RNA was extracted and underwent subsequent cDNA synthesis before 
samples were prepared for analysis by RT-PCR. Quantitative PCR of SGK1 
and SCNN1A were performed on an ABI 7000 system (Applied Biosystems, 
Carlsbad, California).  PCRs were carried out using solutions purchased from 
Primer Design, UK. Protocol conditions consisted of 50 cycles: enzyme 
activation for 10 minutes at 95 C; denaturation for 15 seconds at 95 C; 
fluorogenic data was collected through the SYBR® green channel at 60 C for 
60 seconds; melting curve analysis. Pre-validated primers were purchased 
from Primer Design, UK (Table 7.1.2.1 Primer sequences). As a negative 
control, preparations lacking RNA or reverse transcriptase were used in 
place of the cDNA. RNAs were assayed from three independent biological 
replicates.   
Table 7.1.2.1: Primer sequences. 
Gene Forward primer Reverse Primer bp 
Human 
SCNN1A 
5’-CTGCCAGAGAACTCCTATG-3 5’-TCAATTTTGGGGAAGACAAGATG-3 94  
Human 
SGK-1 
5’-CCCGTCGTCCAATCCTCAT-3 5’-CTTCTGCCTTGTGTCTTGCTA-3 104 
Pre-validated primers. Patent protected, bp, base pairs 
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7.1.2.2 Western blotting 
In brief, proteins (20-40 µg) were separated by sodium dodecyl sulphate 
(SDS) polycrylamide gel electrophoresis (10% or 12% resolving gel) at 40mV 
for 3 hours in electrophoresis buffer containing 25mmol/l Tris, 192mmol/l 
glycine, and 0.1% (wt/ vol) SDS.  Proteins were transferred on to Immobilin P 
membrane in transfer buffer (25 mmol/l Tris, 192 mmol/l glycine, 20% (vol/ 
vol) methanol) for 1 hour at 100 volts, 4 oC. Following protein transfer, 
membranes were blocked for 1 hour in TBS-T (TBS plus 0.1% tween-20) 
containing 5% (wt/ vol) bovine serum albumin (BSA) at 4 oC and subject to 
four separate 20 minute washes.  Membranes were analysed using specific 
polyclonal antibodies against Human SGK-1 (AbCam), Human α-ENaC 
(AbCam), phosphorylated P38, ERK 1/2 and total ERK 1/ 2 (AbCam) at 
dilutions of 1:2000 + 0.5% BSA.  After five, 10 minute washes, the 
membranes were then incubated for 1 hour at ambient temperature with 
corresponding secondary antibodies (horseradish peroxidase- conjugated) 
anti-rabbit (diluted to 1:2000) or anti-mouse (diluted to 1:2000) in TBS-
T+0.05% BSA.  Membranes were then washed for a further five, 15 minute 
washes in TBS-T followed by three 10 minute washes in TBS.  Specific 
proteins were detected using ECL-Plus chemiluminescence detection system 
(Amersham Biosciences) and were visualized after 1-5 minutes exposure of 
membranes to x-ray film.  Blots were probed with an appropriate antibody to 
control for loading inefficiencies for subsequent densitometry analysis of 
protein expression levels (AbCam). 
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7.2 Data analysis 
Auto radiographs were quantified using densitometry (Scion Corp. 2008).  
Statistical analysis of the data was performed using one-way ANOVA test 
with Dunnett’s post test.  Data are expressed as arithmetic mean ± SEM.  N 
denotes number of experiments and P< 0.05 denotes statistical significance. 
7.3 Results 
7.3.1 Expression of SGK-1, and SCNN1A in HCD cells 
Studies confirmed the presence of SGK-1 and SCNN1A mRNA and protein 
in HCD cells.  Optimisation of PCR and subsequent analysis of RNA 
preparations of HCD cells revealed the presence of SGK-1 and SCNN1A 
mRNA. To confirm that mRNA was appropriately translated, protein 
expression was quantified using western blot analysis, revealing bands at 
approximately 75 kDa and 50 kDa, for SCNN1A and SGK-1 respectively. 
7.3.2 Up-regulation SCNN1A expression after treatment with GLP-
1(7-36) 
Serum- and glucocorticoid- regulated kinase (SGK-1) is an important 
regulator of Na+ retention by intensifying the stability and expression of 
SCNN1A/ ENaC.  To test my hypothesis that GLP-1(7-36) down-regulates 
SGK-1 and SCNN1A mRNA and protein levels, HCD cells were treated with 
0.1 nM/ L, 1 nM/ L, 10 nM/ L and 100 nM/ L GLP-1(7-36) amide for 2 hrs, 
4hrs, 12 hrs and 24 hrs. Cells grown under these conditions exhibited a 
modest decrease in SGK-1 mRNA expression which decreased at 4 hours 
(2-fold compared to control (no supplement), P =0.03) at a concentration of 1 
nM GLP-1 (7-36) (Figure 7.3.2.2 Concentration- dependent effects of 
GLP-1 (7-36) on SGK-1 mRNA expression in HCD cells).  Contrary to my 
hypothesis HCD cells treated with 10nM GLP-1(7-36) enhanced SCNN1A 
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mRNA expression 4-fold by 24 hours (P= 0.015) (Figure 7.3.2.3- 
Concentration- dependent (a) and time- dependent (b) effects of GLP-1 
(7-36) on SCNN1A mRNA expression).  Western blotting also showed 
modest increases of SGK-1 (P < 0.05 versus control) with corresponding 
increases in α-ENaC (P < 0.05) protein expression after 24 hrs stimulation 
with 10 nM GLP-1 (Figure 7.3.2.4- Effect of GLP-1 (7-36) on SGK1 protein 
expression; Figure 7.3.2.5 - Effect of GLP-1 (7-36) on α-ENaC protein 
expression). 
7.3.3 α-ENaC signalling pathways 
To elucidate further the cellular signalling pathways involved in the increased 
response to α-ENaC after treatment with GLP-1, I examined the effect of 
GLP-1 treatment on ERK 1/2 phosphorylation in HCD cells.  SGK-1 is 
understood to phosphorylate ERK1/2; this latter also being activated by PKC 
(Soundararajan, 2009). Phosphorylation of ERK 1/2 was demonstrated to 
increase significantly upon stimulation with 10 nM GLP-1 (P < 0.01). At the 
highest concentration of GLP-1 (7-36) (100 nM), ERK1/2 phosphorylation 
was diminished to basal levels. ERK1/2 phosphorylation peaked at 5 
minutes, gradually returning to baseline values by 30 minutes (Figure 
7.3.3.1-  Time- dependent (2-60 minutes) effects of GLP-1 (7-36) on ERK 
1/2 phosphorylation).  This effect was approximately two-thirds the intensity 
of angiotensin II- stimulated ERK1/2 response. Treatment with protein kinase 
inhibitors revealed a 2- fold decrease in ERK1/2 compared to control (no 
supplement) (P < 0.01) after treatment with PKC inhibitor.  Treatment with 
ERK1/2 inhibitor totally abolished this effect which confirmed specificity of 
antibodies for ERK/12 (Figure 7.3.3.2- Effects of 10nM GLP-1 on ERK 1/2 
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protein expression in HCD cells at 5 minutes after incubating in specific 
inhibitors for PKA and PKC).  Treatment of protein kinase inhibitors did not 
clearly show inhibition of α-ENaC protein expression.  The α-ENaC protein 
was not visible in these last experiments suggestive that the cell-line had 
changed at later passages and had ceased producing this protein. 
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Figure 7.3.2.2 - Concentration- dependent effects of GLP-1 (7-36) on 
SGK-1 mRNA expression in HCD cells at a) 4 h and b) 24 h were 
assessed by RT-PCR, compared with basal (no supplement). Ubiquitously 
expressed GapDH was used as control. Data are expressed as relative 
difference of median of basal. A minimum of three independent experiments 
were performed and each experiment was carried out in triplicates. Results 
are analysed using repeated measures ANOVA and Dunnett’s multiple 
comparisons test. Data is expressed as means ± S.E.M.  
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b) Effect of GLP-1(7-36) on SGK-1 mRNA expression at 24 hrs. 
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Figure 7.3.2.3- Concentration- dependent (a) (incubated for 24 hours), 
and time- dependent (b) effects of GLP-1 (7-36) on SCNN1A mRNA 
expression in HCD cells were assessed by RT-PCR, compared with basal 
(no supplement). Ubiquitously expressed GapDH was used as control. Data 
are expressed as relative difference of median of basal. A minimum of three 
independent experiments were performed and each experiment was carried 
out in triplicates. Results are analysed using repeated measures ANOVA and 
Dunnett’s multiple comparisons test. Data is expressed as means ± S.E.M.   
 
a) Effects of various concentrations of GLP-1 (7-36) on SCNN1A (ENaC) 
mRNA expression in HCD cells 
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b) Effects of 10 nM GLP-1 (7-36) on SCNN1A (ENaC) mRNA expression 
in HCD cells 
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Figure 7.3.2.4- Effect of GLP-1 (7-36) on SGK1 protein expression. SGK-
1 levels relative to GapDH is significantly increased in HCD cells compared 
to basal (no supplement) after 24 hrs incubation with 10 nM GLP-1 using 
western blotting. Three independent experiments were performed and each 
experiment was carried out in triplicate.  Group comparison by repeated 
measures ANOVA with post hoc Dunnett’s multiple comparisons test. 
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Figure 7.3.2.5 - Effect of GLP-1 (7-36) on α-ENaC protein expression. α-
ENaC levels relative to GapDH is significantly increased in HCD cells 
compared to basal (no supplement) after 24 hrs incubation with 10 nM GLP-
1 using western blotting. A minimum of three independent experiments were 
performed and each experiment was carried out in triplicate.  Comparison by 
paired t-test was performed with 95% confidence interval. 
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Figure 7.3.3.1- Time- dependent (2-60 minutes) effects of GLP-1 (7-36) 
on ERK 1/2 phosphorylation in HCD cells were assessed by Western 
blotting compared with basal (no supplement).  Data are expressed as 
relative to median of basal. A minimum of three independent experiments 
were performed and each experiment was carried out in triplicate. Group 
comparison by repeated measures ANOVA and post hoc Dunnett’s multiple 
comparisons test. Results show 10 nM GLP-1 to enhance phosphorylation of 
ERK1/2, which peaked at 5 minutes, gradually returning to baseline values 
by 30 minutes. 
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Figure 7.3.3.2- Effects of 10nM GLP-1 on ERK 1/2 protein expression in 
HCD cells at 5 minutes after incubating in specific inhibitors for PKA 
and PKC were assessed by Western blotting compared with basal (no 
supplement).  Data are expressed as relative to median of basal. Four 
independent experiments were performed and each experiment was carried 
out in triplicate. Group comparison by repeated measures ANOVA and post 
hoc Dunnett’s multiple comparisons test. Results show a significant decrease 
in ERK 1/2 expression after co-incubation with 10 nM GLP-1 and PKC 
inhibitor for 5 minutes.  ERK 1/2 inhibitor was used as control.  
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7.4 Discussion 
There are many hormonal regulators of ENaC including the most 
documented hormone, aldosterone, and also angiotensin II, components of 
the renin angiotensin aldosterone system (RAAS). It is also well understood 
that stimulation of P13-K promotes the activity of ENaC through upregulation 
of SGK-1 (Thomas, 2007; 2008).  Conversely, activation of ERK1/2 has been 
shown to suppress ENaC activity and is dependent on activation of PKC 
although some researchers suggest that activation of ERK1/2 stimulates 
channel activity (Thomas, 2008; Krug, 2002).  
  
This is the first study to explore the effects of GLP- 1 on α-ENaC expression 
in the human kidney.  The α- ENaC subunit is understood to be involved in 
transporting Na+ through the channel, whereas β and γ- subunits have a 
regulatory role (Hamm, et al. 2011).  Despite a clear indication from animal 
and human studies that GLP-1 displays actions in the kidney, no studies to 
date have focussed on potential GLP-1 actions in distal portions of the 
nephron, namely the collecting duct where I show GLP-1R to be present and 
functional.  I am able to show GLP-1 (7-36) amide to up-regulate SGK-1 and 
α-ENaC mRNA expression but GLP-1’s action on protein expression was 
less clear.  GLP-1, at a concentration of 1 nM was shown to modestly down-
regulate SGK-1 mRNA at 4 hrs possibly as a consequence of down-
regulation by SGK-1 protein.  SGK-1 and α-ENaC protein expression were 
modestly enhanced after stimulation with 10 nM GLP-1 for 24 hrs but 
surprisingly up-regulation of α-ENaC was not replicated in the experiments 
using PKC inhibitors as the α-ENaC protein could not be visualised.  A 
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possible reason for this was that morphological changes had occurred within 
the cells and that α-ENaC protein had stopped being produced by the cells 
due to the effects of multiple passages.  Nevertheless, cell passages did not 
exceed the recommended maximum of 30 passages.  Analysis by western 
blot showed an increased phosphorylation of ERK1/2 which was attenuated 
by the presence of PKC inhibitors.  Therefore the effect seen in HCD cells 
after GLP-1 administration may be a result of crosstalk between ERK1/2 and 
P13-K signalling pathways (Thomas 2008) (Figure 7.4.1 Possible GLP-1 
signalling of ENaC in the collecting duct).  Highest concentrations (100 
nM GLP-1 (7-36)) displayed little or no effect. 
 
  
 
Figure 7.4.1 Possible GLP-1 signalling of ENaC in the collecting duct. A 
schematic representation of the proposed signalling components of GLP-1R 
activation (in HCD cells) which may lead to sodium reabsorption in the distal 
nephron of the human kidney. Where no evidence exists, hypothesis is 
indicated by a dashed line and “?”. 
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GLP-1 for human GLP-1R is proposed to have an IC50, 0.37 nM (Green, 
2004). Furthermore, DPPIV is reported to be present in the human proximal 
tubule but not in the collecting duct which is interesting as one might not 
expect GLP-1 metabolites to reach the collecting duct in vivo as native GLP-
1 should be fully degraded via the liver and peripheral tissues (muscle, 
connective and adipose) and the remainder by the renal proximal tubule.  
Furthermore, intact GLP-1 has not been detected in urine (Kugler et al, 1985; 
Malm- Erjefalt, 2010).  GLP-1 agonists exenatide and liraglutide are resistant 
to DPPIV, that is to say, enzymatic degradation by DPPIV (and also by 
neutral endopeptidases, NEPs) is dramatically slowed (Malm- Erjefalt, 2010). 
Interestingly, liraglutide is similar to native GLP-1 in that it is eventually 
cleaved by DPPIV into the truncated GLP-1(9-36) amide (Malm- Erjefalt, 
2010).  Exenatide is eliminated solely by glomerular filtration and proximal 
tubular degradation whereas liraglutide does not undergo glomerular filtration 
due to high binding to serum albumin (Malm- Erjefalt, 2010).    
It might have been interesting to explore the effects of other GLP-1 
metabolites, such as GLP-1(9-36) amide. Although once believed to be 
inactive, there is emerging evidence to suggest that the truncated GLP-1 (9-
36) amide display effects independent of GLP-1R or could be an inverse 
agonist to GLP-1R (Thomas & Habener, 2009).  In theory, with consideration 
that DPPIV is concentrated in the tubules, we might expect only small 
amounts (if any) of intact GLP-1 (7-36) metabolite to reach the collecting duct 
and that the majority would be excreted by the tubules (and liver and 
peripheral tissues).  We might also speculate that of the minor metabolites to 
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potentially reach the collecting duct via the tubule, GLP-1(9-36) would be a 
prime candidate due to cleavage by DPPIV.  GLP-1R are present in the 
collecting duct and GLP-1(7-36) did modestly up-regulate α-ENaC and its 
corresponding signalling components.  These results show a paradox as 
they suggest that GLP-1 (7-36) might cause an increase in sodium 
reabsorption in the collecting duct via GLP-1R mediated events which would 
ultimately lead to an increase in blood pressure.  This is contrary to animal 
and human reports which show GLP-1 to lower blood pressure and increase 
natriuresis via the tubules.  It might be pertinent to explore the effects of 
other metabolites which might display opposing or allosteric roles.   
 To conclude, it is not clear how the paradoxical results of this study might be 
reflected in vivo as there is currently a paucity of data into the actions of 
GLP-1 in the collecting duct.  Furthermore, functional studies on ENaC- 
mediated sodium transport have not yet been performed. A possible 
limitation to my studies is that I show supraphysiological doses of GLP-1(7-
36) to initiate activation of PKC family of serine/threonine protein kinases to 
phosphorylate α-ENaC and hence it could only be loosely speculated that (in 
theory) this could result in rapid responses of ENaC which might increase 
sodium reabsorption in the distal nephron ultimately leading to increased 
blood pressure (Thomas, 2008).  The relationship that this reabsorption has 
with subsequent studies in man that have shown a sodium losing 
(natriuresis) needs to be explained.  Much research needs to be conducted 
to establish that a fully functional system is present in the human collecting 
duct cell lines and that sodium reabsorption is increased by GLP-1 in this 
kidney segment.  Experiments could have been greatly improved by 
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confirming absence of DPPIV (and NEP) in the HCD cells and by performing 
sodium transport studies. It might be loosely speculated that if sodium 
reabsorption does occur at the collecting duct, that overall net increases of 
reabsorbed sodium would not exceed sodium loss via the proximal tubules 
and therefore the overall effect of GLP-1 would be to reduce blood pressure.  
Interestingly, GLP-1 infusions have been shown to increase both sodium and 
potassium excretion in rats but these experiments did not confirm GLP-1R to 
be present in distal portions of the kidney in this species (Craijoinas et al, 
2010; Moreno et al, 2002).  Nevertheless, this research indirectly supports 
my findings and suggests that sodium may be being reabsorbed in the distal 
tubule and collecting duct in exchange for potassium. 
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8.0 Final discussion and future directions 
The main action of GLP-1 is to regulate ingested glucose.  GLP-1 is secreted 
from the L-cells of the intestine in response to ingested nutrients and it enters 
the blood stream to direct insulin secretion and to regulate growth and 
apoptosis of pancreatic cells, regulate the uptake of glucagon secretion as 
well as other metabolic processes (Ceriello et al, 2008). 
The action of GLP-1 agonists on blood pressure reduction in T2DM patients, 
as described in Chapter 4, is undoubtedly at least in-part due to the weight 
reducing effects of these agents which is supported by scientific investigation 
into GLP-1 actions on adipocyte dynamics (Ruiz-Grande, 1992). Recent 
literature also suggests GLP-1 to mediate autonomic control of glycaemia 
and satiety by increasing vagal and sympathetic tone and activation of 
hypothalamic nuclei (Hayes, 2012; Griffion et al, 2011; Cabou et al, 2008). 
GLP-1R is located in cardiomyocytes, vascular smooth muscle, endocardium 
and coronary endothelium and recently discussions with Novo Nordisk 
researchers have informed that GLP-1 receptor is also located on the sino-
atrial node.  It is therefore likely that effects of GLP-1 agonists on body 
weight, blood pressure and heart rate are primarily a consequence of 
autonomic response to these agents.  Location of GLP-1R on sino-atrial 
tissue possibly explains the chronotropic effects seen in animals and T2DM 
patients administered GLP-1 (Griffioen et al, 2010; Barragan et al, 1999; 
Gardiner, 2006). Furthermore, Novo Nordisk heart rate data indicates that 
patients with a lower baseline heart rate and hence an assumed increase in 
vagal tone might be susceptible to greater heart rate increases.  Therefore, 
the use of such agents for glucose control and weight reduction must be 
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considered carefully as an increase in heart rate might be a deleterious side 
effect for susceptible individuals.  
Undertaking the meta-analysis highlighted the requirement for more 
standardised reporting of clinical trial results as well as specific concerns as 
to the need for long-term studies into the cardiovascular safety of GLP-1 
agonists. It was surprising that such little emphasis had been placed on 
investigating the chronotropic effects of GLP-1 agonists in trial participants, 
despite indication of this effect from supportive scientific evidence.  
Furthermore, gathering numerical data for the relevant outcomes from trial 
reports was difficult and although clinical trial organisers were very willing to 
assist us in supplying the missing data, it was a lengthy process.  Regardless 
of there being strict (CONSORT) guidelines for reporting randomised trials, 
information was often missing from trial reports including the name of trial 
registry (National Clinical Trial number) which sometimes resulted in difficulty 
when comparing trial reports to the corresponding protocols (Brand, 2009; 
Schulz et al, 2010).  
In Chapter 5 I demonstrated that in murine models closely resembling 
human obesity and diabetes, renal GLP-1R is inhibited and this is possibly a 
consequence of chronic hyperglycaemia. I was also the first to show that 
GLP-1R is present in human collecting duct cells. Glucose was found to 
directly influence GLP-1R expression in immortalised cells of the human 
proximal tubule and collecting duct (Chapter 6).  The presence of GLP-1R in 
renal tissue indicates that a direct receptor-mediated action might occur 
which is influenced by ambient glucose concentrations.  It is possible that 
GLP-1R directed regulation of glucose is occurring in the kidney which needs 
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further investigation.    Experiments in HCD and HKC8 cells could have been 
greatly improved by extending the glucose incubation times to 48 hours to 
more closely mimic chronic hyperglycaemia. However, it is important to 
consider how GLP-1R expression may differ in vivo compared to isolated cell 
lines. Central (brain) GLP-1R is also strictly dependent on glucose and is 
closely linked to the development of hyperinsulinemia through feedback of 
the gut-brain axis during the absorptive state (Cabou et al, 2008; Hayes et al, 
2012). Therefore glucose dependent brain GLP-1R signalling could directly 
link abnormal metabolic function and blood pressure through deregulation of 
central and autonomic control of glucose homeostasis, satiety and gastric 
emptying.  The influence of chronic hyperglycaemia on GLP-1R expression 
in peripheral tissues might directly influence overall glucose control via gut-
brain regulatory feedback mechanisms. Therefore hypothalamic factors in 
the BL/6 and BLK/s mice might contribute to the blunted renal GLP-1R 
expression. Similarly disrupted insulin signalling from the pancreas in 
MycERTAM mice might relay to hypothalamic nuclei and to peripheral organs 
via neuronal afferents to disrupt GLP-1R signalling.  This might be another 
reason why GLP-1R expression was increased in isolated cell lines but 
blunted in vivo where autonomic regulatory neurons would influence GLP-1 
receptor expression.  
In T2DM sodium clearance is inhibited at least in part due to glucose-sodium 
co-transport in the brush border of the proximal tubule and the effects of 
hyperinsulinemia in the distal nephron (Gerich, 2010).  Therefore, a symptom 
of chronic hyperglycaemia is glycosuria and the imminent fate of the diabetic 
patient is a homeostatic response to retain sodium which over time is 
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suggested to contribute to co-morbid hypertension which is prevalent in type 
2 diabetes.  The question of why GLP-1 agonists display more beneficial 
effects on blood pressure remains to be fully researched.  More complex 
mechanisms appear to be involved which in some subjects (about 1 in 3) the 
pronounced weight loss cannot be the full explanation for all those patients 
who experience a reduced systolic blood pressure on these agents. 
Hyperglycaemia is suggested to increase sodium loss and diuresis by the 
effect of glycosuria.  This phenomenon resets the kidneys to sodium 
retention and anti-natriuresis as a secondary effect due to enhanced 
glucose-sodium co-transport in the renal proximal tubule and 
hyperinsulinemia which has been shown to cause sodium retention in the 
distal nephron. There is a paucity of mechanistic studies into the action of 
GLP-1 on sodium transport molecules in the kidney and research thus far 
been fairly inconclusive.  Schlatter and later Crajoinas reported GLP-1 to 
inhibit sodium transport in isolated cells of the porcine proximal tubule via 
cAMP dependent PKA signalling pathways (Schlatter, 2006; Crajoinas, 
2010).  Schlatter was also not able to show GLP-1 to display a direct effect 
on sodium-glucose transporters but did demonstrate incubation with GLP-1 
to result in partial inhibition of NHE3 but he failed to show this with exenatide.  
This is interesting as it indicates that there might be differing mechanisms to 
which these two drugs lower blood pressure although exenatide has been 
shown to increase natriuresis in rodents (Hirata, 2009).  Nevertheless, while 
there is disparity in animals both liraglutide (sharing 97% homology with 
GLP-1 and similar enzymatic degradation to the native peptide) and 
exenatide display comparable effects on blood pressure reduction in human 
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trials.  Furthermore, exenatide (Exendin-4) has been shown to increase 
natriuresis in animals independent of an increase in glomerular filtration rate 
(Hirata et al, 2009). The potential species-specific differences regarding cell 
system used in Schlatter’s study mean it might be pertinent to repeat these 
experiments in cells of the human proximal tubule (HKC8) cells.  Other 
potential species differences were that GLP-1R was not influenced by 
glucose or GLP-1 contrary to my own results that show GLP-1R to be directly 
influenced by glucose in both human proximal tubule and collecting duct 
cells.  It is interesting to note that Schlatter, although using DPPIV inhibitor 
for his cellular work did not consider the potential for GLP-1 or exenatide to 
be degraded by neutral endopeptidases (NEP) which have been reported to 
reside on renal proximal tubule epithelium (Kubaik-Wlekly & Niemir, 2009) so 
the effects seen in his porcine renal cell system may have been the 
consequence of GLP-1 or exenatide degradation to minor metabolites by 
NEP.  It is suggested that up to 50% native GLP-1 is degraded by NEP, 
although this is controversial (Grieve, 2009). 
I have shown that α-ENaC mRNA and associated mediators are up-
regulated by GLP-1 which is possibly through direct GLP-1R- mediated 
action. The disparity as to the concentration of GLP-1 to produce such 
effects is not clear with concentrations of GLP-1(7-36) close to the IC50 
value resulting in down-regulation of SGK-1 mRNA expression but higher 
concentrations of 10 nM eliciting an up-regulation of SGK-1 and α-ENaC 
mRNA and their corresponding proteins at 24 hours and also of 
phosphorylated ERK1/2.  Neither DPPIV nor NEP is reported to be present in 
the collecting duct but I was not able to confirm the absence of DPPIV or 
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NEPs in the human collecting duct cell line utilised in this study without 
further research.  Research in animals has shown that different responses 
are observed at either physiological or supraphysiological concentrations of 
GLP-1 and other analogues although this does appear to be highly 
dependent on route of administration (Bojanowska & Stepniak).  Further 
exploration into dose effects might allow a more solid explanation.  I showed 
GLP-1(7-36) amide to modestly up-regulate α-ENaC and that this may be 
mediated by P13-K and PKC dependent SGK-1 and ERK1/2 signalling 
pathways, respectively.  The finding from this cell model suggest that GLP-1 
might increase sodium reabsorption via the collecting duct which is 
paradoxical to the natriuresis and blood pressure reduction described in 
animals and humans.  However, the incongruity between my results in cell 
lines and the existing literature could be the result of a number of factors.  
For instance, a concert of effects would occur in vivo which would not be 
replicated in a cell system.  It is also possible that GLP-1 displays differing 
regional effects on renal sodium transport, and that it inhibits sodium 
reabsorption in the tubules, but modestly increases reabsorption by the 
collecting duct where sodium balance is finely controlled resulting in a 
greater overall natriuretic than anti-natriuretic effect.  Furthermore, the 
concentration of DPPIV in the tubules might mean that GLP-1 is fully 
degraded in this segment and intact GLP-1 (7-36) fails to reach the collecting 
duct in vivo. Functional GLP-1R is however present in human collecting duct 
cells which might suggest that a proportion of metabolites do reach the 
collecting duct.  It remains unknown whether some active GLP-1(7-36) 
travels to the collecting duct or if the majority could be GLP-1(9-36) or other 
Page 162 of 192 
 
minor metabolites.  Therefore, it might be speculated that if sodium 
reabsorption is occurring via the collecting duct, this effect might be limited to 
isolated collecting duct cell lines.   
To take this thesis further and to bring into context the cardiovascular action 
of GLP-1 or liraglutide, the effects of administration of GLP-1 (9-36) to 
MycER mice could be explored within insulin responsive tissues such as the 
kidney in the absence of endogenous insulin production.  Furthermore, 
mechanistic studies could be repeated in proximal tubule and collecting duct 
cells to explore the action of GLP-1(9-36) or other metabolites on sodium 
transport.   Clinical trials in man using long-acting GLP-1 agonists raise the 
possibility that GLP-1 metabolites reach the collecting duct and thus initiate 
sodium reabsorption via GLP-1R-mediated up-regulation of ENaC.  This 
action might explain why the longer acting GLP-1 agonists are reported to 
have a reduced effect on lowering blood pressure.  Once weekly exenatide 
preparations are currently undergoing phase 3 trials and one might predict 
an extended accumulation in the kidney with these agents.  Long acting 
release formulations for liraglutide, which shares a similar metabolite profile 
to GLP-1, are also under development and early reports suggest they 
increase heart rate but reduce blood pressure less.  Interestingly data pooled 
by meta-analysis from clinical trials into exenatide LAR preparations showed 
a significantly lower mean difference in blood pressure reduction than shorter 
acting formulations compared to active control.  This could be reflected in the 
potential for increased sodium reabsorption via the collecting duct by these 
agents and requires more detailed studies to explore this hypothesis.    
Further research into the actions of these formulations and the 
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corresponding metabolites on sodium reabsorption via ENaC would be 
beneficial. 
 
8.1 Conclusion 
As the principal action of GLP-1 is to regulate glucose, it is probable that 
improvement of overall metabolic control could also play a role in the 
improved blood pressure seen in patients undergoing GLP-1 therapy through 
control of metabolic and cardiovascular homeostasis by GLP-1 produced in 
the brain. Brain GLP-1 is glucose dependent which minimises the risk of 
hypoglycaemia by blunting insulin secretion when insulin levels return to 
normal (Cabou et al, 2008).  Brain GLP-1 has been linked specifically to 
insulin sensitivity and cardiovascular control.  GLP-1 is secreted from 
enteroendocrine cells which controls pancreatic enteroendocrine secretion 
(stimulation of insulin and inhibition of glucagon) and is also synthesized in 
the caudal regions of the nucleus of the solitary tract (Cabou et al, 2008).  
GLP-1 released into the hypothalamus controls food intake, blood pressure 
and heart rate (Yamamoto et al, 2003; Barragan et al, 1999; Hayes et al, 
2012). Central administration of exendin-4 has been demonstrated to 
stimulate intravenous glucose insulin secretion and conversely, centrally 
administered antagonist exendin (9-39) blocks post-prandial glucose induced 
insulin secretion (Knauf et al, 2005). This relay between the gut-brain axis 
leads to hyperinsulinemia as a consequence of increases in brain GLP-1 
which also causes a redistribution of blood flow to mesenteric organs by 
modulation of heart rate and blood pressure through changes in autonomic 
control (Cabou et al, 2008).  It is becoming clear that neuronal circuits in the 
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central nervous system play a crucial role in metabolic and cardiovascular 
homeostasis through increasing insulin sensitivity and vascular effects of 
insulin and the production of nitric oxide in the hypothalamus (Cabou et al, 
2008).  Therefore a central control of glucose metabolism via gut-brain- 
kidney axis is possibly the primary mechanism by which GLP-1 agonists 
displays weight and blood pressure reducing effects with neuronal control of 
insulin secretion and sensitivity being central to such effects.  However, 
modulation of autonomic control mechanisms might result in unfavourable 
side effects such as increased heart rate in patients receiving GLP-1 
agonists. Further research into the long term cardiovascular safety of these 
agents is required, especially in patients with low baseline heart rate who 
might be susceptible to such effects.  
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Appendix 
A1.0 Cell culture techniques and solutions for HCD and 
HKC8 cells 
A1.1 Trypsin solution for subculturing HCD and HKC8 cells: 
20ml 1x PBS     
9ml of 1mM EDTA 
1ml of 2.5% trypsin   
This mixture was either stored at -200C, or at 40C for 10-14 days. 
A1.2 Standard culture medium for HCD cells  
DMEM/Hams-F12 mix containing:  
2% FCS (10ml in 500ml) 
20 mM Hepes (supplement with 1ml 1M Hepes) 
5ml ITS (sigma I1884; final concs: insulin (5 g/ml), transferrin (5 g/ml), 
Na2SeO3 (5 ng/ml))   
5 X10-8M Dexamethasone (2.5μl of 10-2M stock in ethanol, stored at –20) 
  
Store all stocks at -20oC  
A1.3 Normal growth medium for HKC8 cells  
DMEM/Hams-F12 (containing Hepes glutamax) 
5% FCS,  
Feed every other day. 
 
A1.4 Medium for serum free culture for experiments for both 
HCD and HKC-8 cells: 
485ml DMEM/Hams-F12 mix     
5ml ITS [insulin (5 g/ml), transferrin (5 g/ml), Na2SeO3 (5 ng/ml)]  
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62.5 μl T3 ( 20 µg/ml) (stock 1mg in 1ml of 1M NaOH then + 49ml of water, 
store –20oC) 
12.5 μl epidermal growth factor (stock, 100 µg/ml in 0.1% BSA, store –80oC) 
50 μl hydrocortisone hemisulphate (stock, 50 µg/ml; 1mg in 1ml of EtOH + 
19ml H2O, store –20
oC)  
5 ml glutamine (100X stock solution = 0.3 mg/ml) 
All stock solutions were stored at -20oC 
A1.5 Routine Maintenance 
Feeding cells: 
Feed cells every 1-2 days  
Pipette out old medium from flask to waste pot. 
Using fresh pipettes and a good aseptic technique, transfer fresh medium 
(12 -15ml for T-75 flasks; 5ml for T-25 flasks) to the flask. 
Place flask in CO2 incubator which should read 37
0C and 5% CO2. 
A2.   Sub-culturing cells: 
Split when approximately 90% confluent.  Time taken to reach this will vary 
but usually takes 4-7 days if split 1:20. 
Normal growth medium is very low in FCS; therefore inactivate trypsin with 
medium containing a higher FCS concentration.  For example, for 752 cm 
flask, use 3mls of trypsin solution and then deactivate with 10mls of 
DMEM/F12 + 10% FCS. Spin cells 1100rpm, 5 mins and remove medium.  
Re-suspend cells in 20mls normal growth medium; add 1ml to new flask 
(containing approx. 12 mL medium) for stocks. 
 
 Freezing cells (Freeze in FCS with 10% DMSO) 
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Trypsinise cells and spin at 1100 rpm, 5 mins RT. Resuspend pellet in FCS 
with 10%.  
From 1 confluent 75cm2 flask add 2-3ml freezing solution and divide into 2 
cryovials.  
Freeze down slowly at –70oC for a few hours or O/N (put vials inside 
polystyrene packing) and then liquid N2. 
When reviving cells, bring to RT quickly. 
A2.0 Western blotting solutions 
A2.1 Sodium Dodecyl Sulphate (SDS) (4%) 
10 ml 20% SDS solution 
50 ml dH2O 
Solution stored at room temperature (RT) 
 
A2.2 Western blotting Loading buffer 
625 μl Tris-HCl (pH 6.8) 125 mM 
500 μl SDS 4% 
1 ml Glycerol 
200 μl Dithiothreitol (DTT) 
125 μl Bromophenol Blue 
250 μl Distilled H2O 
 
A2.3 10% western blotting gel: 
4 ml Resolving gel 
3 ml Resolving buffer 
5 ml dH2O 
10 µl TEMED 
100 µl 10% APS 
 
A2.4 12% western blotting gel 
5 ml Resolving gel 
3 ml Resolving buffer 
4 ml dH2O 
10 µl TEMED 
100 µl 10% APS 
 
Page 168 of 192 
 
A2.5 Stacking gel 
0.65 ml Resolving gel 
1.25 mL Stacking gel 
3.05 mL dH2O 
50 µl APS 
5 µl TEMED 
 
A2.6 Tris-buffered Saline-Tween (TBS-T) (10X): 0.5M Tris 
Base, 9% NaCl, pH 7.6 
61 g Trizma base 
90 g NaCl 
1 L dH2O 
Mix thoroughly to dissolve and adjust pH with HCL. Store at RT. 
 
 
A2.7 TBS-T (1X) 
TBS-T (10X) diluted (1:10) with dH2O 
 
A2.8 Blocking Solution for PVDF membranes 
10 g bovine serum albumin 
200 ml TBS 0.5% TBS (Tween 20 (0.1% (v/v), Sigma UK) 
 
A2.9 Blocking with immunizing peptide 
Blocking buffer consisting of TBST plus 3% BSA 
Antibody 
Blocking (immunizing peptide) 
 
A3.0 Transfer buffer 
100 ml Tris glycine 
200 ml methanol 
700 ml dH2O  
 
A3.1 Running buffer 
10 X Running buffer 
100 ml in 900 ml dH2O 
 
A4.0 PCR  
A4.1 Gel agarose 
0.5 g agarose 
50 ml 1 x TBE 
1.5 µl ethidium bromide 
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